Does antiretroviral therapy accelerate the speed of physiological ageing through the clonal expansion of mitochondrial DNA mutations? by Bayerri, Carla Roca
 
 
Does antiretroviral therapy accelerate 
the speed of physiological ageing 
through the clonal expansion of 
mitochondrial DNA mutations? 
 
Carla Roca Bayerri 
MRes 
 
Thesis submitted to Newcastle University for the Degree of 
Doctor of Philosophy 
 
Wellcome Trust Centre for Mitochondrial Research 


























The accumulation of mitochondrial DNA (mtDNA) mutations is well described in 
normal human ageing as well as in several diseases of older age. It has been 
suggested that the accumulation of mtDNA mutations within tissues with ageing is 
likely to be predominantly due to the clonal expansion of existing mutations within 
cells, rather than high levels of mutagenesis. Antiretroviral treated HIV-infected 
persons achieve good immune reconstitution, but nevertheless experience an 
increase in many of the common diseases and physiological changes of older age. 
Given the known links between mitochondria and ageing, and mitochondria and HIV 
infection, it is plausible that increased mitochondrial damage may be a biological 
mediator of ageing in HIV.  
MtDNA damage in human brain was investigated in a cohort of HIV+ individuals and 
HIV-uninfected controls. HIV+ cases showed an increase in mtDNA deletions and a 
decrease in mtDNA content. In both cases these accentuated the changes seen with 
age.  
A novel derivative from the PolgA ‘mutator’ mouse model was developed to test the 
role of clonal expansion. The mouse model (‘WtN+’) contained multiple germline 
heteroplasmic mtDNA point mutations on a wild-type inbred nuclear background. 
Mice were aged to different time points, and a subset was dosed with zidovudine, a 
nucleoside analogue antiretroviral drug, known to inhibit mtDNA replication. Clonal 
expansion of mtDNA mutations were analysed in post-mitotic (skeletal muscle) and 
mitotic (colonic crypts) tissues using a combination of molecular and 
immunohistochemical assays. This novel mouse model showed evidence of clonal 
expansion of mtDNA mutations, and a mild frailty phenotype.  
In summary, these experiments increase our understanding of the natural history of 
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Chapter 1. Introduction 
1.1 Mitochondrial origins and evolution 
Mitochondria are unique extra-nuclear autonomous organelles present in almost all 
eukaryotic cells which contain their own genome. Mitochondria populate the majority 
of eukaryotic cells and they are the so-called powerhouses of the cell. 
The endosymbiotic theory of mitochondrial origins was proposed by Lynn Margulis 
(Sagan, 1967; Margulis, 1971). The original theory posited that an anaerobic 
nucleated cell ingested a free-living aerobic bacterium, i.e. the protomitochondrion 
(later called mitochondrion). In this way, mammalian mitochondria were thought to 
originate from an endosymbiotic relationship with an ancient α-proteobacterium more 
than 2 billion years ago.  
The majority of mitochondrial proteins are encoded in the nucleus, suggesting there 
was a gradual endosymbiotic gene transfer from the mitochondrial endosymbiont to 
the host nuclear genome, followed by integration into the host genomic DNA. 
Phylogenetic gene analysis from the α-proteobacterium Rickettsia prowazekii 
confirmed the Rickettsiaceae family to be the evolutionary ancestors of the 
mitochondrion (Sicheritz-Ponten et al., 1998). 
 
1.2 Mitochondrial structure and dynamics 
Mitochondria are double-membrane-bound organelles, with an outer mitochondrial 
membrane (OMM) and a lipid bilayer known as the inner mitochondrial membrane 
(IMM) where respiratory chain complexes are found (Figure 1.1). 
The OMM harbours protein channels and transporters that allow movement of 
metabolites between the cytoplasm and mitochondria such as the voltage-dependent 
anion channel (VDAC), also known as mitochondrial porin. Translocase of the outer 
membrane (TOM) together with inner mitochondrial translocase (TIM) form a protein 
complex aiding entry of nuclear encoded proteins. 
The intermembrane space (IMS) is found between these permeable membranes. 
The IMM encloses the mitochondrial matrix. The matrix contains mitochondrial DNA 
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molecules along with transcription and translation enzymes, and it is where the TCA 
cycle occurs. Figure 1.1 shows a schematic depiction of the mitochondrial 
ultrastructure.  
The first model of the mitochondrial structure, the baffle model of cristae, suggested 
that the IMM folded as invaginations called cristae mitochondriales (Palade, 1953). 
This model was later rendered inexact, as it was found that cristae organised in 
tubular connections that made mitochondria highly dynamic networks (Daems and 
Wisse, 1966). 
 
Figure 1.1. Mitochondrial structure. Schematic showing normal structure of 
mitochondria. 
 
The branching structure of the cytoskeleton forms a network used by mitochondria to 
move and to constantly undergo fusion and division (fission). These two processes 
are quality control responses to environmental stresses (Youle and van der Bliek, 
2012). Mitochondrial fusion occurs when two mitochondria unite the OMM and IMM 
forming one mitochondrion. Mitofusin proteins Mfn1 and Mfn2 control mitochondrial 
fusion of the OMM, and depend on Opa1 for fusion of the IMM. Mitochondrial fission 
happens when one mitochondrion divides to form two mitochondria. Fission occurs in 
order to degrade damaged mitochondria, a mechanism leading to mitophagy 
(autophagy of mitochondria), and is controlled by protein Drp1 helped by Fis1.  
Mitochondrial dynamics vary in different cell types, for instance, mitochondria in 
skeletal muscle are less mobile than in neurons, where they need highly dynamic 
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mitochondria to be able to travel across the cell body to axonal and dendritic 
synapses in order to provide ATP and regulate energy homeostasis. Neurons 
transport mitochondria using neuronal microtubules. Further detail on neuronal 
mitochondria (in the context of HIV) can be found in Section 1.12. 
 
1.3 Oxidative phosphorylation and ATP synthesis 
The majority of adenosine triphosphate (ATP) generation is met by a chain of 
reactions that start outside the mitochondria and end with oxidative phosphorylation 
(OXPHOS). Mitochondria are major producers of ATP. ATP synthesis begins in the 
cytosol of the cell, where anaerobic glycolysis breaks down glucose into pyruvate. 
Pyruvate is imported into the mitochondrial matrix, where pyruvate dehydrogenase 
converts it into acetyl Coenzyme A. Acetyl CoA can also be sourced from oxidation of 
fatty acids. Acetyl CoA is a substrate in the tricarboxylic acid (TCA) or Krebs cycle 
(Krebs and Johnson, 1937) which occurs in the matrix, whereby a series of 
enzymatic reactions release by-products and reducing agents NADH and FADH2 
which will be further needed in the electron transport chain (ETC) of the OXPHOS 
system. NADH donates electrons to complex I and FADH2 to complex II. 
The ETC is composed of transmembrane respiratory complexes I-IV which are 
embedded in the inner mitochondrial membrane and shuttle electrons across the 
respiratory chain complexes, which coupled with proton translocation, is used to 
generate ATP by complex V (Figure 1.2). 
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Figure 1.2. Oxidative phosphorylation. Electrons enter the ETC via complex I and II 
and are shuttled until complex IV (shown by red dotted lines), providing the energy 
required to translocate protons (H+) from the matrix into the intermembrane space 
creating a proton gradient that is used by complex V to synthesize ATP. CoQ is 
coenzyme Q. Cyt c is cytochrome c, acting as an electron carrier. 
 
Complex I, also known as NADH dehydrogenase, is the largest complex of the ETC, 
composed of 45 different subunits (Zhu et al., 2016), seven of which are 
mitochondrially encoded and located in the membrane part of the complex. The 
remainder are nuclear encoded. It oxidises NADH. Complex I dysfunction is the most 
frequently observed OXPHOS defect. Nuclear encoded NDUFB8 subunit has been 
found to be essential to complex I enzymatic activity (Perales-Clemente et al., 2010) 
therefore is very commonly used for investigations of complex I levels using 
immunofluorescence (Rocha et al., 2015; Ahmed et al., 2017). 
Complex II, also known as succinate ubiquinone oxidoreductase, is only comprised 
of four subunits and it is the only OXPHOS complex that is entirely nuclear encoded 
and does not translocate protons to the intermembrane space. The catalytic part is 
called succinate dehydrogenase (SDH). It oxidises succinate to fumarate. Complex II 
deficiency is very rare, in fact the rarest of all OXPHOS complexes, accounting for 
around 2% of reported mitochondrial disease cases (Alston et al., 2012). SDH genes 
are involved with tumour suppressor activity and mutations have been linked with 
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some forms of cancer. Coenzyme Q (ubiquinone) is a mobile electron carrier 
shuttling electrons from complex II to III and thus it is reduced to ubiquinol. 
Complex III, or ubiquinol cytochrome c oxidoreductase, is composed of 11 subunits, 
only one of which – cytochrome b - is mitochondrially encoded. Similarly to complex 
II, complex III deficiency is rare in humans. Electrons are shuttled from complex III to 
complex IV via a mobile electron carrier – cytochrome c. 
Complex IV, or cytochrome c oxidase (COX), is the last complex of the ETC 
translocating protons into the intermembrane space and is in charge of the reduction 
of oxygen to water. Complex IV is comprised of 13 subunits, of which three – MTCOI, 
MTCOII and MTCOIII - are encoded by the mitochondrial genome (Tsukihara et al., 
1996). Complex IV is also commonly affected in human mitochondrial diseases 
(Johnson et al., 1983; Muller-Hocker et al., 1983; Sciacco et al., 1994). Anti-MTCOI 
antibodies or COX activity are common assay targets for immunofluorescence or 
histochemistry protocols of complex IV (Rocha et al., 2015). 
Complex V, known as ATP synthase, is the final step of the OXPHOS pathway and it 
uses the electrochemical gradient created by the electron transfer and proton 
translocation to phosphorylate ADP into ATP. 
Respiratory chain complexes have been found to assemble into supramolecular 
entities named supercomplexes, namely complexes I, III and IV assemble to form 
respirasomes. Some advantages of these supercomplexes have been proposed, 





1.4 Other mitochondrial functions 
The main role of mitochondria is the supply of intracellular energy by ATP production 
through OXPHOS. However, they are also involved in a myriad of functions including 
calcium signalling, cellular metabolism, stress responses, haem synthesis and 
apoptotic cell death (Spinelli and Haigis, 2018). 
Mitochondria are also implicated in the formation of iron sulphur clusters (Stehling 
and Lill, 2013), which are essential in the electron transport of the OXPHOS process. 
The OXPHOS system is responsible for the majority of production of reactive oxygen 
species (ROS) when electron leakage from the ETC reduces oxygen to form 
superoxide (O2-). Superoxide anions are a precursor of peroxide (H2O2) (Murphy, 
2009). Although ROS are potentially a toxic insult to the cell, they are also thought to 
play an important role in cellular signalling pathways. The debated role of ROS in 
ageing is discussed below in Section 1.6. Mitochondrial dysfunction has been linked 
to cancer, neurodegeneration, metabolic diseases and ageing to name but a few 
(Trifunovic and Larsson, 2008; de Moura et al., 2010; Payne and Chinnery, 2015; 
Pinto and Moraes, 2015). 
Recent evidence suggests mitochondria function as a hub in the mammalian innate 
immune system. The involvement of mitochondria in innate immune signalling 
pathways related to microbial infections as well as endogenous stress or injury, has 





1.5 Mitochondrial genetics 
1.5.1 Mitochondrial genome 
In human cells, mitochondrial DNA (mtDNA) is a circular, 16,596-bp, double-stranded 
DNA molecule. The heavy strand (H-strand) is rich in guanine and the light strand (L-
strand) is rich in cytosine. MtDNA codes for 37 genes, out of which 13 encode protein 
subunits of the mitochondrial electron transport chain, the site of OXPHOS, 22 code 
for mitochondrial transfer RNAs (tRNAs) and two for ribosomal RNAs (rRNAs) 
(Anderson et al., 1981). Specifically, these aforementioned 13 mtDNA encoded 
polypeptides of the OXPHOS are genes ND1-6 and ND4L of complex I; cytochrome 
b gene of complex III; genes COI, COII and COIII of complex IV; and genes ATP6 
and ATP8 of complex V (Figure 1.3). The remaining mitochondrial proteins are 
encoded in the nuclear genome, estimated to be ~1,500 (Calvo and Mootha, 2010). 
 
Figure 1.3. Human mitochondrial genome. Schematic representation of the 
mitochondrial DNA molecule. Genes encoding the mitochondrial respiratory chain 
complexes are shown in coloured boxes; green boxes are rRNAs; red circles are 
tRNAs. Image taken from (Chinnery and Hudson, 2013). 
 
 8 
The mitochondrial genome is highly efficient, it lacks introns and is almost entirely 
composed of coding regions except for one ~1 kb noncoding region, called the 
displacement loop (D-loop). The D-loop contains elements which regulate mtDNA 
replication and transcription (Arnberg et al., 1971). 
Despite mtDNA accounting for only 1% of the total cellular DNA, each cell contains 
from a few hundreds to thousands of copies of the mitochondrial genome, depending 
on cellular energy requirements. This is known as mitochondrial DNA copy number 
(CN) and its molecular analyses are widely used in the study of mitochondrial 
diseases (Kollberg et al., 2009; Poulton et al., 2009; Martin-Hernandez et al., 2017). 
MtDNA CN is highly variable and it is believed to be specific to the energy 
requirements of the tissue (Clay Montier et al., 2009), however the exact 
mechanisms regulating mtDNA CN have not been elucidated. 
In this multi-copy state of the mtDNA, when the copies have the same sequence it is 
known as homoplasmy. However, when a mutation occurs, these mutant molecules 
co-exist with wild-type molecules at different levels, a term named heteroplasmy.  
It is believed that mtDNA is packaged into DNA-protein complexes called nucleoids 
and their function has not been fully clarified yet, but they are thought to help with 




1.5.2 Mitochondrial DNA replication, transcription and translation 
MtDNA replication is independent of cell cycle (Bogenhagen and Clayton, 1977) and 
is carried out by the sole mtDNA polymerase, the polymerase gamma (pol ү), 
encoded by the nuclear genes POLG and POLG2 (which codes for a 55 kDa 
accessory subunit) (Kaguni, 2004).  
Mitochondrial DNA polymerase ү has a 3’-5’ exonuclease proofreading activity and in 
conjunction with an mtDNA hexameric twinkle helicase and mtSSB (mitochondrial 
single strand binding protein) forms the machinery for the replication process, called 
the mtDNA replisome (Hudson and Chinnery, 2006). 
The mtDNA molecules are constantly turned over throughout life in mitotic and also 
post-mitotic tissues, a process called ‘relaxed replication’ (Chinnery and Samuels, 
1999). 
The exact mechanism of mtDNA replication has not been fully determined but two 
mtDNA replication models have been proposed; asynchronous (strand displacement) 
and synchronous. In the asynchronous model, transcription with the mtDNA D-loop 
initiates replication at the origin of heavy-strand replication (OH) ‘unidirectionally’ until 
origin of light-strand replication (OL) is exposed and then replicated, synthesising the 
lagging-strand in an anticlock-wise direction (Clayton, 1982). The synchronous model 
suggested that heavy-strand replication is originated at OH ‘bi-directionally’, 
simultaneously with multiple initiation sites for the lagging-strand (Holt et al., 2000). 
The transcription of mtDNA is initiated by mitochondrial transcription factor A (TFAM) 
through the recruitment of mitochondrial RNA polymerase (POLRMT) and 
mitochondrial transcription factor B2 (TFB2M) (Hillen et al., 2018). In the elongation 
step, TEFM increases POLRMT processivity along the DNA strand (Posse et al., 
2015). Mitochondrial termination factor (mTERF1) terminates transcription of mature 
mtDNA transcripts downstream of the 16sRNA gene (Asin-Cayuela et al., 2005). 
Mitochondrial translation is carried out by the mitoribosome in three stages: initiation, 
elongation and termination (Greber et al., 2015). The mitoribosome is a large multi-
subunit complex formed of both RNA (coded by mtDNA genes MTRNR1, MTRNR2 
and tRNAVal/Phe) and protein subunits all encoded within the nuclear DNA (nDNA). 
Elongation of synthesising peptides is promoted by three elongation factors: mtEFTu, 
mtEFTs and mtEFG1 (Mai et al., 2017). Translation termination is performed by two 
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release factors mtRF1a and C12orf65, and ribosome recycling is facilitated by 
mtEFG2 (Lightowlers and Chrzanowska-Lightowlers, 2010). 
 
1.5.3 Mitochondrial DNA repair mechanisms 
The endogenous oxidative environment of the mitochondria leaves mtDNA 
vulnerable to damage. The constant mtDNA turnover also leads to replication errors. 
Repair mechanisms in mtDNA are not as robust and extensive as the ones described 
for nuclear DNA, for instance mtDNA lacks nucleotide excision repair (NER). The 
main mitochondrial repair pathways include base excision repair (BER) and single 
strand break repair (SSB) (Prakash and Doublie, 2015). 
 
1.5.4 Heteroplasmy and threshold effect 
Heteroplasmy is expressed as a percentage, between 1-99%, and refers to the 
proportion of mutant mtDNA molecules in relation to the wild-type, in a single cell or 
tissue. This co-existence of mutant mtDNA species with wild-type is the main driver 
of the phenotypic expression of mtDNA mutations.  
When mutant mtDNA is found above a certain threshold, typically between 70-80 % 
heteroplasmy level, respiratory chain deficiency in a tissue can arise leading to 
mitochondrial dysfunction and potentially organ dysfunction. It is thought that for 
mtDNA deletions a lower threshold of around 60% is enough to produce a 
biochemical defect, whereas for single point mutations a higher level of heteroplasmy 
is required since at low heteroplasmy levels wild-type mtDNA compensates for the 
mutant mtDNA species. This is known as the mitochondrial threshold effect, which is 
believed to vary between tissues and between different mutations types. 
Due to the recessive nature of heteroplasmic mtDNA mutations, cells with low level 
mutated mtDNA molecules can still be respiratory functional but when increased it 
can create a mosaic pattern of cellular mitochondrial deficiency within a tissue. 
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1.5.5 Clonal expansion of mtDNA mutations 
Initially, a single somatic mutation will be present among many other wild-type copies 
of the mitochondrial genome. How can it therefore reach the level required to 
produce a defective phenotype? Two mechanisms could be responsible: either by 
accumulation of de novo mutations or by clonal expansion of pre-existing mutations. 
De novo mutagenesis can happen when different new mutations occur in a single 
cell, whereas a single somatic mutation can undergo clonal expansion due to the 
replication of mtDNA being uncoupled from the cell cycle.  
There are a few theories to explain clonal expansion of mtDNA mutations. Initially, 
the “survival of the smallest” model was proposed, where the deleted mtDNA 
genomes by being the smallest had a replicative advantage and would accumulate 
faster over time (Wallace, 1992). However, this theory only applies to mtDNA 
deletions but does not take into account mtDNA point mutations, which do not affect 
the size of the genome and still clonally expand during ageing (Greaves et al., 2014). 
Another theory, the “survival of the slowest” suggested that mitochondria with mutant 
mtDNA live longer because the respiratory chain is impaired and there is less ROS 
so less oxidative damage (de Grey, 1997). Such a model assumes the clonal 
expansion of mtDNA mutations has reached a threshold high enough to produce a 
defect in the respiratory chain. Over time these theories have been somewhat 
discarded.  
The most recent and sustained theory is simply that ‘random intracellular genetic 
drift’ of mutated and wild-type mtDNA species get randomly amplified via relaxed 
replication, without any specific selective advantage or pressure needed (Elson et al., 
2001). Modelling studies suggest that relaxed replication may be sufficient to lead to 
clonal expansion in post-mitotic cells (Gross et al., 1969; Chinnery and Samuels, 
1999; Elson et al., 2001). 
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1.5.6 Mitochondrial DNA mutations and disease 
The mutational rate of mtDNA is several times higher than that of the nuclear DNA 
(Brown et al., 1979; Linnane et al., 1989) partly because mtDNA is localized 
physically close to the respiratory chain and hence more susceptible to receive 
oxidative damage, also because of the scarce mtDNA repair mechanisms and lack of 
protective histones. These factors together with a low fidelity polymerase γ (Kunkel 
and Loeb, 1981) and the constant turnover of the mtDNA make the mitochondrial 
genome more prone to mutations than its nuclear counterpart. Moreover, since the 
mtDNA is highly compact any mutations are likely to occur in protein-coding or tRNA 
regions and therefore have a downstream effect. A mutation can happen due to 
errors during mtDNA replication or repair (Schon et al., 1989; Krishnan et al., 2008).  
Broadly, there are two main types of mtDNA mutations: point mutations and large-
scale deletion.  
Single mtDNA point mutations occur when a single base is substituted for another. 
Point mutations can be maternally inherited or somatic. More than half of the 
pathogenic mtDNA point mutations are located in mitochondrial tRNA genes, hence 
potentially producing a functional defect (Schaefer et al., 2008). The most common 
and studied point mutations are the mt.3243A>G and mt.8344A>G, involved in 
mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes 
(MELAS) and myoclonic epilepsy with ragged red fibres (MERRF), respectively. 
Large-scale mtDNA deletions remove or rearrange a big part of the mitochondrial 
genome that includes genes coding for proteins or tRNAs. The most well-known 
somatic deletion is the 4977 bp ‘common deletion’ flanked by two 13bp homologous 
repeat sequences at positions 8470-8482 and 13447-13459 (inclusive) (Schon et al., 
1989; Shoffner et al., 1989). In some cases, one of these repeats is deleted. Further 
studies have shown the importance of these direct repeats in the formation of large-
scale mtDNA deletions (Samuels, 2004; Samuels et al., 2004; Guo et al., 2010). The 
4977 bp mtDNA common deletion (CD) is known to cause several diseases including 
Pearson’s syndrome, chronic progressive external ophthalmoplegia (CPEO) and 
Kearns-Sayre syndrome (KSS) (Holt et al., 1988; Zeviani et al., 1988; Moraes et al., 
1989). The mtDNA CD is also well-known to accumulate with age (Corral-Debrinski 
et al., 1992; Lee et al., 1994; Tengan et al., 1997; Bua et al., 2006; Gendron et al., 
2012); and it could even be implicated in cancer (Chen et al., 2011). 
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Currently, it is not known exactly how the mtDNA CD can cause different disease 
phenotypes but some hypotheses argue that the nuclear genome could compensate 
for this defect, thereby allowing transition of mitochondrial phenotypes (Katada et al., 
2013); indicating that mtDNA deletions pose a potential for a phenotype that won’t 
always occur. Besides, mtDNA CD could simply reveal a phenotype when 
heteroplasmy is present above a critical threshold. Conversely to point mutations, 
large-scale deletions are rarely inherited. They mainly localise in the major arc of the 
mitochondrial genome, between the two origins of replication, OH and OL. The 
mechanisms implicated in deletion formation are not fully elucidated, but very recent 
single-molecule analysis of the mtDNA CD revealed a replication impairment 
combined with abnormal break repair as the cause (Phillips et al., 2017). 
Phenotypic expression varies between different tissues, for instance high energy 
demanding post-mitotic tissues such as muscle and brain are thought to be more 
vulnerable to the effects of mtDNA mutations. This tissue specificity, seen in 
mitochondrial diseases, is likely to dictate to some extent the expression of a clinical 
phenotype. 
Mitochondrial diseases are complex heterogeneous multi-systemic disorders typically 
affecting several high energy demanding organs such as skeletal muscle and 
nervous systems. Since a large proportion of OXPHOS genes are encoded by the 
nuclear genome, mitochondrial disease can either come from defects in the mtDNA 
or in the nDNA. Mitochondrial disease prevalence is difficult to estimate, but a recent 
study in the North East of England found the prevalence to be less rare than 
previously thought, affecting up to ~1 in 4,300 adults in the UK (Gorman et al., 2015). 
The first mtDNA point mutation linked to disease was mt.11778G>A in ND4 gene of 
complex I which would present as homoplasmic and be one of the pathogenic 





Figure 1.4. Genotype-phenotype correlations in human mitochondrial disease. 
MtDNA mutations are depicted with the associated clinical presentations. CPEO, 
chronic progressive external ophthalmoplegia; LHON, Leber hereditary optic 
neuropathy; LS, Leigh syndrome; MELAS, mitochondrial myopathy, encephalopathy, 
lactic acidosis, and stroke-like episodes; MERRF, myoclonic epilepsy and ragged red 
fibres; MILS, maternally inherited Leigh syndrome; NARP, neurogenic weakness, 
ataxia, and retinitis pigmentosa; PS, Pearson syndrome. Image taken from (Tuppen 




1.5.7 Mitochondrial DNA inheritance and the genetic bottleneck 
Mitochondrial genetics differs from nuclear genetics in many aspects but mainly 
because the mitochondrial genome is inherited and transmitted through the maternal 
line, as opposed to the nuclear genome being inherited in a biparental diploidy 
Mendelian manner. Despite the predominance of this theory (Pyle et al., 2015b), 
paternal inheritance of mtDNA has been observed in humans on a handful of cases 
(Schwartz and Vissing, 2002; Luo et al., 2018) and some paternal mtDNA leakage 
has been reported in the animal kingdom (Gyllensten et al., 1991; Kondo et al., 1992; 
Zhao et al., 2004; Sherengul et al., 2006; Nunes et al., 2013; Dokianakis and 
Ladoukakis, 2014) and remains a contentious area of debate.  
Through a mammalian mtDNA genetic bottleneck, a mother can pass on different 
levels of heteroplasmic mutations to their offspring, thus either constraining or quickly 
segregating mtDNA mutant species.  
In terms of female germ line, a germline bottleneck is thought to reduce the number 
of mtDNA molecules per cell during embryonic development. Indeed, a reduction of 
mtDNA in the germline of mice in some studies showed for the first time the 
existence of a genetic bottleneck (Cao et al., 2007; Cree et al., 2008; Wai et al., 
2008).  
The constriction-expansion balance of mtDNA heteroplasmic subpopulations in the 
maternal germline is important in maintaining a purifying selection against deleterious 
mutations (Fan et al., 2008; Stewart et al., 2008). 
 
1.5.8 Mitochondrial haplogroups 
The evolution and geographic radiation of subgroups within the human population 
with mtDNA sequence variants led to the formation of mitochondrial haplogroups. 
These variants are homoplasmic and were fixed in the mitochondrial phylogenetic 
tree through radiation of maternal lineages many thousands of years ago. The origin 
of the mitochondrial eve is set in Africa, where it gave rise to macrohaplogroup L. 
MtDNAs radiated and from L others emerged, macrohaplogroups M and N, which left 
Africa and started a founder effect in the other continents (Wallace, 2015). 
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1.6 Mitochondrial DNA and Ageing 
During the natural course of human ageing, somatic (acquired) mutations accumulate 
in the mitochondrial genome but it is still unclear how active the role of these 
mutations is and whether they cause the ageing observed or they are a 
consequence. 
Although mtDNA mutations originating throughout life are assumed to be age-related, 
it is unknown whether they occur early or late in life. Some of these mutations could 
actually be passed down the maternal line but not detected with the technologies 
available. Recent work has pointed to the direction of inheritance of low-level 
heteroplasmic variants from the maternal line (Li et al., 2010; Payne et al., 2012; Guo 
et al., 2013). This heteroplasmic variant level can vary markedly among different 
tissues of the same individual (He et al., 2010). 
One of the prevailing theories of ageing was initially proposed by Harman in the 
1950s, the ‘free radical theory’ which postulates that ageing is due to the deleterious 
effect of endogenous reactive oxygen species (ROS), a by-product generated during 
normal activity of the OXPHOS system, inflicting progressive cumulative cellular 
dysfunction and thus tissue damage (Harman, 1956). Some years after, Harman’s 
original theory was renamed to ‘mitochondrial theory of ageing’ because 
mitochondria, namely the electron transport chain, are an important source of 
intracellular ROS production (Harman, 1972). 
 
Since then, it has been commonly thought that mtDNA mutations in ageing are driven 
principally by a ‘vicious cycle’ of mitochondrial ROS leading to oxidative damage to 
mtDNA, causing respiratory chain dysfunction and further ROS production.  
According to this theory, mtDNA mutations would be enhanced and propagated in an 
exponential manner, which is however, not the case. Many studies have failed to 
prove an increase in age-related oxidative damage (Tengan et al., 1997; Mott et al., 
2001; Kennedy et al., 2013; Itsara et al., 2014). This lack of consistent evidence 
makes this theory inconclusive and arguable.  
At the moment the theory of clonal expansion of pre-existing mutated mtDNA 
molecules seems to be more plausible than a continuous ROS vicious cycle, as 
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reviewed by Pinto and Moraes, who propose that ROS plays a simple stress-
mediating role in the context of molecular damage (Pinto and Moraes, 2015). 
Trifunovic and colleagues challenge the original oxidative damage theory since they 
found no increased ROS production in their study with mice with an error-prone 
polymerase, suggesting that respiratory dysfunction itself could be enough to trigger 




1.6.1 PolgA ‘mutator’ mouse model of mitochondrial ageing 
A few years ago, two groups independently provided the first descriptions of a mouse 
model with a defective mtDNA polymerase (Trifunovic et al., 2004; Kujoth et al., 
2005). These knock-in mice have a proofreading-deficient version of the 
mitochondrial DNA polymerase γ by a point mutation (D257A) in the catalytic PolgA 
subunit, which leads to accelerated accumulation of mtDNA mutations and a 
prematurely aged phenotype, i.e., hair loss, weight loss, greying, kyphosis, frailty, 
reduced subcutaneous fat, osteoporosis, thymic involution, loss of bone and muscle 
mass (Trifunovic et al., 2004; Kujoth et al., 2005). 
‘Mutator’ mice homozygous for this allele (PolGmut/mut) show a severe progeroid 
phenotype, whereas heterozygous mice (PolGwt/mut) do not, and rather show a normal 
phenotype (Trifunovic et al., 2004; Kujoth et al., 2005). 
It was reported by the Loeb group that mtDNA deletions were more abundant in 
PolGmut/mut mice in comparison to the PolGwt/mut ones, suggesting that deletions may 
be responsible for the reduced lifetime of homozygous mice (Vermulst et al., 2008). 
However such finding has subsequently been refuted as the deletions seen were not 
true canonical deletions, i.e., smaller circular mtDNA species with part of the genome 
deleted, but rather were linear mtDNA species that were probably ‘replication dead-
ends’ from the faulty pol γ (Williams et al., 2010). 
The previous papers focused on somatic mutations but in a recent paper by Ross, 
Stewart and colleagues, it was shown that mtDNA mutations could also be 
transmitted down the maternal germline and drive an ageing phenotype. In their 
study, mice which inherited low levels of germline mtDNA mutations had a shorter 
lifespan and a more severe aged phenotype compared to the ones that did not (Ross 
et al., 2013). 
Although the PolgA mouse has proved very useful for studies of mitochondrial 
deficiency and ageing, it does have some limitations in modelling the situation in 
humans. For example, it has continuous production of very high levels of somatic 
mtDNA mutations, whereas humans have low levels (possibly germline transmitted) 
with gradual clonal expansion; the ageing phenotype may well be driven more by 
mitochondrial dysfunction in stem cells (starting during embryogenesis), rather than 
in post-mitotic tissues in adult life. In this thesis, I did not use the standard PolgA 
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mouse model to study clonal expansion but I created a new mouse model as there 
are currently no good models of clonal expansion. 
The mouse mitochondrial genome was completely sequenced in early 1980s 
showing mouse mtDNA overall sequence and organisation is very homologous to 
human mtDNA (Bibb et al., 1981). Sequence homology is higher in mouse 
mitochondrial tRNA genes to their human analogues compared to rRNA genes and 
protein-coding genes. The overall locations of mouse mtDNA genes are in almost 
identical positions to human mtDNA, but the mouse mtDNA is shorter (16,299 bp) 
than the human because the D-loop region is shorter. The mtDNA common deletion 
spanning 4977 bp in humans is in fact shorter in mice, 3867 bp, but still involves the 
major mitochondrial arc (Figure 1.5) (Tanhauser and Laipis, 1995; Zhang et al., 
2013). 
 
Figure 1.5. Mitochondrial genome maps. Schematic representation of the mtDNA 
molecule and common deletion in humans (A) and mice (B). Image taken from 




1.7 Human Immunodeficiency Virus 
The human immunodeficiency virus 1 (HIV-1) is the most prevalent and first 
discovered subtype of the HIV virus. HIV-1 is hereafter referred to as HIV in this 
thesis. HIV is an enveloped retrovirus that infects the host immune system cells and 
results in declining CD4+ lymphocyte counts, leading to acquired immune deficiency 
syndrome (AIDS). 
According to the World Health Organization, nearly 38 million people around the 
world were living with HIV in 2018. 
The envelope of the virus, derived from the host cell membrane, is composed of 
surface glycoprotein 120 (gp120) and transmembrane glycoprotein gp41. The core of 
the virus is composed of capsid protein p24 and the p17 matrix core protein, which 
helps maintain viral structure. In the core, there are also two identical copies of 
single-stranded RNA (ssRNA) and three essential enzymes; reverse transcriptase 
(RT), protease and integrase. 
After infection, the virus particle using its gp120 attaches to the receptor CD4 on the 
cell surface with the help of a co-receptor. The major co-receptors are CXCR4 and 
CCR5, primarily expressed in T-cells and macrophages, respectively but they can 
also express both. Binding of gp120 to CD4 receptor aided by the co-receptor results 
in a conformational change in gp120, allowing gp41 to unfold and insert its 
hydrophobic terminus into the host cell membrane. Gp41 draws the virus towards the 
host cell. After attachment, viral and host cell membranes fuse resulting in the viral 
RNA genome entering the cytoplasm of the cell where it is reverse-transcribed from 
ssRNA into proviral DNA using the HIV-1 reverse transcriptase (HIV-RT). This linear 
viral cDNA is integrated into the host cell nuclear DNA with the help of the viral 
integrase. Using the host cell machinery, it initiates transcription of viral mRNA 
species which are transported to the cytoplasm and translated into proteins being 
later cleaved by the protease, creating more virus particles and causing infection of 
nearby cells (Figure 1.6). 
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Figure 1.6. Replicative life cycle of HIV-1 and stages for the intervention of 
antiretroviral drugs (in red). Red arrow indicates the reverse transcription step, which 
is blocked by NRTIs and NNRTIs. Adapted from (Furtado et al., 1999). 
 
1.7.1 Markers of HIV disease progression 
CD4 T-cell count is commonly used to monitor the progress of HIV infection. 
However, decline in CD4 cell count can take several years to reach low levels. HIV-
infected individuals with controlled viraemia have between 500-1500 cells/mm3, 
which is considered a normal CD4 count. When CD4 count declines to less than 200 
cells/mm3, posing a risk of acquiring opportunistic infections and cancers, this is used 
to diagnose AIDS. The most common opportunistic infections in HIV are 
Pneumocystis pneumonia, Kaposi’s sarcoma, cytomegalovirus, tuberculosis and 
candidiasis. Other AIDS-related infections include other bacterial, viral, fungal and 
protozoal infections. Recent results from the START study showed that initiation of 
antiretroviral therapy in HIV patients with a CD4 count of more than 500 cells/mm3 
was more beneficial than starting therapy after CD4 count had declined to 350 




1.8 HIV treatment 
1.8.1 Antiretroviral therapy (ART) 
A variety of antiretroviral drugs can now target different stages of the HIV replication 
cycle. Entry into the host cell can be blocked by fusion inhibitors or chemokine 
receptor (CCR) antagonists. Antiretroviral regimens like nucleoside reverse 
transcriptase inhibitors (NRTIs) or nonnucleoside reverse transcriptase inhibitors 
(NNRTIs) lead to inhibition of reverse transcription. The action of viral integrase can 
be blocked by integrase inhibitors (INIs). Protease inhibitors (PIs) stop the viral 
protease. 
Therefore the main classes are: NRTIs, NNRTIs, PIs, INIs, fusion inhibitors and 
CCR5 antagonists. Almost all patients are on highly active antiretroviral therapy 
(HAART) which is a combination of two NRTIs with a third class of drug, usually a PI, 
NNRTI or INI (Dieterich, 2006). 
NRTIs are the longest established class and still the key mainstay of therapy. NRTIs 
inhibit transcription of viral RNA into proviral DNA. Zidovudine (also known as 
azidothymidine or AZT) was the first NRTI drug approved by the U.S. Food and Drug 
Administration in 1987 for the treatment of HIV infection. It was very widely used for 
many years, initially alone and later as part of HAART. Currently the most commonly 
used NRTIs include abacavir (ABC), lamivudine (3TC) and emtricitabine (FTC). Also 
very commonly used is tenofovir, as TDF (tenofovir disoproxil fumarate) or TAF 
(tenofovir alafenamide), which is an NtRTI (nucleotide RTI). AZT, didanosine (ddI), 
zalcitabine (ddC) and stavudine (d4T) are also NRTIs but are no longer used in 
developed countries due to toxicity. AZT and d4T have however been widely used 




1.8.2 NRTI antiretroviral drugs and mtDNA replication 
In the case of thymidine analogues, they are incorporated into the mitochondria in a 
phosphorylated or unphosphorylated form. AZT undergoes a series of 
phosphorylations, until it reaches its active triphosphate form.  
The first phosphorylation is done either by the thymidine kinase 1, if AZT is found in 
the cytoplasm, or by thymidine kinase 2, if it is found in the mitochondria (Arner and 
Eriksson, 1995). Both isoforms perform the same activity but in different cell 
compartments. Thymidylate kinase carries out the second phosphorylation, from 
AZT-monophosphate to AZT-diphosphate. Finally, nucleoside diphosphate kinase 
phosphorylates AZT into its triphosphate form, yielding the pharmacologically active 
AZT, which will then inhibit HIV reverse transcription (Lewis and Dalakas, 1995). 
A membrane protein, named mitochondrial deoxynucleotide carrier, transports 
phosphorylated NRTIs and nucleosides into the mitochondria (Dolce et al., 2001). 
However, this mechanism of NRTI entry into the mitochondria still needs further 
understanding. 
AZT has a chemical structure very similar to the nucleotide thymidine, one of the 
DNA constituents (Figure 1.7). During the developing DNA chain, the phosphate 
group of thymidine binds with the 3’ –OH functional group of the preceding 
nucleotide, and so forth. However, AZT does not have the 3’ –OH group, instead it 
has an azido group (-N3) which cannot form a bond with the phosphate group from 
the following nucleotide (Lewis and Dalakas, 1995). Therefore, AZT incorporation by 
HIV reverse transcriptase into the viral elongating DNA chain will abruptly halt 
reverse transcription.  
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Figure 1.7. Diagram of the chemical structure from thymidine and zidovudine (AZT), 




This process not only occurs during HIV reverse transcription but also during normal 
mtDNA replication by polymerase γ. The mitochondrial polymerase γ is not able to 
differentiate between thymidine and AZT given their analogy. As mentioned earlier, 
after their activation, NRTIs inhibit HIV reverse transcription and also polymerase γ, 
although the affinity of NRTIs for pol γ is estimated to be some orders of magnitude 
lower than that for HIV-RT. NRTIs’ inhibition of mtDNA polymerase γ causes mtDNA 
depletion (content reduction) and leads to mitochondrial dysfunction, a process 
known as the polymerase ү hypothesis (Lewis and Dalakas, 1995).  
Additionally, Lim and Copeland suggested that NRTIs not only inhibit the replication 
activity of the polymerase γ but also its inherent 3’-5’ exonuclease activity (Lim and 
Copeland, 2001).  
Some studies showed that antiretroviral switch from a highly toxic to a nontoxic NRTI 
allows the recovery of mtDNA content (McComsey et al., 2005b), however more 
studies are needed to better understand this. 
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1.9 Pathogenesis of NRTI-induced mitochondrial toxicity 
The hallmark toxicity of NRTIs is mitochondrial toxicity which clinically manifests as 
myopathy, neuropathy, lactic acidosis, lipodystrophy and very occasionally, hepatic 
failure. When NRTI-treated HIV positive patients first displayed these symptoms, they 
were recognised as being typical of hereditary mitochondrial diseases. Zidovudine-
associated myopathy was first seen in several studies of treated patients (Helbert et 
al., 1988; Dalakas et al., 1990; Arnaudo et al., 1991; Peters et al., 1993). However, 
the molecular mechanism linking AZT-induced toxicity and muscle disease was not 
elucidated until some years later, when the polymerase γ hypothesis was proposed. 
In studies of NRTI toxicity, mitochondrial damage can be biochemically measured in 
various ways such as looking at electron transport chain function, hydrogen peroxide 
production, mtDNA point mutations and deletions and mtDNA copy number (Koczor 
et al., 2010). 
The effects of anti-HIV therapy on mtDNA mutations have been studied using blood 
tissue (Bartley et al., 2001; Martin et al., 2003; McComsey et al., 2005a; Ortiz et al., 
2011; Jitratkosol et al., 2012; Liu et al., 2013; Li et al., 2017). However, blood is a 
mitotic tissue that replicates at a high rate, which might cause the loss of mtDNA 
mutations. Therefore, post-mitotic tissues such as brain and muscle tissues could be 
a better choice for looking at mtDNA mutations. The effect of anti-HIV therapy was 
studied using rodent cardiac muscle tissues, but comparable studies have not yet 
been performed on human cardiac muscle and brain tissues (Walker et al., 2004a; 




1.10 HIV and Ageing 
The era of HAART has meant that HIV infection evolved from being a fatal infection 
to a now manageable chronic disease for most patients. Although antiretroviral 
therapy allowed for a higher life expectancy, it does not fully restore immune health in 
most infected individuals. Furthermore, several non-AIDS comorbidities are 
associated with long-term ART-treated HIV. But in general, it is not clear to what 
extent comorbidities are driven by residual effects of the virus or by the ART, likely 
both have a role. 
Nowadays, antiretroviral treated HIV-infected persons achieve good immune 
reconstitution and an increased life expectancy, but nevertheless their average 
lifespan remains shorter compared to uninfected individuals, and they experience an 
increase in many of the common diseases and physiological changes of older age 
(Currier et al., 2003; Valcour et al., 2004; Brown and Qaqish, 2006; Desquilbet et al., 
2007; Erlandson et al., 2013).  
As mentioned before, given the known links between mitochondria and ageing 
(Taylor et al., 2003; Kujoth et al., 2005; Short et al., 2005; Bender et al., 2006; Bua et 
al., 2006; Vermulst et al., 2008), and mitochondria and HIV infection (Arnaudo et al., 
1991; Shikuma et al., 2001; Cote et al., 2002; Miura et al., 2003), it is plausible that 
increased mitochondrial damage may be a biological mediator of ageing in HIV.  
Previous work by B. Payne and colleagues has demonstrated that antiretroviral 
treated persons have an excess of cells containing mtDNA mutations, but the 
mechanism remains to be fully determined (Payne et al., 2011). In silico modelling 
suggests that the increase may be consistent with an acceleration of clonal 
expansion of mtDNA mutations within cells, particularly in the setting of exposure to 
certain NRTI antiretroviral drugs. Conversely, other authors suggested that HIV 
infection or therapy may be mutagenic for mtDNA (Martin et al., 2003; Walker et al., 
2004a; Jitratkosol et al., 2012). Which model is correct will dictate the natural history 
of the mitochondrial defect in later life. 
It is well established that certain NRTI antiretroviral drugs cause inhibition of the 
mtDNA polymerase γ leading to mtDNA depletion. It is therefore plausible that NRTI 
treatment also leads to increased mtDNA mutations, and that this may play a role in 
driving ageing phenotypes in HIV. 
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DdI is a strong inhibitor of pol γ and as such is expected to most likely affect clonal 
expansion (Lim and Copeland, 2001; Payne et al., 2011). AZT is a weak inhibitor but 
potentially causes mutagenesis (Balcarek et al., 2010; Cooper and Lovett, 2011). 
TDF and ABC do not inhibit pol γ and thus do not produce mtDNA depletion (Birkus 
et al., 2002). 
 
1.11 HIV, immune activation and chronic inflammation 
HIV causes a massive decline in the T cell population, in particular CD4. However, in 
HIV infection, only 5-10% of immune cells that undergo apoptosis are actually HIV 
infected. CD4 T-cells that are not lost through the direct effects of HIV infection may 
instead be lost due to the host’s immune response to the infection. This progressive 
CD4 lymphocyte loss is a hallmark of AIDS. 
Infected T-cells are eliminated using some of the host’s innate immune pathways. 
Host cell interferon-γ-inducible protein 16 (IFI16) detects a build-up of viral transcripts 
inside the abortively infected cell, activating an inflammatory cascade within the cell 
(inducing interferon-β) which goes on to activate pyroptosis - the host cell self-
destructs because of an inflammatory environment (Monroe et al., 2014). 
IFI16 activates caspase-1, which stimulates production of interleukin-1β. Inside the 
cell, IL-1β creates an inflammatory environment, which triggers pyroptosis (Man et 
al., 2017). Pyroptosis is caspase-1 dependent (Doitsh et al., 2014). IL-1β gets 
exposed to other neighbouring CD4 cells, undergoing pyroptosis as well and creating 
a chain reaction of CD4 cell loss. All of this propels a vicious cycle of chronic 
inflammation because of the proinflammatory signals that are being released which 
keep activating the host immune cells, leading to more cell death. 
CD4 lymphocyte death following HIV infection can also be mediated through a 
different pathway. When integrase tries to integrate the viral cDNA into the host cell 
nuclear genome it creates DNA nicks to help with insertion. Host cell DNA-PK senses 
DNA breaks, triggering apoptosis (Cooper et al., 2013). Apoptosis is very similar to 
pyroptosis, but pyroptosis is triggered by inflammation whereas apoptosis is triggered 
by damage signalling. If integrase succeeds and the cell produces virions, when HIV 
protease cleaves the viral precursors it can also cleave and activate other proteins 
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called caspase-3 and caspase-8, which will again trigger apoptosis. CD8 T-cells 
detect infected CD4 cells because these show viral surface proteins, they destroy 
them. 
However, the majority of CD4 T-cell death is of uninfected ‘bystander’ cells, which 
leads to immune system failure (Holm and Gabuzda, 2005; Garg et al., 2012; Garg 
and Joshi, 2017). When T-cells become exposed to HIV, even if they do not become 
infected by it, they display antigens in their surface, which are detected by dendritic 
cells transporting them to the lymph nodes. So uninfected T-cells that have ‘seen’ 
HIV will gather in lymph nodes. Within lymph tissues, pyroptosis will occur again, 
driven by endogenous inflammation. 
This ‘bystander’ CD4 cell death was seen to be prevented by entry inhibitors, fusion 
inhibitors and NNRTIs, but not by the NRTI AZT (Doitsh and Greene, 2016); 
suggesting that elongation during reverse transcription is needed for the cell death 
events. Despite these recent findings, they do not fully explain why some HIV 
patients in ART still display persistent chronic inflammation. Additional important 
factors driving chronic inflammation in treated HIV include the presence of co-
infections such as CMV (cytomegalovirus), as well as lifestyle factors. 
Chronic immune activation and inflammation, leading to immune senescence is likely 
to be a major contributor to the age-related diseases that have been observed in HIV 




1.12 HIV and neurocognitive disorders 
Neurocognitive impairment (NCI) associated with HIV continues to be present in the 
HIV-infected population despite the widespread use of HAART. This excess of NCI is 
seen even when controlled for other comorbidities. A severe form of HIV-associated 
neurocognitive disorders (HAND), known as HIV-associated dementia (HAD), is less 
prevalent now owing to HAART, however mild and heterogeneous impairment, which 
include subclinical neuropsychological impairment (ANI) and mild cognitive motor 
disorder (MCI), are still persistent in up to one-half of people living with HIV (PLWH) 
in the US population, according to the CHARTER study (Heaton et al., 2010; Heaton 
et al., 2015). Recent European data, e.g. from the COBRA study, suggested lower 
rates than reported in the US data (Cole et al., 2018; De Francesco et al., 2018). The 
pattern of neurocognitive impairments in PLWH now more closely resembles that 
seen in other common neurodegenerative disorders, rather than that seen in HAD. 
The exact mechanisms whereby HIV causes NCI are not fully understood but are 
likely to be multifactorial, slowly changing and may plausibly include a strong ‘legacy’ 
effect of neuronal damage prior to initiation of HAART. The main current hypothesis 
is that persistent low-grade inflammation from monocytes and macrophages, 
vascular disease and microglial activation play a key role in causing HAND, even 
within the setting of successful HAART. Recently, it has become increasingly evident 
that impaired CNS function is linked to monocytic infection with HIV (Burdo et al., 
2013; McGuire et al., 2015).  
HIV infects and depletes CD4+ T lymphocytes, along with macrophages and 
dendritic cells. Many studies have reported the role of tissue macrophages acting as 
reservoir for HIV virus (Igarashi et al., 2001; Groot et al., 2008; Coleman and Wu, 
2009; Koppensteiner et al., 2012; Malim and Bieniasz, 2012; Abbas et al., 2015). 
Similarly, microglial cells, a type of macrophage resident in the brain, express 
receptors linked to HIV tropism including CD4, CCR5, CXCR4 and CCR3 (Ghorpade 
et al., 1998; Albright et al., 1999). Microglia are therefore susceptible to HIV infection 
and spread (Cenker et al., 2017), and are believed to be infected at a very early 
stage of the disease (An et al., 1999). Microglia are long-lived cells which, due to the 
continuous cell division they are subject to, may provide an archive of HIV virus and 
therefore a persistent reservoir in the brain. Thus, viral reservoirs of latent and active 
infections present a challenge to antiretroviral therapy (Schnell et al., 2011; Joseph et 
al., 2015). Moreover, there is wide variability of ART penetrance across the blood-
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brain barrier into the CNS. This effect has been quantified using the CNS 
penetration-effectiveness rank (CPE) (Letendre et al., 2008). However such model 
has not proven consistent yet in improving treatment in HAND (Baker et al., 2015). 
Brains of HAND patients have displayed neuronal mitochondria with aberrant 
morphology compared to HIV-infected but not cognitively impaired peers (Avdoshina 
et al., 2016; Fields et al., 2016). Neurons are high energy demanding cells, 
containing large quantities of mitochondria per cell. Mitochondria in neurons provide 
ATP to axonal and dendritic terminals for healthy synapses and maintenance of 
energy homeostasis. Thus, neuronal dysfunction and neuronal loss are often 
associated with changes in mtDNA. In keeping with this hypothesis, in vitro studies 
have shown that HIV proteins may exhibit direct neurotoxicity associated with 
mitochondrial dysfunction. In particular, the viral envelope protein gp120 triggers 
neurotoxic pathways that lead to altered neuronal mitochondrial dynamics and 
function (Avdoshina et al., 2016). HIV gp120 and HIV trans-activator of transcription 
(tat) are known to induce HIV-related neurotoxicity, and mitochondrial dysfunction by 
impairing neuronal mitophagy in human primary neurons (Teodorof-Diedrich and 
Spector, 2018). Tat has also been reported to increase mitochondrial fission in 
neurons (Rozzi et al., 2018). These alterations are believed to elicit HIV-mediated 
neurodegeneration. Neurons are likely to be exposed to such viral proteins owing to 
the productive infection of adjacent glial cells. HIV does not infect primary neurons 
but does infect glial cells (also called neuroglia) including astrocytes. However, viral 
proteins like gp120 and tat do penetrate neurons in vitro and could therefore trigger 
molecular events to potentially cause neurocognitive impairment. HIV gp120 has also 
been found to induce apoptosis in in vitro human primary neurons and has been 
linked to HAD pathogenesis (Jana and Pahan, 2004). Gp120 not only has been 
observed to cause cell death in some types of neurons in vitro (Dawson et al., 1993), 
but also in vivo in brains from rodents (Bansal et al., 2000). Altogether these 
inflammatory factors have been proposed to contribute in the environment causing 
neuronal injury in HAND (Figure 1.8). 
The possible role of ART in causing neurotoxicity, including by a mitochondrial 
mechanism was reported in some studies. Particularly, NRTI-associated peripheral 
neuropathy in HIV patients has been associated with mitochondrial toxicity (Moyle 
and Sadler, 1998; Dalakas, 2001; Dalakas et al., 2001; Kallianpur and Hulgan, 2009; 




Figure 1.8. Neuropathogenic factors contributing to HIV-associated neurocognitive 
disorders. Infected macrophages and microglial cells release neurotoxic viral proteins 
that contribute to the activation of astrocytes and subsequent inflammation of the 
environment leading to neuronal injury. Image taken from (Saylor et al., 2016). 
 
Optimal markers for HAND remain poorly defined, but have been recently reviewed 
elsewhere (Clifford and Ances, 2013; Clifford, 2017). Given the fact that thanks to 
ART HIV-infected individuals now live longer and have an increased burden of 
comorbidities, it is therefore more difficult to diagnose NCI that is truly HIV-related 
and not from age-associated neurocognitive disorders in this population. Current 
evaluation and management guidelines used in HAND patients show convergence in 
that NCI assessment should be performed only in symptomatic cases (Underwood 




1.13 Research Aims 
The hypothesis was that mtDNA mutations are a mediator of ageing in HIV, by clonal 
expansion of mtDNA mutations leading to accelerated physiological decline. 
The aims of the project were: 
1) To develop a model of clonal expansion of mtDNA mutations in ageing. 
2) To determine whether NRTI therapy accelerates clonal expansion. 
3) To determine whether mtDNA damage contributes to the pathogenesis of HAND. 
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Chapter 2. Methods 
2.1 Ethical guidelines 
The human study was approved by the ‘Newcastle and North Tyneside 2 Research 
Ethics Committee’ (reference 17/NE/0015). 
The mouse study was carried out under the Project Licence Number 70/8623. My 
personal licence (PIL) number was I7CC5B565. 
 
2.2 PolgA mouse model 
2.2.1 Breeding and husbandry 
PolgAwt/mut mice were originally provided as a kind gift from Dr Michael Keogh 
(Newcastle University) and bred back to a C57BL/6J (B6, Charles River Laboratories) 
nuclear background as further explained in Chapter 4. C57BL/6J mice are the most 
widely used inbred strain, with minimal genetic drift, most well characterised and the 
first one to be sequenced. C57BL/6J, also known as black 6 mice, were used as a 
background strain for the generation of the PolgA WtN+ mouse model. The WtN+ 
derivative of the PolgA mutator mouse contained a germline mtDNA mutational burst 
on a wild-type inbred nuclear background; this clonal expansion mouse model was 
named ‘WtN+’ and is hereafter referred to as such in this thesis.  
Mice were maintained on 12-hour light/dark cycles with ad libitum access to filtered 
water and normal mouse pellet diet. Mice were allocated into two study plans 
according to Home Office regulations, the methods described in this thesis were 
performed according to the relevant guidelines provided by the Project Licence 
regulations (see Appendix 10.3 for study plan details and Appendix 10.4 for the 





Genotyping was carried out at weaning time, at 4 weeks old. Mice were genotyped 
as follows. QIAamp DNA Mini Kit (Qiagen) was used to extract total DNA from 
clipped ear tissue, as per manufacturer’s guidelines. For the final elution stage, 200 
µl Buffer AE were added to the centre of the membrane and allowed to incubate at 
room temperature for five minutes before centrifugation at full speed for one minute. 
DNA samples were stored in the -20°C freezer and used in subsequent analysis 
described in this thesis. The primer sequences used to genotype the mice are, 
CTTCGGAAGAGCAGTCGGGTG for the forward primer and 
GGGCTGCAAAGACTCCGAAGG for the reverse. Primers for genotyping annealed 
to the PolgA gene in chromosome 7. PCR reactions were performed in a 19 μl 
master mix containing nuclease-free H2O, 1X Green GoTaq Reaction Buffer 
(Promega), 0.2 mM dNTP Mixture, forward and reverse primers (0.4 μM each), 0.25 
U GoTaq DNA Polymerase to which was added 1 μl of DNA sample. Reactions were 
run on an Applied Biosystems® Veriti® 96 well thermal cycler (Thermo Fisher 
Scientific). PCR conditions consisted of one cycle at 94°C for 60 seconds; then 30 
cycles of 94°C for 30 seconds, 60°C for 30 seconds, 72°C for 60 seconds; ending 
with 72°C for 3 minutes. Products were analysed on 1% agarose gel at 75V for 30 
minutes. PolgAwt/wt is identified by a single 520 bp band while PolgAmut/mut is identified 
by a single 720 bp band size. For heterozygous PolgAwt/mut mice two bands at 520 bp 
and 720 bp were expected to be present as they have two alleles (Figure 2.1). 
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Figure 2.1. Agarose gel analysis of genotyping products of two mice brothers. Two 
bands (520 bp and 720 bp) are present for the first sample, heterozygous. One band 
(520 bp) is present for the second sample, wild-type. GeneRuler 1 kb Plus DNA 
Ladder SM1333 (Thermo Fisher Scientific) was loaded in the first lane. 
 
2.2.3 Phenotypic testing 
Mice were observed and clinically scored, blind to genotype and treatment, on a 
weekly basis. Phenotyping was carried out at 35 and 47 weeks of age (and 18 weeks 
for the clinical score values). Frequencies of interim measurements were subjected to 
change if weekly observation of mice suggested any problems. All phenotyping was 
done by a single female observer to minimise the effects of animal stress on the 
measurements. 
 
2.2.4 Clinical scoring 
Clinical scores were collected and registered for the defined criteria in the printed 
sheets in Appendix 10.1. A clinical score sheet was available to guide the scoring of 
the animals (Appendix 10.2). Scores included weight, appearance of the coat, skin 
tone, behaviour, posture and mobility, abdominal distension, foot colour and faeces. 
The animal had to be culled if: it had three separate scores of 2; it had a single score 
of 3; there was over 20% weight loss; there was persistent temperature below 33°C 
(if the temperature was low, animal was monitored a few times at 5 minute intervals 
to see if it recovered. Normally the scores are well correlated with the temperature. 
Low temperatures are only a concern if they are scoring considerably high as well). 
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Following our study plan guidelines, due to their genotype WtN+ animals had to be 
clinically scored once a week whereas wild-type animals were allowed to be scored 
at the established weeks (18, 35 and 47). 
 
2.2.5 Open field tests 
Mice in their home cages were first allowed 10 minutes to acclimatise to the room. 
Open field tests were carried out using a computer application called MouseTrapp 
(Neurolytical) (Mabrouk et al., 2014) on a touch-screen tablet inside a white acrylic 
box with a specially cut slot for the tablet to slide into the bottom. Tablet was placed 
in the slot at the bottom of the opaque-walled test chamber, ensuring that the down 
arrow on the bottom left hand side was still exposed as this was used to stop 
recording the data at the end of the test. The mouse was gently placed in the centre 
of the 13.5 x 22 cm tablet surface and timed for 6 minutes after MouseTrapp was 
started. A clear plastic lid was used to cover the chamber. The observer stepped 
away from the cage to avoid looking inside and distracting the animal, which was 
allowed to ambulate freely. The open field test generated general locomotor activity 
data. For each session, a spreadsheet was automatically generated containing the 
number of steps the animal made, number of rears, distance travelled, length and 
velocity of each step. These features were important for assessing both the quality 
and quantity of animal movement and can be useful in studying animal motor 
function. The tablet and box were both cleaned with a 70% ethanol solution between 
tests in order to hide animal clues. 
 
2.2.6 Metabolic treadmill tests 
A metabolic treadmill test was carried out using the Metabolic Modular Treadmill 
(Columbus Instruments), to determine the consumption and production rates of 
oxygen and carbon dioxide. Only a selected group of representative females were 
chosen for this test (n=5 WtN+ and n=5 wild-type). The metabolic system, Oxymax, 
measured the concentration of these gases by comparing the amount being supplied 
into the treadmill chamber to that of gases leaving the chamber where the animal 
was placed. O2 and CO2 gas sensors were calibrated before the experiment began. 
O2 and CO2 values were adjusted and kept within range throughout the tests. Mice 
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were acclimatised for 15 minutes per day for 4 days prior to this test by being placed 
inside the enclosed motionless treadmill chamber.  
For the experimental observations, mice were placed on the running lane inside the 
sealed chamber making sure they were settled before the experiment began. First, 
mice were rested for 15 minutes before running for 20 minutes at 12 m/min speed on 
the transparent treadmill as shown in Table 2.1. Oxymax software recorded gas 
exchange measures every 30 seconds. Chamber rear bumpers were occasionally 
used to gently push the mice on their hindquarters in case they slid back. The 
animals remained visible and it was ensured they were safe at all times. Each mouse 
performed the test once at each time point.  
Step  Speed (m/min) Ramp (s) Hold (s) 
1 0 0 900 (15 mins) 
2 12 10 1200 (20 mins) 
Table 2.1. Running protocol for the Metabolic Modular Treadmill. Total of 35 minutes, 
5 minutes were allowed for system warm up. Data was collected every 30 seconds, 
as animals rested for the first 15 minutes and then they were ran for 20 minutes. 
 
Once the exercise was over, the treadmill lane was cleaned and brushed with 
disinfectant spray first and then 70% ethanol solution. 
 
2.2.7 Grip strength testing 
Instrument was assembled prior to the performance of the front limbs grip test. 
Animals were held by the first proximal part of the tail and gently placed above the 
grid. The mouse was moved down until its front legs grabbed the grid approximately 
in the middle. While the mouse was grasping, its position was lowered to a horizontal 
position. The animal was pulled following the axis of the sensor until the grasp was 
released. The grip test measurement took 3 seconds from the first grasp to the 
release and the pulling movement was slow but regular. All these steps above were 
performed smoothly without abrupt movement. A constant velocity movement is the 
insurance of repeatable tests. The maximum force developed by the mouse was 
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displayed on the screen. Three repeats were performed per each mouse and values 
were recorded in grams. 
 
2.2.8 Videos 
The selected mice were videoed for 3 minutes after being placed on top of an 
upturned weighing box in a defined square area. Additionally, a brief video was also 
taken of the abdomen to look for abdominal distention, foot colour and detect faeces 
build up. These videos were performed to provide additional validation of the health 




Mice were culled at three time points, 18, 36 and 48 weeks old. A longer time point of 
76 weeks was also taken for a group of WtN+ females. All organs were harvested 
and weights were recorded (Appendix 10.5). Organs were snap-frozen as quickly as 
practicable, certainly within minutes following harvest. This is because basic 
mitochondrial histochemistry requires intact respiratory chain enzyme activities. 
Specimens were used in the following ways: mounted for cryosectioning, formalin 
fixed-paraffin-embedded (FFPE) tissue and stored for nucleic acid extraction. Any 
associated fat from the tissues was dissected out. 
Specimens were mounted for cryosectioning using a sterile dissection kit, aimed to 
dissect two neat cubes of muscle tissue with well-preserved orientation from the 
centre of the specimen, each of 5-10 mm in each dimension. Skeletal muscle from 
mouse quadriceps was transversely oriented and mounted onto a strip of filter paper 
(Whatman) using a thin layer of OCT cryo-embedding matrix. Samples were snap-
frozen by brief immersion in liquid-phase isopentane, cooled in liquid nitrogen (-
160°C) and then transferred the mounted specimen into a specimen bag (pre-cooled 
in liquid nitrogen), sealed and placed in liquid nitrogen pending transfer to -80°C 
freezer for storage. Other tissues were snap-frozen in liquid nitrogen, then stored at -
80°C.  
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FFPE tissue blocks were fixed in formalin for 24 hours and then the solution was 
changed to freshly made 70% ethanol, before being sent to the biobank for 
embedding of the FFPE tissue blocks. 
 
2.3 DNA extraction from human tissues 
2.3.1 Homogenisation and DNA purification from frozen human brain tissue 
DNA from frozen human frontal cortex (grey matter) was either supplied as DNA 
extract by the biobanks, or extracted locally using commercial kits according to 
standard manufacturer’s methods. Brain tissue from HIV positive subjects was 
processed in the Containment Level 3 laboratory. 
The biobanks included TNRC (Texas Repository for AIDS Neuropathogenesis 
Research), CNTN (California NeuroAIDS Tissue Network), UCLA (National 
Neurological AIDS Bank, NNAB), Manhattan HIV Brain Bank (MHBB) and Edinburgh 
biobank. 
DNA concentration was quantified using the Nanodrop ND-1000 Spectrophotometer 
(Labtech International). 
 
2.4 DNA extraction from mouse tissues 
2.4.1 Homogenisation of frozen mouse skeletal muscle and mouse colon 
A maximum of 25 mg of frozen tissue was used for each sample. Skeletal muscle 
was placed in a porcelain mortar, chilled with liquid nitrogen and manually ground 
with a porcelain pestle until powdered. Liquid nitrogen was used to keep the samples 
and instruments cool at all times. Powdered tissue was carefully transferred into a 
1.5 ml microcentrifuge tube. In between stages of this process, skeletal muscle tissue 
samples were kept in liquid nitrogen. 
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2.4.2 Homogenisation of frozen mouse brain 
Frozen mouse brain was placed in a petri dish kept on dry ice in order to keep the 
sample frozen. Tissue from the frontal pole area was shaved using a sterile chilled 
scalpel and carefully transferred into a 1.5 ml microcentrifuge tube.   
  
2.4.3 DNA purification from frozen mouse skeletal muscle, brain and colon 
DNA isolation from homogenised skeletal muscle, colon and brain samples was 
performed using a QIAamp DNA Mini Kit (Qiagen) according to the manufacturer’s 
guidelines as outlined in the ‘DNA Purification from Tissues’ protocol in the QIAamp 
DNA Mini and Blood Mini Handbook (05/2016). For the final elution stage, 200 µl 
Buffer AE were added to the centre of the membrane and allowed to incubate at 
room temperature for five minutes before centrifugation at full speed for one minute. 
DNA concentration was quantified using the Nanodrop ND-1000 Spectrophotometer. 
 
2.5 Quantitative PCR to Measure Mitochondrial DNA Copy Number and 
Common Deletion Levels in Human Tissue 
In order to measure mitochondrial DNA copy number (CN) in human homogenate 
tissue, a quantitative real-time PCR (qPCR) assay was used. The nuclear-encoded 
housekeeping gene Beta-2-microglobulin (B2M, Genbank accession ID: NM_004048, 
NG_012920.2 Chromosome 15) and the mitochondrially encoded NADH-ubiquinone 
oxidoreductase core subunit 1 gene (MT-ND1, Genbank accession ID: 
NC_012920.1) were used respectively as nDNA and mtDNA targets.  
 
2.5.1 Mitochondrial DNA m.δ4977 bp common deletion level assay 
The mitochondrial gene MT-ND4 is usually lost during large-scale deletions, which 
involve the major arc of the mitochondrial genome, whilst MT-ND1 remains undeleted 
in the molecule. A triplex MT-ND1/MT-ND4/B2M qPCR assay is used frequently to 
detect deletions (Pyle et al., 2010; Pyle et al., 2015a; Pyle et al., 2016), but it will only 
detect relatively high deletion heteroplasmy levels (≥25%). The m.δ4977 bp 
mitochondrial ‘common deletion’ (CD), flanked by two 13 bp homologous repeat 
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sequences at positions m.8470-8482 and m.13447-13459 (inclusive), removes 
various genes including MT-ND4 as depicted in Figure 2.2. A triplex qPCR assay with 
CD/MT-ND1/B2M amplicons was designed to allow low-level deletion detection 
(down to ~10-4) and is a much more sensitive assay for deletions than the MT-
ND1/MT-ND4/B2M assay. This assay is however specific to the CD, rather than 
detecting all major deletions. 
 
Figure 2.2. Schematic representation of the triplex qPCR assay used to detect the 
mtDNA 4977 bp common deletion. Depicted are the distribution of 13 bp homologous 
repeats for the common deletion (blue), MT-ND1 and MT-ND4 genes (purple and 
yellow respectively), the primers for template amplification (pink) and the primers for 
qPCR amplification (green). Image adapted from (Chen et al., 2011). 
 
The proportional level of mitochondrial DNA molecules containing the m.δ4977 bp 
common deletion was quantified as previously done in our group (Samuels et al., 
2017) but the nuclear gene B2M was added to create a triplex real-time qPCR assay 
(CD/MT-ND1/B2M genes) so that mtDNA CN and CD levels could be calculated at 
the same time. The level of CD per mtDNA copy per cell was determined by 
comparison with the copy number of the MT-ND1 gene (further explained in Section 
2.5.7). The results were expressed on a logarithmic scale in line with the observed 




2.5.2 Preparation of reagents 
All stock primers and probes (IDT) used in real time qPCRs were resuspended using 
Ambion® nuclease-free water (ThermoFisher Scientific) under the UV sterilizing PCR 
cabinet (UVP) to obtain working concentrations of 10 μM and stored at -20°C. All 
PCR reactions were set up on ice. 
 
2.5.3 Generation of qPCR standard templates 
Quantitative standards for the triplex CD/MT-ND1/B2M qPCR assay were prepared 
by PCR generated templates. 
The MT-ND1 and B2M standards were generated using a control DNA sample. The 
qPCR CD standard was generated using a DNA sample from a patient with 
progressive external ophthalmoplegia (PEO), kindly provided by Professor Rob 
Taylor (Newcastle University), with a known level of the δ4977 mtDNA common 
deletion. Primer sequences for the generation of the ND1, B2M and CD template are 
in Table 2.2. 
 
Table 2.2. Primers used to generate standard templates using PCR for the human 
triplex qPCR assay. 
 
PCR reactions were performed in a 24 μl PCR master mix containing: 1X MyTaq™ 
Reaction Buffer (includes dNTPs, MgCl2 stabilizers and enhancers), one unit of 
MyTaq™ HS DNA Polymerase (Bioline), 400 nM of each forward and reverse 
primers and dH2O. Approximately 30 ng of DNA was loaded into each reaction well of 
0.2 ml 8-Strip PCR tubes (StarLab) and run on an Applied Biosystems® Veriti® 96 
well thermal cycler (ThermoFisher Scientific). PCR conditions consisted of an initial 
denaturation at 95°C for one minute, followed by 30 cycles of denaturation at 95°C 
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for 15 seconds, annealing at 61°C (for MT-ND1 and B2M genes) or 58°C (for CD 
template) for 15 seconds, extension at 72°C for 10 seconds.  
 
2.5.4 Agarose gel electrophoresis 
Amplified template PCR products (n=12) were pooled and mixed with Orange G 
loading buffer (50% glycerol, Orange G powder (Sigma Aldrich Company Ltd) and 
50% water) and loaded into a single large well on a 1% agarose gel (1 g agarose 
(Bioline) in 100 ml 1X TAE buffer, and 0.4 mg/μl UltraPure™ ethidium bromide 
(Invitrogen)). GeneRuler 1 kb Plus DNA Ladder (ThermoFisher Scientific) and a 
negative PCR product used as a negative control were also mixed with Orange G 
dye and loaded into single separate wells. Agarose gels were electrophoresed at 75 
V for one hour in 1X TAE buffer. 
 
2.5.5 Purification and quantification of standard templates 
Agarose gels were imaged using the UVP GelDoc-It™ imaging system (UVP). The 
gel-extracted fragment was extracted using the QIAquick gel extraction kit (Qiagen), 
as per manufacturer guidelines. Template concentrations were measured using the 
Nanodrop ND-1000 Spectrophotometer. Template DNA copy number concentrations 
were calculated using Equation 2.1. All template DNA was multiplexed together to 
obtain a starting copy number each of a 1010 ng/µl, which was then diluted 1:10 to 
obtain a 109 ng/µl stock to be stored at -20°C until required. 
 
Equation 2.1. Formula used to calculate starting mitochondrial DNA copy number 
(copies/µl). C is DNA concentration in nanolitres (10-9), L is amplicon length in base 




2.5.6 Quantitative PCR for mtDNA copy number quantification 
All qPCR reaction plates were set up in a UV hood to minimise DNA contamination. 
The multiplexed 109 ng/µl DNA standards were diluted in a tenfold serial dilution of 
1x108 to 1x102 ng/µl. The triplex qPCR mastermix was prepared in an 18 μl reaction 
volume containing 1X iTaq™ Universal Probes Supermix (Bio-Rad), 300 nM of each 
forward and reverse B2M and CD primers, 75 nM of each forward and reverse MT-
ND1 primers, 200 nM of each TaqMan™ probe and dH2O; with 2 µl of standard or 
DNA sample, loaded into a Hard-Shell 96-well PCR plate (Bio-Rad) covered with a 
Microseal® ‘B’ adhesive sealing film (Bio-Rad) to seal the plate. The qPCR 
amplification primers and Taqman™ probe sequences are found in Table 2.3 and 
Table 2.4, respectively.  
 
Table 2.3. Primers for the qPCR amplification of mitochondrial and nuclear genes 
used in the δ4977 mtDNA common deletion quantification and copy number assay. 
Primers from Integrated DNA Technologies. 
 
All DNA standards were measured in duplicate and controls and DNA samples in 
triplicate on a CFX96 Touch™ Real-Time PCR detection system (Bio-Rad). The 
qPCR conditions were: initial denaturation at 95°C for three minutes; followed by 40 
cycles of: denaturation at 95°C for 10 seconds, followed by annealing and extension 
at 62°C for one minute. 
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Table 2.4. Taqman™ probes for the triplex qPCR assay. MT-ND1 gene was labelled 
with fluorescent HEX dye. Common deletion was labelled with fluorescent Cy5 dye. 
B2M was labelled with fluorescent FAM dye. Probes synthesised by Integrated DNA 
Technologies. 
 
The CD probe was designed using Primer3 software online and it sits on the repeat 
region of the common deletion. All primers were screened using Primer-BLAST to 
confirm no nuclear gene homology (Ye et al., 2012). 
 
2.5.7 Determining mtDNA copy number and common deletion level in 
homogenate tissue 
Analysis of the qPCR data was performed using Bio-Rad CFX manager 3.1 software. 
For each fluorophore, sample replicates with greater than 0.5 Ct standard deviation 
were removed from analysis and repeated in the following plate run. Control DNA 
samples were used in every plate to assess their Ct values were consistent 
throughout the consecutive plate runs. Intercept and slope values were averaged for 
every fluorophore (HEX, FAM and Cy5) across all qPCR plates in order to correct the 
starting quantity (SQ) data generated from the standard curve analysis. Standard 
curves were only acceptable when negative control contamination was above 35 Ct 
values and when efficiencies were greater than 85%. Raw data was exported into 
Microsoft Excel. MtDNA copy number was calculated as an average of each 
individual sample replicate Ct value, using Equation 2.2, and is reported in this thesis 
as copies per cell (copies/cell). 
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Equation 2.2. Calculation for mtDNA copy number using SQ mean values generated 
from Ct data using standard curves. 
 
Common deletion level was calculated using Equation 2.3 and is reported in this 
thesis as common deletion per copy of mtDNA genome (CD/mtDNA genome copy). 
 
Equation 2.3. Calculation of common deletion level using SQ mean values generated 
from Ct data using standard curves. 
 
2.6 Quantitative PCR to Measure Mitochondrial DNA Copy Number in Mouse 
Tissues 
In order to measure mitochondrial DNA copy number in mouse homogenate tissue, a 
quantitative PCR assay was used. The nuclear-encoded housekeeping gene Beta-
Actin (β-Actin) was used as the nuclear reference gene (Genbank accession ID: 
NC_000071.6, Chromosome 5) and the mitochondrially encoded NADH-ubiquinone 
oxidoreductase core subunit 5 gene (MT-ND5) (Genbank accession ID: 
NC_005089.1) was used as the mtDNA molecule reference. Reagents were 




2.6.1 Generation of qPCR standard templates 
Quantitative standards for the duplex MT-ND5/β-Actin qPCR assay were prepared by 
PCR generated templates. The following steps for this protocol were carried out in a 
UV hood to minimise DNA contamination. Primer sequences for the generation of 
qPCR templates can be found in Table 2.5. 
 
Table 2.5. Primers used to generate standard templates using PCR for the mouse 
duplex qPCR assay. Primers from IDT. 
 
All PCR reactions were set up on ice. PCR reactions were performed in a 24 μl PCR 
master mix containing: 1X ImmoBuffer (Bioline), one unit of Immolase DNA 
Polymerase (Bioline), 4 mM MgCl2, 0.2 mM of dNTPs, 0.3 μM of each forward and 
reverse primers and dH2O. Approximately 20 ng of DNA was loaded into each 
reaction well of 0.2 ml 8-Strip PCR tubes (StarLab) and run on an Applied 
Biosystems® Veriti® 96 well thermal cycler (ThermoFisher Scientific). PCR 
conditions consisted of an initial Hot Start denaturation at 95°C for seven minutes, 
followed by 39 cycles of denaturation at 95°C for one minute, annealing at 55°C (for 
MT-ND5) or 63°C (for β-Actin) for one minute, extension at 72°C for two minutes, 
followed by a final extension step at 72°C for 10 minutes.  
Agarose gels along with purification and quantification of standard templates were 




2.6.2 Quantitative PCR for mtDNA copy number quantification 
The multiplexed 109 ng/µl DNA standards were diluted in a tenfold serial dilution of 
1x108 to 1x102 ng/µl. The duplex qPCR mastermix was prepared in a 18 μl reaction 
volume containing 1X iTaq™ Universal Probes Supermix (Bio-Rad), 300 nM of each 
forward and reverse MT-ND5 and β-Actin primers, 200 nM of each TaqMan™ probe 
and Ambion® nuclease-free water (ThermoFisher Scientic); with 2 µl of standard or 
DNA sample, loaded into a Hard-Shell 96-well PCR plate (Bio-Rad) covered with a 
Microseal® ‘B’ adhesive sealing film (Bio-Rad) to seal the plate. The qPCR 
amplification primers and Taqman™ probe sequences are found in Table 2.6 and 
Table 2.7, respectively.  
 
Table 2.6. Primers for the qPCR amplification of mitochondrial MT-ND5 and nuclear 
β-Actin genes used for the determination of mtDNA copy number in mouse tissues. 
Primers from IDT. 
 
All DNA standards were measured in duplicate and controls and DNA samples in 
triplicate on a CFX96 Touch™ Real-Time PCR detection system (Bio-Rad). The 
qPCR conditions consisted of an initial denaturation at 95°C for three minutes; 
followed by 39 cycles of: denaturation at 95°C for 10 seconds, followed by annealing 
and extension at 58°C for one minute. 
 
Table 2.7. Taqman™ probes for the duplex qPCR assay. MT-ND5 gene was labelled 
with fluorescent HEX dye. β-Actin was labelled with fluorescent FAM dye. Probes 
synthesised by Integrated DNA Technologies. 
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Mitochondrial DNA copy number was determined as described in Section 2.5.7, in 




2.7.1 Cryosectioning and microtome sectioning 
Skeletal muscle sections of 10 µm thickness were cut onto glass slides using the 
Cryo-star HM 560M cryostat which was maintained at -20°C. Skeletal muscle 
sections were left to air dry at room temperature for one hour before storing at -80°C 
until required for further use. After immunofluorescence staining, skeletal muscle 
sections were stored at -20°C. 
Formalin-fixed paraffin-embedded (FFPE) colon blocks were sectioned at 4 µm onto 
glass slides using a microtome. FFPE colon slides were stored in the fridge at 4°C. 
After dewaxing and immunofluorescence staining, FFPE colon slides were kept at -
20°C. 
A 5X TBST solution was freshly prepared on the same day before the 
immunofluorescence protocols began, composed of 2 L of dH2O, 121 g of Trizma® 
base (Sigma-Aldrich), 90 g NaCl (Sigma-Aldrich), 5 ml of Tween20 (Sigma-Aldrich) 
and pH adjusted to 7.6. A 1:5 dilution was performed to obtain 1X TBST working 
buffer. 
 
2.7.2 Quadruple immunofluorescence for mouse skeletal muscle 
Sections cut 10 µm thick were removed from the -80°C freezer and allowed to air dry 
for one hour before encircling each section using a hydrophobic pen. Sections were 
fixed in 10% formalin for ten minutes at room temperature in the fume hood followed 
by three five minute washes with 1X TBST. Sections were permeabilized in a 
gradient of freshly made methanol; 70% for ten minutes, 95% for ten minutes, 100% 
for twenty minutes, 95% for ten minutes and 70% for ten minutes before another 
three five minute washes with 1X TBST. Sections were protein blocked for one hour 
at room temperature with 10% normal goat serum (diluted in 1X TBST). Slides were 
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washed in 1X TBST for five minutes while M.O.M™ (mouse on mouse) working 
solutions were prepared. The M.O.M™ (Vector® Laboratories) Immunodetection kit 
was used to localize mouse primary antibodies on mouse tissues and reduce 
background staining caused by the presence of endogenous mouse IgG in the tissue 
section. The M.O.M™ Mouse IgG Blocking Reagent was prepared by adding two 
drops of stock solution to every 2.5 ml of 1X TBST. The M.O.M™ diluent was 
prepared by adding 600 µl of M.O.M™ Protein Concentrate stock solution to every 
7.5 ml of 1X TBST. Sections were incubated for one hour at room temperature in 100 
µl of the working solution of M.O.M™ Mouse IgG Blocking Reagent prepared as 
described. After that, a five minute wash with 1X TBST was performed before 
incubating the slides for five minutes at room temperature in 100 µl of the working 
solution of M.O.M™ diluent prepared as described. Slides were then washed for five 
minutes with 1X TBST. Approximately 100 µl of primary antibody cocktail diluted in 
M.O.M™ diluent was then applied to the OXPHOS sections from each sample and a 
no primary control (NPC) cocktail consisting of only laminin (muscle fibre boundary 
marker) antibody with M.O.M™ diluent was applied to the corresponding NPC 
sections. Primary antibody concentrations can be found at Table 2.8. Covered 
sections were incubated in a humidified chamber at 4°C overnight. The following day, 
slides were washed for two ten minute washes in 1X TBST on a shaking platform at 
70 rpm. Approximately 100 µl of the secondary antibody cocktail was applied to all 
the sections, NPC and OXPHOS, and incubated in a humidified and dark chamber at 
4°C for two hours. Secondary antibody concentrations can be found at Table 2.8. 
Sections were washed for two ten minute washes in 1X TBST on a shaking platform 
at 70 rpm. Sections were covered with approximately 100 µl of streptavidin 
conjugated secondary antibody (Alexa647) and incubated in a humidified and dark 
chamber for two hours at 4°C. Sections were washed for two ten minute washes in 
1X TBST on a shaking platform at 70 rpm. Sections were then mounted in ProLong® 




Table 2.8. Primary and secondary antibodies used for quadruple 
immunofluorescence in mouse skeletal muscle sections. Information regarding 




2.7.3 Fluorescence microscopy for mouse skeletal muscle 
Fluorescent images were captured at 20x magnification using the Celldiscoverer 7 
widefield fluorescence microscope (ZEISS) containing filter cubes for the following 
wavelengths: 405, 488, 546 and 647nm. ZEN blue software was used to capture 
images. Exposure times were set for each channel to reduce background 
fluorescence and avoid over exposure before starting the image acquisition. Full 
skeletal muscle OXPHOS and NPC sections were scanned and tiled using the 
channel 405, laminin, as a reference. Tiled images were stitched and saved as a .czi 
file for image analysis. Snaps at 20x magnification were also taken for illustrative 
examples for publication. 
Mean fluorescent intensities were quantified for each channel using an in-house 
analysis software coded for by MatLab 2015a for skeletal muscle fibres. Membrane 
marker laminin (405nm channel) was used to isolate individual fibres automatically. 
Any unwanted areas including folded tissue, fibres containing freezing artifacts or 
those over background were removed manually. The mean optical density (OD) for 
the 488, 546 and 649 channels was automatically measured in each individual fibre.  
 
2.7.4 Quadruple immunofluorescence for mouse colon  
FFPE sections cut 4 µM thick were incubated in a 37°C oven for five days. Slides 
were labelled accordingly and incubated in a 60°C oven for 45 minutes. Antigen 
retrieval buffer was prepared (EDTA pH 8.0, 0.416g per 500 ml dH2O). Slides were 
deparaffinised and rehydrated through an alcohol series; 100% EtOH 1 (5 minutes), 
100% EtOH 2 (5 minutes), 95% EtOH (5 minutes), 70% EtOH (5 minutes) and placed 
in dH2O for 5 minutes. Antigen retrieval was carried out using a pressure cooker for 
40 minutes. Sections were transferred to dH2O quickly to prevent the sections from 
drying before three five minute washes in 1X TBST. Each section was encircled 
using a hydrophobic pen. Sections were blocked with 10% NGS in 1X TBST for one 
hour at room temperature. About 100 µl of primary antibody cocktail was then applied 
to the OXPHOS sections from each sample and 10% NGS was applied to the 
corresponding NPC sections. Primary antibody concentrations can be found at Table 
2.9. Covered sections were incubated in a humidified chamber at 4°C overnight. 
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Table 2.9. Primary and secondary antibodies used for quadruple 
immunofluorescence in mouse colon sections. Information regarding dilution factor 




The following day, sections were washed for two ten minute washes in 1X TBST on a 
shaking platform at 70 rpm. If slides were stained for complex I and III then a biotin 
labelled secondary antibody diluted in 10% NGS was applied and sections incubated 
for two hours at room temperature. Sections were washed for two ten minute washes 
in 1X TBST. About 100 µl of the secondary antibody cocktail was applied to all the 
sections, NPC and OXPHOS, and incubated at 4°C for two hours. Secondary 
antibody concentrations can be found at Table 2.9. Sections were washed for two ten 
minute washes in 1X TBST. Hoechst was added to all the sections as a nuclear 
counterstain and incubated in the dark at room temperature for 15 minutes. Sections 
were washed for two ten minute washes in 1X TBST. Sections were then mounted in 
ProLong® Gold Antifade Mountant (ThermoFisher), left to air dry overnight and 
stored in the -20°C freezer. 
 
2.7.5 Confocal microscopy for mouse colon 
Images were captured using the Nikon A1 upright confocal microscope containing 
filters for the following wavelengths: 405, 488, 546 and 647nm. Nikon NIS-Elements 
software was used to capture images. For the NPC sections, one image was 
captured using the 20x objective and for the OXPHOS sections, five representative 
images across the whole section were captured using the 20x objective. 
Fluorescence in the 405nm channel was used to define the nuclear boundary of the 
colonic crypts and thus to identify them during analysis. ImageJ Fiji software 
(Schindelin et al., 2012) was used to manually circle individual colonic crypts and 




2.7.6 Quantitative immunofluorescence 
Quadruple immunofluorescence data generated from skeletal muscle fibres and 
colonic crypts was analysed using an R script written by Dr John Grady (Newcastle 
University). Values for each channel were corrected for non-specific background by 
subtracting the OD in the NPC from those generated from the OXPHOS labelled 
section. Values obtained were log transformed. Z-scores were generated for each 
channel, using the mitochondrial mass marker levels of VDAC (for fibres) or 
TOMM20 (for colonic crypts) to normalise the values.  
Fibres and colonic crypts were classified as normal (z>-3), intermediate positive (z 
from -3 to -4.5), intermediate negative (z from -4.5 to -6) or negative/deficient (z<-6) 
for each protein i.e., complex I, III, IV and V for colonic crypts, and complex I and IV 
for fibres. Fibres (VDAC) and colonic crypts (TOMM20) were also classified by levels 
of mitochondrial mass markers as very low, low, normal, high or very high. Z-plots 
were then produced. This protocol has been validated for skeletal muscle by 
members of our lab (Rocha et al., 2015). 
 
2.8 Laser microdissection of single cells 
Individual cells were captured by laser microdissection using a Zeiss Laser Capture 
Microdissection microscope with Palm Robo v4.6 using the Closecut + AutoLPC 
function for glass slides. Cut settings were as follows: energy = 46 and focus = 74 
and the LPC settings were: energy = 15 and delta = 5. Two 0.2 ml eppendorfs were 
inserted in the TubeCollector and 15 µl of lysis buffer was added to each cap. 
Eppendorfs were kept on ice, prior to being quickly centrifuged to bring the tube 
contents to the bottom before incubating. 
 
2.8.1 Single cell lysis buffer 
Lysis buffer was made up of 0.5 M Tris-Hcl, 0.5% Tween 20 and 1% Proteinase K 
immediately before the laser microdissection experiment and kept on ice. Captured 
cells in 15 µl of lysis buffer were quickly centrifuged and incubated at 55°C for 16 
hours (Liu, 2010), followed by 10 minutes at 95°C. Lysates were stored at -20°C. 
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2.9 Mitochondrial DNA enrichment for Next Generation Sequencing 
The entire mitochondrial genome was enriched before being deep-sequenced using 
Illumina MiSeq. Two overlapping primer sets were used to amplify the mtDNA by 
long-range PCR, in both human and mouse mtDNA.  
 
2.9.1 Long-Range PCR and agarose gel electrophoresis 
Human mitochondrial DNA was enriched using long-range PCR (LR-PCR). Two 
overlapping amplicons covering the entire human mtDNA were amplified using two 
primer sets as previously described by members of our lab (Coxhead et al., 2016). 
Long-range PCR reactions were performed in a 24 μl master mix containing 
nuclease-free H2O, 1X Takara PrimeSTAR GXL Buffer (Mg2+ plus), 0.2 mM dNTP 
Mixture, forward and reverse primers (0.2 μM each), 0.625 U Takara PrimeSTAR 
GXL DNA Polymerase (Takara Bio Company) and 1 μl of DNA sample. Reactions 
were run on an Applied Biosystems® Veriti® 96 well thermal cycler (Thermo Fisher 
Scientific).  
PCR conditions consisted of an initial denaturation at 94°C for one minute, followed 
by 35 cycles of denaturation at 98°C for 10 seconds, annealing at 60°C for 15 
seconds and extension at 68°C for 10 minutes, and one with a final extension step at 
72°C for 10 minutes. LR-PCR primer sequences can be found in Table 2.10. 
 
Table 2.10. Forward and reverse primer sequences and product sizes covering the 
entire human mitochondrial genome for enrichment prior to next generation 




Fragment 1 spanned from position m.6222 to m.16133 and fragment 2 from m.15295 
and m.7773, mapped in Figure 2.3. 
 
Figure 2.3. Schematic of the human mitochondrial genome, mapped with the two 
overlapping fragments used for amplification. Numbers indicate the primer base pair 
positions. (F) indicates binding position for the forward primer and (R) for reverse. 
 
Long-range PCR reactions for mouse mtDNA amplicons were performed as 
described above for human. For mouse mtDNA, PCR conditions consisted of an 
initial denaturation at 98°C for 30 seconds, followed by 35 cycles of denaturation at 
98°C for 30 seconds, annealing at 54°C (fragment 1) or 50°C (fragment 2) for 30 
seconds and extension at 68°C for 12 minutes, and one with a final extension step at 
72°C for 10 minutes.  
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Two sets of overlapping primers were used to cover the entire mouse mitochondrial 
genome using LR-PCR. Mouse LR-PCR primer sequences can be found in Table 
2.11. 
 
Table 2.11. Primer sequences and product sizes for the LR-PCR amplification of 
mouse mitochondrial genome used for next generation sequencing. Primers from 
IDT. 
 
Fragment 1 spanned from position m.1628 to m.10737 and fragment 2 from 
m.10059-m.2315, mapped in Figure 2.4. 
 
Figure 2.4. Schematic of the mouse mitochondrial genome, mapped with the two 
overlapping fragments used for amplification. Numbers indicate the primer base pair 
positions. (F) indicates binding position for the forward primer and (R) for the reverse 
primer. 
 
Products were analysed on a 0.8% agarose gel containing SYBR Safe DNA Gel 
Stain (Thermo Fisher Scientific) at 55V for 1h in 1X TAE buffer. 5 μl of Orange G 
loading buffer (50% glycerol, Orange G powder (Sigma Aldrich Company Ltd) and 
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50% water) was mixed with 5 μl of PCR product. GeneRuler 1kb Plus DNA ladder 
SM1333 (Thermo Fisher Scientific) was loaded in the first lane. 
 
2.10 Next Generation Sequencing (NGS) using Illumina MiSeq platform 
2.10.1 Rationale for choosing NGS for mitochondrial DNA 
NGS, or massively parallel sequencing, has become a potent and prevailing tool in 
research with a great potential for the study of mtDNA mutations. MtDNA mutations 
present at a low heteroplasmy level (<~20%) cannot be detected by conventional 
sequencing technologies such as Sanger Sequencing. More powerful instruments 
are necessary for the study of low-level mtDNA heteroplasmy. Technologies with 
high depth and breadth of coverage enable the investigation of very low-level 
variants (down to 2% heteroplasmy level or lower), whilst providing coverage of the 
entire mtDNA genome.  
Illumina GA/MiSeq platform is a high throughput sequencing technology, and has 
proved cost-efficient for sequencing large numbers of small genomes such as 
mtDNA. The Illumina platforms have sequencing error rates that compare favourably 
with most other platforms. 
 
2.10.2 Product purification and pooling 
After enrichment of mtDNA, the LR-PCR products were purified using the AgenCourt 
AMPure XP bead technology (Beckman Coulter). This system utilizes paramagnetic 
bead technology for high-throughput purification of PCR amplicons by binding 100 bp 
and larger amplicons to the beads. Using a washing procedure, excess reaction 
components and contaminants can be removed. AMPure XP beads were added to 
the samples in a ratio of 1.8 µl bead:1 µl PCR product, pipette mixed thoroughly and 
incubated for five minutes to allow PCR products to bind to the magnetic beads. The 
PCR plate was then placed onto the Magnet Plate (96S Super Magnet Plate, 
ALPAQUA) for two minutes to separate beads from the solution. The cleared solution 
was aspirated from the plate without disturbing the brown bead ring, which was then 
washed twice with freshly made 70% ethanol. The bead ring was left to air dry a few 
minutes to ensure all traces of ethanol were removed. After removal from the magnet 
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plate, beads were eluted into 30 µl of nuclease-free H2O, pipette mixed thoroughly 
and incubated at room temperature for one minute. The PCR plate was then placed 
back onto the Magnet Plate for one minute to separate beads from the solution and 
the eluate was transferred to a new PCR plate. The concentration of the samples 
was measured using the Qubit™ dsDNA Broad Range Assay kit (ThermoFisher 
Scientific) on the Qubit 3.0 Fluorometer as per manufacturer’s guidelines. 
MtDNA fragments originating from the same individual sample were then pooled 
together to a concentration of 10 ng/µl per sample. Two subsequent dilutions were 
performed on the same day as the library preparation began, to get to a final 
concentration of 0.2 ng/µl per sample. 
 
2.10.3 Library preparation 
The library preparation was performed using the Nextera XT DNA Library Preparation 
Kit (Illumina Inc., CA, USA) in order to “tagment”, amplify, normalise and pool the 
samples. Multiplexed pools were sequenced using Illumina MiSeq v3.0 sequencing 
platform in 250 bp paired-end reads. To avoid run-specific amplification variation, 
wild-type and WtN+ mouse samples were randomly mixed in every sequencing run. 
 
2.11 Bioinformatics analysis pipeline 
Paired-end fastq files were obtained from the MiSeq platform. Bioinformatic 
sequence analysis and variant calling is described as follows. All bioinformatics steps 
were performed as part of an in-house custom pipeline scripted by Fiona Robertson. 
The post-run fastq files of each sample were first assessed for quality via FASTQC v. 
0.11.5 (Andrews, 2010), before all duplicate reads were removed by Fastuniq v. 1.1 
(Xu et al., 2012). Thereupon, de-duplicated read sets were aligned to the selected 
genome using BWA, v. 0.7.15, invoking the mem module (Li and Durbin, 2009), 
against genome versions GRCh37 (GCA_000001405.1, human), or mm10 
(GCA_000001635.2, mouse). Sorting and indexing of alignments was performed 
using Samtools v.1.3.1 (Li et al., 2009). Variant calling was preformed using VarScan 
v.2.3.7 (Koboldt et al., 2012) and then annotated via the ENSEMBL VEP tool. v90 
(Zerbino et al., 2018), with merged cache files: 
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homo_sapiens_merged_vep_90_GRCh37 and 
mus_musculus_merged_vep_90_GRCm38, with inclusion of the respective dbSNP 
databases - sourced: NCBI (Sherry et al., 2001). Python scripts were used to extract 
coverage data. Further custom scripts are available (upon request) for downstream 
filtering of variant annotation data to ease further analysis and visualisation.  
 
2.12 Post-bioinformatic quality control 
Post-bioinformatic quality control was performed in order to ensure high-quality 
comparisons. Samples were removed if coverage was <99% at a minimal depth of 
1000x (further explained for each results Chapter). Heteroplasmic variants were 
defined as >2% but <98%. Homoplasmic variants were defined as >98%. 
 
2.13 Statistical Analyses 
Graphs were produced in Prism v5.04 and all statistical analysis were performed in 
IBM SPSS Statistics v23. Specific tests used are described in the methods and 





Chapter 3. Investigating the relationship between mitochondrial 
DNA damage in human brain and HIV infection 
3.1 Introduction 
Patients with long-term treated HIV exhibit features of premature and accelerated 
biological ageing. Mitochondrial dysfunction and mtDNA damage are also well-
recognised in people living with HIV (PLWH). Largely these phenomena are 
considered to be complications of antiretroviral therapy (ART), especially with certain 
drugs of the nucleoside analogue reverse transcriptase inhibitor (NRTI) class. Whilst 
NRTIs principally inhibit HIV reverse transcriptase, they may also inhibit the mtDNA 
polymerase, pol γ, leading to mtDNA depletion (Arnaudo et al., 1991; Casademont et 
al., 1996; Dalakas et al., 2001; Lim and Copeland, 2001; Cote et al., 2002; Walker et 
al., 2004b; Buffet et al., 2005; Haugaard et al., 2005; Cherry et al., 2006). More 
recently, it has been demonstrated, by our group and others, that NRTI therapy may 
also result in an increase in somatic mtDNA mutations in several tissues including 
skeletal muscle, blood, and the renal tract (Martin et al., 2003; Lehmann et al., 2011; 
Payne et al., 2011; Jitratkosol et al., 2012; Samuels et al., 2017). In addition, there is 
some limited evidence that HIV per se may also reduce mtDNA content, at least in 
lymphocytes (Miura et al., 2003).  
Neurocognitive impairment remains prevalent in PLWH in the mild forms of HIV-
associated neurocognitive disorder (HAND). NRTI-induced neurotoxicity in the brain 
was reported in a few studies in mice (Zhang et al., 2014; Zhang et al., 2015). 
However to this date, only a single study has looked at mtDNA in human brain in HIV 
infection but within the context of methamphetamine use, showing association 
between mitochondrial injury, HIV DNA levels and neurocognitive function (Var et al., 
2016).  
It is therefore plausible that HIV infection and/or ART is associated with an excess of 
mtDNA damage in the brain and therefore with HAND. 
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3.2 Experimental Aims 
This study aimed to determine whether antiretroviral treated HIV-infected persons 
have evidence of mtDNA damage in the brain, and whether this potentially 
contributes to neurocognitive impairment. 
 
3.3 Methodology 
3.3.1 Cohort of brain samples 
Snap-frozen post-mortem frontal grey matter samples were obtained from the 
National NeuroAIDS Tissue Consortium (NNTC) (https://nntc.org/), the Edinburgh 
Brain and Tissue Bank (www.ed.ac.uk/clinical-brain-sciences/research/edinburgh-
brain-and-tissue-bank), and the Newcastle Brain Tissue Resource (NBTR) 
(https://nbtr.ncl.ac.uk/). Frontal cortex brain tissue was processed as previously 
described in Section 2.3. Both HIV positive cases and HIV negative controls were 
studied. In light of the known associations between mtDNA changes and age, 
controls of comparable age range were specifically included to the cases, but also 
older controls to determine whether the effects of HIV/ART on brain mtDNA mirrored 
those seen in normal ageing. Donors with other (non-HIV associated) brain pathology 
and with opportunistic infections of the brain were excluded. Maximum time to 
autopsy was 24h. Clinical and neurocognitive testing data were taken from the last 
antemortem study visit (maximum 6 months antemortem). Brain bank donors had 
given informed consent for retention of their tissue for research purposes, and the 
present study was approved by local research ethics committee (ref. 17/NE/0015). 
 
3.3.2 Real-time PCR for mtDNA copy number and common deletion assay 
MtDNA content was expressed relative to cell content and was measured in triplicate 
by multiplex real-time qPCR amplification of mitochondrial gene MT-ND1 and the 
nuclear-encoded housekeeping gene B2M. In addition to mtDNA quantification, 
proportional levels of the 4977 bp mtDNA ‘common deletion’ (CD) were expressed 
relative to mtDNA content, and measured by allele-specific qPCR as detailed in 
Section 2.5, where primers and probe sequences for this assay are also found. 
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Data for mtDNA copy number (CN) and CD levels were age-normalised by correcting 
for the regression coefficient for age in the HIV negative control group. 
 
3.3.3 Next generation sequencing of human mitochondrial DNA 
Whole human mtDNA was enriched using long-range PCR. Primer sequences and 
LR-PCR details found in Section 2.9.1. 
MtDNA point variants were measured on an Illumina MiSeq platform as described in 
Section 2.10. Paired-end fastq files were obtained from the MiSeq platform. 
Bioinformatic sequence analysis and variant calling is described in Section 2.11. 
MtDNA point variants present at 2% to 98% heteroplasmy were reported. 
 
3.3.4 Large-scale mtDNA deletions 
Screening for large-scale mtDNA deletions was performed by LR-PCR in fragment 1 
amplicon of the human mtDNA used for sequencing in Section 2.9.1.  
 
3.3.5 Neurocognitive testing 
Neurocognitive testing data used in the present study included the following 
parameters and were provided by Dr David Moore (HIV Neurobehavioral Research 
Program, University of California). Primary neurocognitive diagnosis ranged in four 
categories: neurocognitively normal, subclinical neuropsychological impairment 
(ANI), mild cognitive motor disorder (MCI) and HAD; in accordance to the “Frascati 
Criteria” classification (Antinori et al., 2007). These HAND sub-classifications were 
extensively reviewed elsewhere (Table 3.1) (Clifford and Ances, 2013). Frascati 
criteria classifies HAND based on poor neurocognitive function in at least two 









1 SD below mean, 2 
cognitive domains 
No Impairment in activities 
of daily living 
Mild Neurocognitive 
Disorder (MND) 
1 SD below mean, 2 
cognitive domains 
Impairment in activities of 
daily living 
HIV Associated Dementia 
(HAD) 
2 SD below mean, 2 
cognitive domains 
Marked impairment in 
activities of daily living 
Table 3.1. Categories of HIV-associated neurocognitive disorder (HAND), Frascati 
criteria. Of note, for HAND diagnosis other etiology of dementia must be ruled out 
and confounding effect of substance use or psychiatric illness must be considered. 
Neurocognitive testing should include evaluating at least five domains including 
attention-information processing, language, abstraction-executive, complex 
perceptual motor skills, memory (including learning and recall) simple motor skills or 
sensory perceptual skills. Appropriate norms must be available to determine the 
number of domains in which performance is below 1 standard deviation (SD). 
Functional status is typically evaluated by self report but may be corroborated by a 
collateral source. No agreed upon measures exist for HAND criteria. Table and 
information taken from (Clifford and Ances, 2013). 
 
Other neurocognitive outcome data were composite scores including Global T-Score, 
Global Deficit Score (GDS) and Abstraction Executive Domain Deficit Score. Global 
T-Score and Global Deficit Score were obtained from the same tests however the 
former showing normalised test scores and the latter categorised into deficit scores. 
The component tests of the cognitive batteries used are detailed in Appendix 10.6. 
Abstraction executive functioning domain was specifically studied as this may best 




The GDS approach is used to detect and classify HIV-associated neurocognitive 
disorders (Blackstone et al., 2012). GDS is a continuous measure that takes into 
account the deficits across the neuropsychological tests by converting T-scores into 
deficit scores from 0 (no impairment) to 5 (severe impairment) and then averages 
them into a global deficit score (Table 3.2). 
Descriptor T scores Deficit Score 
Normal > 40 0 
Mild 39-35 1 
Mild-to-Moderate 34-30 2 
Moderate 29-25 3 
Moderate-to-Severe 24-20 4 
Severe < 19 5 
Table 3.2. Scores and descriptors for the global deficit score. A cut-off score of ≥ 0.5 
is used to determine impairment on the GDS (Blackstone et al., 2012). 
 
3.3.6 Statistical analysis 
Statistical testing was performed using SPSS 24 (IBM). Log10 transformation of CD 
values were used to approximate a normal distribution and allow for parametric 
testing. Non-parametric testing (Spearman correlation) was used for analyses of 




The study included a total of 90 donors (50 HIV positive, 40 HIV negative). Donor 
demographic and clinical characteristics are detailed in Table 3.3. 
Variable HIV- controls HIV+ cases 
Number of samples N=40 N=50 
Age at death, years (range) 66.1±18.3 (29-91) 49.2±9.6 (32-70)a 
Gender (M/F) 28/12 40/7a 
CD4 cell count, cells/µl (range) - 143±193 (2-1043) 
Log10 HIV RNA plasma viral load 
(range) 
- 3.9±1.6 (1.6-6) 
Number of patients on any ART at 
last assessment (yes/no) 
- (31/11)b 
Number of patients ever on ART 
during disease duration (yes/no) 
- (39/3)b 
Nadir CD4 cell count (range) - 62±67 (0-257) 
CD4/CD8 cell count (range) - 0.25±0.4 (0.01-1.82) 
Table 3.3. Demographic characteristics of HIV-uninfected controls and HIV+ cases 
used for the analysis. N is number. ART is antiretroviral therapy. Gender is displayed 
as the number of males/females. All other values are displayed as mean ± standard 
deviation. Range are (minimum – maximum) values. aAge at death and gender 
information only available for n=47 HIV+ cases. bART information only available for 




Detailed list of antiretroviral drug regimens for HIV patients, at time of death 
(considered time of last assessment) and for previous exposure, can be found in 
Appendix 10.7, together with a list of drug abbreviations. 
 
3.4.1 Cellular mitochondrial DNA content 
There was a borderline significant inverse correlation between mtDNA content and 
age at death in the combined group of cases and controls (r=-0.2, n=90, p=0.05). 
This association was however highly significant within the HIV-negative controls (r=-
0.5, n=40, p=0.001), but not in HIV+ cases (r=-0.1, n=50, p=0.4) (Figure 3.1). 
 
Figure 3.1. Mitochondrial DNA copy number levels against age at death for HIV 
positive cases and HIV negative controls. MtDNA content correlated significantly with 
age at death in controls but not in HIV+ cases. Every dot represents a sample. Y is 
for years. 
 
Given the large literature linking changes in mtDNA with age, along with the strong 
effect observed here in our HIV- controls, all subsequent analyses of mtDNA content 
were corrected for age at death based on the data for HIV negative control subjects 
as described previously (regression coefficient, -5.512 mtDNA copies per year).  
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It was then determined whether HIV status independently affected mtDNA content. 
Decreased mtDNA content (age-corrected mtDNA genome copies per cell) was 
associated with positive HIV status (mean (SE); HIV+, 726 (24), n=47; HIV-, 887 (28), 
n=40; unpaired t-test, p<0.001; Figure 3.2). 
 
Figure 3.2. Mitochondrial DNA copy number levels (age-corrected) for HIV positive 
cases and HIV negative controls. HIV positive status was associated with lower 
mtDNA content. Every dot represents a sample. P is p-value. Dotted line at mean. 
 
The effect of HIV clinical and treatment factors on mtDNA content amongst HIV 
positive cases was then investigated. There were no significant correlations between 
mtDNA content and immunological parameters or HIV viral load: current CD4 
lymphocyte count (r=0.14, n=44, p=0.4; Figure 3.3A); current CD8 lymphocyte count 
(r=0.05, n=24, p=0.8; Figure 3.3B); log10 HIV-1 RNA plasma viral load (r=-0.22, n=44, 
p=0.14; Figure 3.3C); nadir CD4 lymphocyte count (r=0.16, n=24, p=0.5; Figure 
3.3D); current CD4/CD8 ratio (r=-0.11, n=23, p=0.6; Figure 3.3E).  
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Figure 3.3. Mitochondrial DNA copy number levels (age-corrected) against HIV 
immunological parameters for HIV positive cases. MtDNA content showed no 
significant correlation with CD4 cell count (A), CD8 cell count (B), log10 HIV-1 RNA 
plasma viral load (VL) (C), nadir CD4 (D) or CD4/CD8 cell ratio (E). Every dot 




Furthermore, there was no association between ART and mtDNA content, based 
either on current exposure to any ART at the time of last assessment (on ART, 722 
(30), n=31; not on ART, 717 (52), n=11; p=0.9, Figure 3.4), or history of exposure to 
one or more of those NRTIs which most strongly inhibit the mitochondrial pol γ in 
vitro, that is, the di-deoxy-nucleoside analogues [d-drugs]: didanosine (ddI), 
zalcitabine (ddC), stavudine (d4T) (d-drug, 692 (35), n=23; no d-drug, 752 (40), 
n=17; p=0.27, Figure 3.5). 
 
Figure 3.4. Mitochondrial DNA copy number levels (age-corrected) for HIV positive 
cases who were taking (ART) or not (NO ART) any antiretroviral medication at the 
time of their last assessment. MtDNA content levels were not significantly different 
regarding exposure to any ART or not. Every dot represents a sample. Dotted line at 
mean. 
 
Figure 3.5. Mitochondrial DNA copy number levels (age-corrected) for HIV positive 
cases who took d-drugs or not (no d-drugs) at any point throughout their course of 
treatment. MtDNA content levels were not associated with exposure to d-drugs. D-
drugs: ddI, ddC and d4T. Every dot represents a sample. Dotted line at mean. 
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Specific analysis of the individual d-drugs showed no significant association between 
mtDNA copy number and the d-drug exposure (ever exposed compared with never 
exposed) for ddI (ddI 694 (42), n=18; no ddI, 737 (33), n=22; p=0.4; Figure 3.6A), 
ddC use (ddC 774 (59), n=10; no ddC, 699 (29), n=30; p=0.2; Figure 3.6B) or d4T 
use (d4T 671 (35), n=21; no d4T, 769 (37), n=19; p=0.06; Figure 3.6C). Although it 
has relatively low potential of pol γ inhibition, zidovudine (AZT) is also considered to 
be mitochondrially toxic. AZT did not show a significant association between its use 
and mtDNA copy number (AZT, 743 (36), n=23; no AZT, 683 (38), n=17; p=0.3; 
Figure 3.6D). 
 
Figure 3.6. Mitochondrial DNA copy number levels (age-corrected) for HIV positive 
cases who took specific antiretroviral drugs or not at any point throughout their 
course of treatment. MtDNA content levels were not associated with exposure to ddI 




3.4.2 MtDNA large scale deletions and δ4977 common deletion levels 
No large-scale mtDNA rearrangements were detectable by LR-PCR. Using the 
sensitive CD-specific qPCR assay, the total burden of mt.δ4977 deletion mutation 
was estimated at the whole-tissue level. MtDNA common deletion levels were 
significantly correlated with age at death in both HIV+ patients (r=0.3, n=50, p=0.04) 
and more strongly in uninfected controls (r=0.5, n=40, p=0.0005) (Figure 3.7). 
 
Figure 3.7. Mitochondrial DNA common deletion levels against age at death for HIV 
positive cases and HIV negative controls. Common deletion content showed a 
significant correlation with age at death in both HIV+ cases and controls. Every dot 





Again correcting for age at death based on data from HIV negative controls 
(regression coefficient, 0.0158 log10CD/mtDNA per year), positive HIV status was 
independently associated with higher proportional levels of the CD (log10CD, mean 
(SE); HIV+, -3.67 (0.05), n=47; HIV-, -3.86 (0.08), n=40; p=0.046; Figure 3.8).  
 
Figure 3.8. Mitochondrial DNA common deletion levels (age-corrected) for HIV 
positive cases and HIV negative controls. MtDNA CD levels were higher in HIV 
positive cases compared to HIV negative controls. Log10 is a logarithmic scale of 10. 




Amongst HIV positive cases, there were no significant correlations between mtDNA 
CD levels and immunological parameters or HIV viral load: current CD4 lymphocyte 
count (r=-0.13, n=44, p=0.4; Figure 3.9A); current CD8 lymphocyte count (r=0.13, 
n=24, p=0.6; Figure 3.9B); log10 HIV-1 RNA plasma viral load (r=-0.06, n=44, p=0.7; 
Figure 3.9C); nadir CD4 lymphocyte count (r=-0.05, n=24, p=0.8; Figure 3.9D); 
current CD4/CD8 ratio (r=0.05, n=23, p=0.8; Figure 3.9E). 
 
Figure 3.9. Mitochondrial DNA common deletion levels (age-corrected) against HIV 
immunological parameters for HIV positive cases. Common deletion content showed 
no significant correlation with CD4 cell count (A), CD8 cell count (B), log10 HIV-1 
RNA plasma viral load (VL) (C), nadir CD4 (D) or CD4/CD8 cell ratio (E). Every dot 
represents a sample. 
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Furthermore, there was no association between ART and mtDNA CD levels, based 
either on current exposure to any ART (on ART, -3.70 (0.06), n=31; not on ART, -
3.66 (0.07), n=11; p=0.7; Figure 3.10), or specific history of d-drug exposure as 
defined before (d-drugs, -3.68 (0.08), n=23; no d-drugs, -3.66 (0.06), n=17; p=0.8; 
Figure 3.11).  
 
Figure 3.10. Mitochondrial DNA common deletion levels (age-corrected) for HIV 
positive cases who were taking (ART) or not (NO ART) any antiretroviral medication 
at the time of their last assessment. MtDNA CD levels were not significantly different 





Figure 3.11. Mitochondrial DNA common deletion levels (age-corrected) for HIV 
positive cases who took d-drugs or not (no d-drugs) at any point throughout their 





Specific analysis of the individual d-drugs showed no significant association between 
mtDNA CD and the d-drug exposure (ever exposed compared with never exposed) 
for ddI (ddI -3.67 (0.09), n=18; no ddI, -3.68 (0.05), n=22; p=0.9; Figure 3.12A), ddC 
(ddC -3.65 (0.1), n=10; no ddC, -3.68 (0.05), n=30; p=0.8; Figure 3.12B) or d4T use 
(d4T -3.67 (0.08), n=21; no d4T, -3.68 (0.06), n=19; p=0.9; Figure 3.12C). AZT did 
not show a significant association between its use and mtDNA CD (AZT, -3.6 (0.07), 
n=23; no AZT, -3.75 (0.08), n=17; p=0.18) (Figure 3.12D). 
 
Figure 3.12. Mitochondrial DNA common deletion levels (age-corrected) for HIV 
positive cases who took specific antiretroviral drugs or not at any point throughout 
their course of treatment. MtDNA CD levels were not associated with exposure to ddI 




3.4.3 Neurocognitive impairment and mtDNA  
The association between mtDNA content and neurocognitive impairment was 
investigated. Based on the categorical classification of NCI (normal, ANI, MCI, HAD) 
no association was seen (one-way ANOVA, p=0.33; Figure 3.13).  
 
Figure 3.13. Mitochondrial DNA copy number levels (age-corrected) for HIV+ patients 
clustered in groups regarding their neurocognitive diagnosis (NN: neurocognitively 
normal; ANI: subclinical neuropsychological impairment; MCI: mild cognitive motor 
disorder; HAD: HIV-associated dementia). There was no difference between the 




This lack of association was also true of global T-score (r=-0.20, n=30, p=0.28; 
Figure 3.14A), and global deficit score (GDS; r=0.15, n=30, p=0.4; Figure 3.14B). In 
view of the anatomical site of tissue studied, the frontal cortex, executive function 
was also assessed. Here there was a trend towards association between deficit 
score for this cognitive domain and mtDNA content albeit not reaching statistical 
significance (r=0.31, n=33, p=0.077; Figure 3.14C). 
 
Figure 3.14. Mitochondrial DNA copy number levels (age-corrected) against HIV 
neurocognitive testing parameters for HIV positive cases. MtDNA content showed no 
significant correlation with neurocognitive function assessments including global T-
score (A), global deficit score (B) and abstraction executive domain deficit score (C). 




Regarding mtDNA CD, based on the categorical classification of NCI (one-way 
ANOVA p=0.37; Figure 3.15), global T-score (r=-0.10, n=30, p=0.6; Figure 3.16A), 
GDS (r=0.09, n=30, p=0.6; Figure 3.16B), or executive function (r=0.23, n=33, 
p=0.20; Figure 3.16C), no associations were seen between neurocognitive function 
and mtDNA CD levels.  
 
Figure 3.15. Mitochondrial DNA common deletion levels (age-corrected) for HIV+ 
patients clustered in groups regarding their neurocognitive diagnosis. There was no 




Figure 3.16. Mitochondrial DNA common deletion levels (age-corrected) against HIV 
neurocognitive testing parameters for HIV positive cases. MtDNA CD showed no 
significant correlation with neurocognitive function assessments including global T-
score (A), global deficit score (B) and abstraction executive domain deficit score (C). 




There was no association between mtDNA content and CD levels in HIV+ cases, in 
uninfected controls and in both groups pooled (r=0.10, p=0.4, n=87; Figure 3.17). 
 
Figure 3.17. Mitochondrial DNA copy number levels (age-corrected) against 
mitochondrial DNA common deletion levels (age-corrected) for both HIV positive 
cases and HIV negative controls. No correlation was found between mtDNA content 




CD4 T-cell levels were analysed for HIV+ cases regarding the neurological 
subcategories and there were no significant differences (mean (SE); NN, 171 (41), 
n=19; ANI, 152 (58), n=13; MCI, 123 (49), n=23; HAD, 151 (38), n=27; Kruskal-Wallis 
test, p=0.3; Figure 3.18). 
 
Figure 3.18. CD4 T-cell count values for HIV+ patients clustered in groups regarding 
their neurocognitive diagnosis. There was no difference between the groups in terms 




HIV patient RNA plasma viral load values (log10 transformed, viral log) showed no 
differences between the neuro subcategories (NN, 3.6 (0.4), n=19; ANI, 3.6 (0.5), 
n=12; MCI, 4.3 (0.3), n=22; HAD, 4 (0.3), n=27; Kruskal-Wallis test, p=0.6; Figure 
3.19). 
 
Figure 3.19. Plasma viral values for HIV+ patients clustered in groups regarding their 
neurocognitive diagnosis. There was no difference between the groups in terms of 
HIV RNA plasma viral load values (viral log). Viral log is log10 of viral load (in viral 
copies/mL). Dotted line at mean. 
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3.4.4 Deep resequencing of human mtDNA point variants 
Bioinformatic analysis was performed as described in Section 2.11. Samples were 
removed if coverage was <99% at a minimal depth of 1000x (see coverage graph in 
Appendix 10.8). 86 samples (48 cases, 38 controls) achieved adequate sequence 
coverage and quality for analysis. Homoplasmic mtDNA variants (defined here as 
base positions with a variant present at ≥ 98% frequency) were examined in order to 
establish that background mtDNA sequence context was not a confounder of the 
analyses of heteroplasmic mtDNA point variants. A median of 30 (IQR, 12.75-34) 
homoplasmic variants per sample in HIV positive cases was observed, which did not 
differ significantly from HIV negative controls (median 23.5, IQR 11.75-33, Mann 
Whitney p=0.3). Furthermore, the number of homoplasmic variants per sample 
showed no correlation with age at death (Spearman; HIV+, r=0.07, p=0.6; HIV-, r=-
0.05, p=0.8), or with number of heteroplasmic variants per sample (HIV+, r=-0.16, 
p=0.3; HIV-, r=0.22, p=0.19).  
Heteroplasmic mtDNA point variants were therefore next analysed. Protein coding 
and D-loop variants were the most abundant in both HIV+ and HIV- subjects (Figure 
3.20). 
 
Figure 3.20. Heteroplasmic mtDNA point variants detected by deep resequencing 
(Illumina MiSeq). Every dot is an mtDNA variant. Y axis is heteroplasmy frequency. 
D-loop are variants found in the mtDNA displacement loop. Coding are variants in the 
protein-coding regions. rRNA is ribosomal RNA. tRNA is transfer RNA. 
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Total variant load, expressed here as the number of base positions showing 
heteroplasmic mtDNA variants, was a median of 2 per sample (IQR 1-4) in both HIV 
positive cases and HIV negative controls. For both groups, variants were most 
commonly seen in the mtDNA non-coding D-loop (mean of 2.6 variants per sample, -
2.64 log10 per base position), followed by protein-coding genes (1.6 variants per 
sample, -3.85 log10 /bp). rRNA variants (0.3 per sample, -3.92 log10 /bp) and tRNA 
variants (0.1 per sample, -4.16 log10 /bp) were comparatively rare (Figure 3.21). 
Within protein-coding regions, mtDNA variants were classed as synonymous 
substitutions, where amino acid sequence is not modified, and non-synonymous 
substitutions, altering the amino acid sequence of the protein. Synonymous variants 
were not significantly different between HIV+ and HIV- samples (p=0.6) (Figure 3.21). 
There was a handful of HIV+ samples that appeared to have an excess of non-
synonymous variants compared to the HIV- group but statistically this did not reach 
significance (p=0.1) (Figure 3.21). 
 
Figure 3.21. Heteroplasmic mtDNA point variants per sample. Number of base 
positions showing variants per case, according to HIV status and variant type. Every 
dot represents a sample. D-loop are variants found in the mtDNA displacement loop. 
Syn is for synonymous variants. Non-syn is for non-synonymous variants. rRNA is 




Similar to the findings for mtDNA content and mtDNA deletions, there was a 
significant effect of age on the number of heteroplasmic mtDNA point variants in HIV 
negative controls (r=0.43, p=0.007, Figure 3.22). However, after correction of variant 
load per case for this age effect, there remained no significant difference between 
HIV positive cases and HIV negative controls (p=0.19).  
 
Figure 3.22. Number of base positions showing variants per case, according to age 




Finally, as mtDNA point variants present at high heteroplasmy levels are likely to 
have greater functional effects than those at low levels, a variant burden per sample 
was weighed for variant heteroplasmy levels (expressed here as variants per bp per 
106 mtDNA genome copies). Again there was a significant association of variant 
burden with age in HIV negative controls (r=0.34, p=0.038, Figure 3.23), but no effect 
in HIV positive (r=0.17, p=0.2). 
 
Figure 3.23. MtDNA variants per case, weighted for variant heteroplasmy. Bp is base 





This study aimed to understand mtDNA damage in the human brain at the whole-
tissue level in the setting of HIV infection, antiretroviral treatment and ageing. On all 
measures studied, the expected changes with age were observed: decreased 
mtDNA copy number, increased deletions, and increased point mutations.  
Although increased mtDNA point mutations with age are expected, to this author’s 
knowledge, this is the first study to report mutations using an NGS approach which 
captures the whole mtDNA genome in this setting. 
The multiplex qPCR was used to determine mtDNA copy number and prevalence of 
the age-associated mt.δ4977 common deletion in frontal cortex tissue of HIV positive 
cases and age-adjusted HIV-uninfected controls. Regarding cellular mtDNA content, 
mitochondrial DNA copy number was significantly lower in HIV-positive cases 
compared to HIV-uninfected controls. Within the HIV+ cohort, mtDNA CN was not 
associated with any of the established HIV disease progression biomarkers, CD4 T-
cell count and HIV RNA viral load. Other disease-monitoring markers: CD4/CD8 ratio, 
nadir CD4 count and CD8 lymphocyte count were also not associated with mtDNA 
content. Similarly, no significant association was found between mtDNA content and 
ART at the time of last assessment, whether that be ART in general, any 
polymerase-γ inhibiting ART, or specific mitochondrially toxic medications. Regarding 
4977 bp common deletion levels, mtDNA age-associated CD was significantly higher 
in HIV-positive cases compared to HIV-uninfected controls. Within the HIV+ cohort, 
mtDNA CD was not associated with any of the established HIV disease progression 
biomarkers and other T cell count markers. As observed for mtDNA content, there 
was no association found between mtDNA CD and any of the ART parameters. 
Furthermore, there was no effect of mtDNA parameters, mtDNA CN and age-
associated common deletion, on neurocognitive impairment measurements. 
Taken together, these data showed for the first time that mtDNA quantity and quality 
decrease in the frontal cortex of the brain of PLWH. Increasing age was associated 
with an increase in mtDNA mutation load (both mtDNA point variants and deletions), 
and a decrease in cellular mtDNA content. These findings are in keeping with the 
published literature on mtDNA changes in the ageing human brain. In the case of 
both mtDNA content and mtDNA deletions, HIV infection appeared to augment these 
age-associated changes. By a simple analogy, the observed effects of HIV were 
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equivalent to ~32 year (for mtDNA content) and ~12 year (for mtDNA deletions) age 
advancement. Interestingly the data (Figure 3.22 and 3.23) also seemed to show a 
trend towards the same phenomenon for mtDNA point variants, but this did not reach 
statistical significance. 
Most prior data on mtDNA changes in PLWH have suggested that the predominant 
driver of mtDNA depletion and mutation is ART, and especially the historical NRTIs 
which inhibit pol γ. In contrast, these results show strong effects of HIV infection per 
se, but not of ART or of specific NRTIs. One of the explanations could be because 
the penetration of ART into the CNS is variable, but drug levels are always 
significantly lower than those seen in plasma. As NRTI-induced mitochondrial toxicity 
is dose-dependent, it is plausible that drug levels achieved in the CNS are below a 
threshold at which significant mtDNA damage will occur. Another possibility, not 
mutually exclusive, is that the cells of the CNS are more sensitive to the effects of 
HIV itself on mtDNA compared with many other tissues. Thus when observing 
changes in mtDNA, the HIV effect is dominant over any ART effect. 
A plausible hypothesis to argue why HIV infection itself resulted in the reduction in 
mtDNA quantity and quality in the brain of HIV+ individuals compared to HIV-
uninfected controls could be explained by a HIV-mediated neurotoxicity associated 
with mitochondrial dysfunction. As previously described in the literature, a number of 
HIV viral proteins have been shown to be released in vitro from HIV-infected cells, 
including lymphoid, monocytic and glial cells, during viral replication and to infect 
these cells in the central and peripheral nervous system, where they also act as viral 
reservoirs, posing a challenge for ART (Furtado et al., 1999; Coleman and Wu, 2009; 
Castellano et al., 2017; Castellano et al., 2019). 
The nature of post-mortem brain tissue samples used in this study inevitably places 
some limits on the generalisability of these findings to healthy PLWH. Whilst cases 
with other CNS pathology or opportunistic infections were excluded, the HIV cohort 
as a whole shows advanced HIV (mean CD4 cell count 143 cells/µL). In a larger and 
more homogenous set of cases, it would be important to establish whether consistent 
viral suppression and immune reconstitution is associated with attenuation of the 




In conclusion, PLWH with predominantly advanced disease, have abnormalities of 
mitochondrial DNA quality and quantity in the brain. These changes appear to 
augment those seen due to the normal ageing process, giving weight to the 
hypothesis that HIV infection may adversely affect biological pathways of ageing 





Chapter 4. Generation of the PolgA ‘WtN+’ mouse model of clonal 
expansion of mitochondrial DNA mutations in ageing 
4.1 Introduction 
MtDNA mutations reach high levels within individual cells by a process known as 
clonal expansion. Recent data suggest that the accumulation of mtDNA mutations 
within tissues with ageing is likely to be predominantly due to the clonal expansion of 
existing mutations within cells, rather than high levels of mutagenesis (Greaves et al., 
2014). It is not currently known however whether clonal expansion is a modifiable 
process which can affect the rate of physiological ageing.  
The PolgA ‘mutator’ mouse contains an error-prone mtDNA polymerase γ. The 
homozygous mouse produces very high levels of mtDNA mutations, and has a 
premature ageing phenotype with early death (Trifunovic et al., 2004; Kujoth et al., 
2005). More recently, it has been appreciated that female heterozygous PolgA mice 
produce offspring with germline mtDNA mutations. These germline mutations 
enhance the phenotype and indeed can lead to a mildly accelerated ageing 
phenotype even when bred back to a wild-type nuclear background (Ross et al., 
2013). Trapping germline heteroplasmic mtDNA mutations on a wild-type nuclear 
background therefore potentially provides a model with which to study clonal 
expansion.  
 
4.2 Aims of this investigation 
To develop and characterise a mouse model with which to define the natural history 




4.3.1 PolgA ‘WtN+’ mouse model generation 
The ‘WtN’ derivative of the PolgA ‘mutator’ mouse, as described by Ross and 
colleagues (Ross et al., 2013), contains ‘trapped’ germline mtDNA mutations, bred 
back to a wild-type inbred nuclear background (C57BL/6J). This method was adapted 
by breeding once through a homozygous PolgA female in order to produce offspring 
with a larger ‘burst’ of germline mtDNA mutations. These were then ‘trapped’ by 
breeding back to the wild-type nuclear background. I termed this derivative ‘WtN+’ to 
denote the greater expected number of germline mtDNA mutations. Maternal 
generations of WtN+ mice were produced as follows. PolgAwt/mut females (n=5) in G0 
(generated from a homozygous mother) produced PolgAwt/wt female offspring (G1) 
which were used to produce PolgAwt/wt female offspring (n=5) in G2 and in turn to 
produce the experimental animals (G3) (Figure 4.1). Since mtDNA is exclusively 
maternally transmitted, germline mtDNA mutations were passed down the maternal 
line. It was anticipated that this breeding strategy would lead to a high degree of 
similarity in germline mtDNA mutations between experimental animals of the G3 
generation, thus facilitating easier comparison of clonal expansion of these specific 
mutations within different groups. 
As a control group, mice without germline mtDNA mutations were generated by 
crossing C57BL/6J females with male littermates of the breeding WtN+ females. 
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Figure 4.1. Generation of WtN+ mice. Two intercrosses were needed to generate one 
female PolgAmut/mut. Homozygous PolgAmut/mut females were initially generated to 
create a large germline mtDNA mutational ‘burst’. PolgAmut/mut mothers produced 
offspring with multiple germline heteroplasmic mtDNA mutations. Backcrossing to 
wild-type male mice restored wild-type polymerase function, but retained germline 
mtDNA mutations. G2 females were used to generate the experimental mice (G3). 
Thus, all experimental mice would start with the same pool of germline mutations.  
 
This breeding programme encountered fertility issues, which improved with 
successive generations. Average litter size (abortions and early neonatal deaths of 
pups were not counted) for G0 mothers was 2.5, for G1 was 6.5 and for G2 was 6.4. 
The proportion of successful crosses, i.e., the ones that resulted in a litter of at least 
one live pup, was 40% for G0 mothers, 67% for G1 and 83% for G2. When breeding 
wild-type animals, the average litter size was 7 and the successful crosses were at 
90%. 
Detailed mitochondrial cellular and molecular analyses in the experimental mice, G3, 
by age and genotype are presented in Chapter 6. Further phenotypic data are  
presented in Chapter 5. 
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4.3.2 Tissue processing  
Clipped ear tissue was taken at weaning (age ~4 weeks) and was used for 
genotyping (described in Section 2.2.2), qPCR for mtDNA content, and next 
generation sequencing to define the pool of transmitted germline mtDNA mutations. 
All other tissues were dissected during organ harvesting. Dissecting of mouse tissues 
was previously explained in Section 2.2.9. DNA used for qPCR and NGS was 
extracted from tissue homogenates as described in Section 2.4.  
 
4.3.3 Real-time PCR for mtDNA copy number  
MtDNA content was expressed relative to cell content and was measured in triplicate 
by multiplex real-time qPCR amplification of mitochondrial gene MT-ND5 and the 
nuclear-encoded housekeeping gene β-Actin. Primers and probe sequences for this 
assay are found in Section 2.6. 
 
4.3.4 Next generation sequencing of mouse mitochondrial DNA 
Whole mouse mtDNA was enriched using long-range PCR. Primer sequences and 
LR-PCR details found in Section 2.9.1.  
MtDNA point variants were measured on an Illumina MiSeq platform as described in 
Section 2.10. Paired-end fastq files were obtained from the MiSeq platform. 
Bioinformatic sequence analysis and variant calling is described in Section 2.11. 
Ensembl sequence reference used was mm10 (NC_005089.1). MtDNA point variants 
present at 2% to 98% heteroplasmy were reported. 
 
4.3.5 Quadruple immunofluorescence for mouse tissues 
Quadruple immunofluorescence staining and quantification for mouse colon and 
skeletal muscle was performed as detailed in Section 2.7. 
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4.3.6 Statistical analysis 
Statistical testing was performed using SPSS 24 (IBM). Non-parametric testing 
(Spearman correlation and Kruskal-Wallis tests) was used for analyses of mtDNA 




All experimental animals were generated from the same PolgAmut/mut grandmother. In 
this Chapter, a comparison of mitochondrial parameters in the female mice of each 
generation is reported. For the comparisons presented here, mice in each generation 
(G0-G3) were culled at a very similar time point, ~70 weeks [±5w] of age. Deep 
sequencing results were all obtained from ear tissue at 4 weeks old.  
 
4.4.1 Cellular mitochondrial DNA content in mouse tissue homogenates 
MtDNA content (mtDNA genome copies per cell) did not vary significantly in ear snip 
tissue between the four female mice generations used for breeding of the 
experimental colony (mean (SE) mtDNA copies/cell; G0, 72 (4), n=5; G1, 81 (8), n=5; 
G2, 86 (9), n=5; G3, 73 (4), n=38; one-way ANOVA, p=0.55; Figure 4.2). 
 
Figure 4.2. Mitochondrial DNA copy number levels in ear tissue for the four mouse 
generations used for breeding of the experimental colony. Ear snipped tissue was 
taken during mice weaning. MtDNA CN in ear was not significantly different between 
generations at 4 weeks old. G stands for generation. Every dot represents a mouse. 
Line at mean. 
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MtDNA copy number in homogenised colon was significantly higher in G0 compared 
with female WtN+ mice of generations G2 and G3 (G0, 329 (16), n=3; G2, 154 (9), 
n=5; G3, 195 (5), n=6; one-way ANOVA, p<0.0001; Figure 4.3). G1 was not included 
in the statistical analysis owing to a single data point, but appears comparable to 
G2/G3. Tukey’s multiple comparison test also showed a significant increase in 
mtDNA content from G2 to G3 (p<0.05). 
 
Figure 4.3. Mitochondrial DNA copy number levels in homogenised colon for the four 
mouse generations used for breeding of the experimental colony. MtDNA CN in colon 
was significantly different between generations 0, 2 and 3. G stands for generation. 
Every dot represents a mouse. Top p-value is for one-way ANOVA between G0, G2 
and G3. P-value between G2 and G3 is for Tukey’s multiple comparison test. Line at 




MtDNA copy number in homogenised skeletal muscle did not differ significantly 
between female mice generations (G0, 2315 (232), n=3; G2, 2426 (440), n=5; G3, 
1573 (204), n=6; one-way ANOVA, p=0.15; Figure 4.4). G1 was not included in 
statistical analysis as single data point only.  
 
Figure 4.4. Mitochondrial DNA copy number levels in homogenised skeletal muscle 
for the four mouse generations used for breeding of the experimental colony. MtDNA 
CN in skeletal muscle was not significantly different between generations 0, 2 and 3. 
G stands for generation. Every dot represents a mouse. Line at mean. All mice were 




MtDNA content in homogenised frontal cortex was significantly high in G0 compared 
with the other female mice generations, G2 and G3 (G0, 1862 (87), n=2; G2, 826 
(106), n=5; G3, 618 (118), n=6; one-way ANOVA, p=0.0005; Figure 4.5). G1 was not 
included in statistical analysis as single data point only. Tukey’s multiple comparison 
test showed no difference in mtDNA content from G2 to G3. 
 
Figure 4.5. Mitochondrial DNA copy number levels in homogenised frontal cortex for 
the four mouse generations used for breeding of the experimental colony. MtDNA CN 
in brain was significantly different between generations 0, 2 and 3. G stands for 
generation. Every dot represents a mouse. P is p-value for one-way ANOVA between 
G0, G2 and G3. Line at mean. All mice were culled at ~70 weeks [±5w] of age. 
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4.4.2 Deep resequencing of mouse mtDNA point variants 
Next generation sequencing of the mitochondrial genome using Illumina MiSeq, of 
ear snip samples from the mice pedigree was performed. Generations of WtN+ mice 
sequenced were as follows: G0 (n=5, PolgAwt/mut), G1 (n=1, PolgAwt/wt), G2 (n=5, 
PolgAwt/wt) and G3 (n=27, i.e., a subset, PolgAwt/wt).  
Additionally, ear snip mtDNA of founder heterozygous PolgA mice (F0 hets, n=4) was 
sequenced in order to descriptively compare purely somatic mtDNA variants, 
expected on the F0 hets, to purely germline mtDNA variants, expected in the WtN+ 
cohort.  
G0 mice (as they were heterozygous for the PolgA genotype) should contain a small 
number of somatic mtDNA variants in addition to germline variants. G1-G3 should 
contain almost entirely germline variants, as there were almost no somatic mtDNA 
variants expected in wild-type C57BL/6J mice. 
MtDNA variants were only reported if they had greater than 2% heteroplasmy based 
on the observation that variants at >1% heteroplasmy are almost never seen in wild-
type C57BL/6J mice. In fact, wild-type C57BL/6J mice sequencing results showed no 
mtDNA variants (data not plotted). 
The distribution of variants across the mouse mitochondrial genome was plotted 
along with their heteroplasmy levels (Figure 4.6). Variants in the G0 mice appeared 
relatively evenly distributed across the mtDNA genome. Variants in the WtN+ mice of 
generations G1 to G3 were clearly clustered at specific base positions, reflecting the 
transmission only of a subset of initial variants. Variants in the F0 heterozygous mice 















































































































































The heteroplasmy levels of variants of each type were analysed in each generation 
of mice. MtDNA point variants were filtered and categorised according to whether 
they were non-coding variants (NC, principally in the D-loop); protein-coding variants, 
which were further sorted into non-synonymous substitutions, altering the amino acid 
sequence of the protein, and synonymous if the amino acid sequences were not 
modified; rRNA and tRNA variants. Median and maximum heteroplasmy levels 
increased significantly in all mtDNA variant types across successive generations. 
Coding gene variants, both synonymous (p<0.0001) and non-synonymous 
(p<0.0001), increased significantly in heteroplasmy more rapidly than other variant 
types (Figure 4.7). Non-coding (p=0.038), rRNA (p<0.0001) and tRNA (p<0.0001) 
variants also increased significantly in heteroplasmy throughout generations G0-G3. 




























































































































































































































































The same data were expressed in terms of number of variants observed at any 
heteroplasmy level by variant type in each generation of mice, normalised to the 
number of nucleotide ‘at risk’, i.e., nucleotide positions of that type. It was shown that 
for each variant type, the variant frequency of coding (p<0.0001), rRNA (p<0.0001) 
and tRNA (p=0.011) variants significantly decreased with successive generations 
which did not reach statistical significance for non-coding variants, but the number of 
observations were small (Figure 4.8). Again, variant frequency in F0 heterozygous 
































































































































































































































From the same dataset again, each variant seen was weighted by its heteroplasmy 
level. This metric therefore combined variant count and heteroplasmy data and is 
considered as a measure of overall ‘mutational burden’. These data suggested that 
coding gene variants were better tolerated than other variant types across 
generations as they reached higher mutational burdens (p=0.002; Figure 4.9). As per 
previous analysis, F0 heterozygous mice had very minimal mutational burden in 















































































































































































































The transmission of individual mtDNA variants within mother/offspring pairs was 
examined and categorised according to mtDNA variant type. First, the heteroplasmy 
level shifts between mother and offspring were plotted, as mean shift and SEM for 
each variant transmission observed (as each mother produced multiple offspring with 
differing variant heteroplasmy levels). This analysis showed that there was a clear 
relationship between maternal and offspring variant heteroplasmy levels, but there 
were clear shifts away from the expected line. There was also a spread of 
heteroplasmy levels for each individual variant within multiple offspring of the same 
mother (Figure 4.10). In order to determine whether there was systematic selection 
against certain variant types, the slopes of the regression lines were then compared 
for each variant type (Figure 4.11).  
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Figure 4.10. Shift in heteroplasmy level of mtDNA variant type between WtN+ mother 
and offspring. X axis is maternal heteroplasmy and Y axis is offspring heteroplasmy. 
Dots are mean and vertical lines are SEM for each variant observed. NC is non-
coding; non-syn is non-synonymous; syn is synonymous; rRNA is ribosomal RNA; 
tRNA is transfer RNA. Expected is a positive linear correlation line of r=1 and 
slope=1. 
 
All slopes produced from linear regression for non-coding, non-synonymous, 
synonymous, rRNA and tRNA variant shifts between mother and offspring were 
different from the expected slope=1. Slopes suggested selection against non-coding 
(slope 0.6, 95% CI [0.4, 0.8]), rRNA (slope 0.7, 95% CI [0.64, 0.79]) and tRNA (slope 
0.76, 95% CI [0.61, 0.91]) variant shifts. There was also a selection for protein-coding 
non-synonymous (slope 1.2, 95% CI [1.17, 1.27]) and synonymous (slope 1.08, 95% 
CI [1.02, 1.14]) variant shifts. Slopes also differed significantly between each other 
(p<0.0001; Figure 4.11). This fitted with the above data suggesting that coding gene 
variants were subject to less negative selection than other variants. The explanation 
for the ‘positive selection’ of synonymous/non-synonymous variants could be that the 
genetic bottleneck allowed random drift (including drift to higher heteroplasmy levels), 
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especially of those variants that were already at quite high heteroplasmy levels. So it 
was those variants that drifted upwards that were more likely to get passed on. 
 
Figure 4.11. Shift in heteroplasmy level according to mtDNA variant type between 
WtN+ mother and offspring. X axis is maternal heteroplasmy and Y axis is change in 
variant heteroplasmy between mother and offspring. Dots are samples. Solid lines 
are regression lines plotted for each variant type and dotted lines are 95% 
confidence interval for each line. NC is non-coding; non-syn is non-synonymous; syn 
is synonymous; rRNA is ribosomal RNA; tRNA is transfer RNA. Expected is a 




Since complex I (CI) defects are the most frequently encountered type of OXPHOS 
dysfunction, specific complex I non-synonymous mtDNA variants between 
generations G0-G3 were analysed. Complex I mtDNA variant counts (Figure 4.12A) 
and variant frequency per bp (Figure 4.12B) significantly decreased by generation, as 
observed in the protein-coding mtDNA variants in previous analyses shown above 
Figure 4.8. In the same way as described for coding variants, CI non-synonymous 
variants significantly reached higher mutational burdens (Figure 4.12C). 
 
 
Figure 4.12. Complex I non-synonymous mtDNA variants by generation. (A) Number 
of complex I non-synonymous mtDNA variants by generation. (B) Variant frequency 
by generation. Y axis is variants per base pair. (C) Variant load by generation. Y axis 
is heteroplasmy per base pair. Each dot is an individual mouse. P is p-value for 
nonparametric one-way ANOVA between G0, G2 and G3. G stands for generation. 
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4.4.3 Immunofluorescence for mitochondrial respiratory complexes activity 
Quadruple immunofluorescence was used to detect OXPHOS activity in 
mitochondrial respiratory chain complexes I, III, IV and V, in individual colonic crypts. 
Complex deficiency was expressed as a z-score, relative to young healthy control 
(C57BL/6J) mice. Z-scores above -3 were considered normal, below -6 were 
deficient. For each complex, colonic crypts classified as z<-3 included those below 
the normal threshold; z<-4.5 included intermediate and deficient; and z<-6 only 
included fully deficient crypts. Log10-transformed values of complex deficiency were 
used.  
In successive generations of WtN+ female mice, there was a decrease in the 
proportion of complex I deficient crypts (z<-3), which was significant between G2 and 
G3 (p=0.03; Figure 4.13A). This is in keeping with the decrease in number of mtDNA 
mutations seen in successive generations. Data in G3 are shown for the late time 
point (~70w [±5w]).  
Complex III deficient colonic crypts (z<-3) significantly decreased between G2 and 
G3 of WtN+ female mice (Figure 4.13B). Complex IV and complex V were not 
significantly affected throughout any of the generations G1-G3, but deficiency of 
these complexes was very rare (Figure 4.13C/D). 
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Figure 4.13. OXPHOS complexes deficiency in colonic crypts of female WtN+ mice 
throughout generations 1, 2 and 3. Levels of complex I (A), complex III (B), complex 
IV (C) and complex V (D) deficiency were plotted. Severe overall deficiency was only 
seen in complex I. G stands for generation. Z is z-score. CI is complex I. CIII is 
complex III. CIV is complex IV. CV is complex V. Dots are mean ± SEM for each 
generation and deficiency z-score. Shading represents different cut-offs for classing 
crypts as deficient (z-scores of <-6 / <-4.5 / <-3). P is p-value for unpaired t-test of z<-




Quadruple immunofluorescence was used to detect OXPHOS activity in complexes I 
and IV in individual skeletal muscle fibres. For each complex, individual fibres were 
classified into groups as per colonic crypts. For complex I, there was a trend of 
decreasing proportions of deficient fibres across generations G0 to G1, becoming 
near absent in G2/G3, although this did not reach statistical significance (Figure 
4.14A). Defects were minimal in all generations for complex IV (Figure 4.14B). 
 
Figure 4.14. OXPHOS complexes deficiency in skeletal muscle fibres of female WtN+ 
mice throughout generations 0, 1, 2 and 3. Levels of complex I (A) and complex IV 
(B) deficiency were plotted. G stands for generation. Z is z-score. CI is complex I. 
CIV is complex IV. Dots are mean ± SEM for each generation and deficiency z-score. 
Shading represents different cut-offs for classing crypts as deficient (z-scores of <-6 / 




The WtN+ derivative of the PolgA mutator mouse contained a germline mtDNA 
mutational burst on a wild-type inbred nuclear background (C57BL/6J). There were 
some challenges in breeding the mice. Initial intercrosses to produce a homozygous 
mutant female were successful as was generation of heterozygous female offspring 
from this female, which were expected to contain high levels of germline mtDNA 
mutations (G0). Low fecundity was however encountered at the stage of breeding 
from the G0 female mice by back-crossing them with wild-type male mice to restore 
polymerase γ function in the offspring. As founder heterozygous PolgA mice, i.e., 
those without germline mtDNA mutations, usually breed well, it is assumed that the 
high numbers of germline mutations introduced may have been responsible for the 
low fertility, small litter sizes and miscarriages that were observed. Ross, Stewart and 
colleagues found that the germline-transmitted mtDNA mutations that they introduced 
into heterozygous mice (PolgAwt/mut) led to reduced fertility, together with other health 
impairments. These mice produced low litter sizes when intercrossed with male 
heterozygous ‘mutator’ mice to generate homozygous (PolgAmut/mut) mice. However, 
backcrossing with wild-type mtDNA improved litter sizes (Ross et al., 2013). These 
findings by the Larsson group somewhat contradicted the observations in this study, 
as I observed reduced fertility also when backcrossing to wild-type. However, as our 
G0 heterozygous animals were the offspring of a homozygous PolgAmut/mut mother, 
rather than a heterozygous mother as used in the original Ross paper, the greater 
burden of germline mtDNA mutations that I generated is likely to have further 
exacerbated low fecundity. Once the G1 generation of WtN+ mice was established, 
breeding was then normal or near normal. 
To further investigate fecundity in this mouse model, future work could examine 
oocytes and embryos from these mice to determine whether I am seeing embryonic 
lethality or adult infertility. 
Cellular mtDNA content in mouse tissue homogenates from the offspring of the 
homozygous PolgAmut/mut mother showed no significant difference in ear tissue taken 
at early life stage, 4 weeks old, between G0-G3 female generations. Such lack of 
difference indicates that successive generations of these female mice produced from 
the mutator mouse were born with a very similar amount of mtDNA content and that 
the germline mtDNA mutations introduced did not have an effect on mtDNA copy 
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number in early life. Similarly, no differences in mtDNA CN were observed in skeletal 
muscle at 70 weeks of age, which correlates with the findings obtained in quadruple 
immunofluorescence for complex I and complex IV, showing minimal defects. In 
contrast, mtDNA CN in colon at 70 weeks of age was significantly elevated in G0 
when compared to the following generations. The regulation of colon mtDNA CN in 
successive generations G1-G3 may indicate a compensatory response, as G1-G3 
showed a decrease in respiratory chain complex I deficiency. At the age of 70 weeks, 
mtDNA CN levels in frontal cortex were also significantly higher in G0, and decreased 
in successive generations G1, G2 and G3, again suggesting a possible 
compensatory regulation of mtDNA levels in response to the germline mtDNA 
mutational burst. Unfortunately, no immunofluorescence or sequencing was 
performed in these brain samples, as the main focus of this investigation were colon 
and skeletal muscle.  
The results for the ear clipped tissue (age ~4 weeks) cannot be compared in the 
same manner as the other tissues, because colon, skeletal muscle and brain were 
taken at the point of euthanasia (age ~70 weeks). MtDNA content in ear tissue 
accounted for purely mtDNA germline transmission whereas colon, skeletal muscle 
and brain results were likely to be subjected to clonal expansion of germline mtDNA 
mutations (and in the case of G0 only, also of somatic mtDNA mutations). 
Deep sequencing of the mitochondrial genome in ear clipped specimens obtained at 
weaning showed that, although the increase in heteroplasmic variants across 
generations was significant for all types, high levels of heteroplasmy were achieved 
mostly in protein-coding gene variants (synonymous and non-synonymous) in 
generation 3 as opposed to rRNA and tRNA variants. Protein-coding region mtDNA 
variants were tolerated to reach higher levels. In contrast, rRNA and tRNA variants 
did not reach high heteroplasmy levels in the last generation, indicating a plausible 
mechanism for selection against these mutations during germline transmission 
(results from Figure 4.7). These findings disagree with those from Stewart and 
colleagues’ where they saw a strong purifying selection against non-synonymous 
variants but less intense in rRNA or tRNA variants in mtDNA mutator mice (Stewart 
et al., 2008), whereas here protein-coding variants seemed to be less selected 
against compared to tRNA mutations. Moreover, Stewart et al did not look at all the 
mtDNA variant types and track each variant’s heteroplasmy in the way presented in 
this investigation, making our data more reliable.  
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In terms of overall variant frequency, mtDNA sequencing indicated a strong selection 
against mutations in protein-coding genes, rRNA and tRNA genes, as showed in 
previous Figure 4.8. Such purifying pattern of mtDNA variants per bp is consistent 
with the known maternal germline purifying selection (Stewart et al., 2008; Stewart 
and Larsson, 2014).  
Founder heterozygous PolgA mice were sequenced in order to compare their mtDNA 
variant load to that of the WtN+ mice. Basically, newly formed somatic mtDNA 
mutations (which should be all that F0 heterozygous contain) did not reach very high 
heteroplasmy levels compared with the variants seen in the WtN+ animals. This 
probably suggests that the series of embryonic bottlenecks that the mtDNA variants 
pass through once ‘trapped’ in the germline of WtN+ mice allows them to 
progressively ‘ratchet up’, hence the increases in heteroplasmy seen with each 
generation, from the initial low heteroplasmy levels seen for somatic mtDNA variants. 
Number of mtDNA variants per base pair are also lower in the F0 heterozygous than 
any of the WtN+ mice (Figure 4.8), but this is likely because the WtN+ mice were 
generated through a homozygous mutator mother, which will create a lot more new 
variants than a heterozygous mother. 
Quadruple immunofluorescence in colon showed complex I deficiency decreased 
within generations G1-G3 in WtN+ female mice. The same significantly decreasing 
trend of deficiency was observed for complex III between G1-G3, however complex 
IV and V were not affected. Comparison of these changes to those seen for the 
mtDNA mutations on deep sequencing, showed that the earlier generations (which 
had the highest levels of respiratory chain deficiency) were those with the highest 
numbers of mutations at baseline, rather than those with the highest baseline 
heteroplasmy levels.  
Skeletal muscle showed no significant complex I and complex IV defect levels across 
generations, presumably because mtDNA point mutations generally need to achieve 
extremely high heteroplasmy levels to cause OXPHOS defects in skeletal muscle, as 
opposed to mtDNA deletions. 
Overall, the level of all respiratory complexes deficiency decreased along 
generations. 
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Z-scores of -3 to -4.5, which have been termed as ‘intermediate positive’ for studies 
of human skeletal muscle, should be interpreted with caution in the present study 
because no previous studies have validated criteria for respiratory chain intermediate 
crypts in mice. However, in order to make analysis more practical, z-scores of -3 





This breeding strategy successfully produced a new derivative of the PolgA mouse 
‘WtN+’ which transmitted multiple mtDNA point mutations down the maternal line. 
These mutations showed a full range of heteroplasmy levels, and showed expected 
features of drift of mutation levels within mother/offspring pairs, and selection against 
certain mutation types. 
Breeding through a homozygous PolgA mother led to an increase in germline mtDNA 
mutations, but at the expense of reduced fertility in its offspring. 
Point mutations were well conserved through successive generations of WtN+ mice, 
suggesting that this model can be taken forward as a tool in which to track the clonal 





Chapter 5. Phenotypic characterization of the PolgA ‘WtN+’ mouse 
5.1 Introduction 
Phenotyping scoring systems are an important tool for evaluating mouse models of 
various diseases. The mtDNA ‘mutator’ mouse contains a deficient proofreading pol 
γ, which accumulates high levels of somatic mtDNA mutations during its life and a 
premature progeroid phenotype including hair loss, weight loss, shortened lifespan, 
reduced subcutaneous fat, greying, sarcopenia, kyphosis, anaemia and cardiac 
hypertrophy (Trifunovic et al., 2004; Kujoth et al., 2005; Trifunovic et al., 2005). 
These features of accelerated ageing in homozygous mutator mice were not 
detected in heterozygous mice, even though they showed higher mtDNA mutations 
compared to wild-type mice (Trifunovic et al., 2004; Vermulst et al., 2007). However, 
it was later reported that despite the motor function in heterozygous mice not being 
affected, significant metabolic defects were reported showing that both homozygous 
and heterozygous PolgA mice exhibit mitochondrial dysfunction (Dai et al., 2013), 
although possibly reached at a different threshold in each genotype. 
In the present study, a series of non-invasive methods were used to phenotype the 
WtN+ mice, our derivative of the PolgA mtDNA ‘mutator’ mouse, and compared with 
wild-type control mice (wt). The use of standardised phenotypic tests has become 
common practice when developing mouse models in order to characterise particular 
genotypes and link them to behavioural phenotypes.  
Open field activity tests are a popular assessment tool used to investigate animal 
ambulatory behaviour and locomotor function, although the animal’s intrinsic 
response to stimuli and exploration is not fully understood. Metabolic treadmill tests 
are widely used as a way to characterise the cardiovascular fitness of mice 
(Petrosino et al., 2016), of importance because age-related cardiomyopathy has 
previously been reported in mutator mice (Zhang et al., 2003; Dai et al., 2010). 
Moreover, exercise has been proven to alleviate the muscle ageing phenotype in the 
mutator mice (Safdar et al., 2011; Safdar et al., 2016) not by reducing the mtDNA 
mutational load but by decreasing the non-mutational oxidative DNA damage. 
Forelimb grip strength tests have been used for many years to detect skeletal muscle 
dysfunction in mice, particularly in rodent models of neuromuscular disorders 
(Takeshita et al., 2017). The International Mouse Phenotyping Consortium (IMPC) 
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created a phenotyping pipeline called IMPReSS which is seen as the gold-standard 
for mouse phenotyping methodology; in which open field and grip strength tests are 
considered mandatory tests and calorimetry (metabolic treadmill) as non-mandatory 
(Dickinson et al., 2016).  
Modelling the age-related changes across the lifespan of mice aims to make a 
correlation to those observed in humans. Studies comparing life phases in C57BL/6J 
mice and humans showed that although they both have different maturational rates, 
i.e. rates in mice are faster than humans; there are some life phase equivalents 
between them (Figure 5.1). Adult mice from 12-24 weeks (3-6 months) would be 
equivalent to humans ranging from 20-30 years old. Mice from 40-56 weeks (10-14 
months) would correlate to 38-47 years in humans; and finally an old stage of 72-96 
weeks in mice would correlate to 56-69 years old in humans (data from The Jackson 
Laboratory website). 
 
Figure 5.1. Life history stages in C57BL/6J mice in comparison to human beings. 
Data adapted from Flurkey, Currer, and Harrison, 2007. “The mouse in biomedical 
research” in James G. Fox (ed.), American College of Laboratory Animal Medicine 
series (Elsevier). Figure taken from the JAX® website. 
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5.2 Aims of this investigation 
The goal was to use functional assessments to determine the phenotype of the 
animals in the study, PolgA WtN+ mice, in three representative lifespan time points; 




5.3.1 Mouse cohort 
Mice were sexed during genotyping. Genotyping was carried out at 4 weeks old, 
which was the weaning time, and littermates were separated in different cages 
according to genotype and sex. Further genotyping details were detailed in Section 
2.2.2. 
 
5.3.2 Phenotypic testing 
Phenotypic tests included clinical scoring, open field tests, metabolic treadmill and 
grip strength tests as described in Section 2.2. 
 
5.3.3 Statistical analysis 
Differences between mice groups were carried out using two-way ANOVA, or two-
tailed unpaired t-test as appropriate. When one-way ANOVA was significant, a post 
test for multiple comparisons between means was performed if relevant. P<0.05 was 




5.4.1 Body weight  
Weight measurements were recorded during clinical scoring as detailed in Section 
2.2.4. Mice were weighed at a similar time of day to avoid circadian fluctuations. 
Whilst regular weights were performed for monitoring animal welfare, the three key 
phenotyping time points (18, 35, 47 weeks) are presented here as outcome data 
(Figure 5.2). Data were analysed for both sexes and genotypes: WtN+ females, 
WtN+ males, wild-type females and wild-type males. 
 
Figure 5.2. Growth curves of WtN+ and wt mice. This plot shows the mice body 
weight at the three key time points (18, 35, 47w; the dot is mean and error bars are 
SEM; weights from ±1w). (F) is female and (M) is male. (g) is grams and (w) is 
weeks. 
 
A two-way ANOVA was performed for each sex, to assess whether there was an 
interaction between age and genotype on weight. For females, both age (p<0.0001) 
and genotype (p=0.0004) are significantly associated with weight. For males, only 
age is associated (p<0.0001) with weight. In both sexes, there was no interaction 
between age and genotype on weight. 
Upon tissue dissections, all organs were weighed and there were no consistent 
effects of WtN+ genotype observed. 
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5.4.2 Open field tests 
Data were retrieved from the tablet tracking software following open field testing. 
Measurements were used from the first 300 seconds (5 minutes) of the test where 
the mouse was allowed to freely explore the open field. Locomotor activity collected 
by the MouseTrapp (Neurolytical) software included: number of touches (n), number 
of rears (n) (number of times the mouse stood on its hind paws), total distance 
moved (cm), average velocity (cm/millisecond) and average step length (total number 
of touches divided by total distance travelled, in cm). 
On one-way ANOVA there was no significant difference between any of the groups at 
35 and 47 weeks old in any of the measures; the number of touches or steps (Figure 
5.3A), the rearing events (Figure 5.3B), the distance explored (Figure 5.3C), the 




Figure 5.3. Dot plot figures showing the open field test values for both sexes, 
genotypes and age. Open field values measured were number of touches (A), 
number of rears (B), distance explored by the mice (C), the velocity they kept (D) and 
the step length (E). Each dot represents an individual animal. Line at mean. (n) is 
number. (cm) is centimetre. (cm/ms) is centimetre per millisecond. (F) is female and 
(M) is male. W is weeks. 
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For open field activity tests, a longer time point of 75 weeks was also taken for a 
subset of WtN+ females (n=5) along with the time points of 35 and 47 weeks. This 
75-week female time point was then compared to the previous time points in WtN+ 
female mice only. One-way ANOVA showed significant differences between the 
WtN+ females at the three time points (35, 47 and 75 weeks) in number of touches 
(p=0.0006; Figure 5.4A), distance moved (p<0.0001; Figure 5.4C), velocity (p=0.002; 
Figure 5.4D) and step length (p=0.02; Figure 5.4E) but not in rearing behaviour 
(Figure 5.4B). Despite these statistically significant differences, none of the 
parameters appeared to show a progressive change with ageing.  
 132 
 
Figure 5.4. Dot plot figures showing the open field test values for WtN+ females 
across the three time points (35, 47 and 75 weeks old). Open field values measured 
were number of touches (A), number of rears (B), distance explored by the mice (C), 
the velocity they kept (D) and the step length (E). Dots represent individual mice. 
Line at mean. (n) is number. (cm) is centimetre. (cm/ms) is centimetre per 




5.4.3 Metabolic treadmill tests 
Metabolic parameters were measured while the mice were at rest during the first 15 
minutes and for the following 20 minutes during exercise. Owing to the complexity of 
the protocol, metabolic treadmill was performed on a subset of representative 
females (n=5 WtN+ and n=5 wild-type). The metabolic treadmill provided cardio-
metabolic parameters including volume of oxygen consumption (VO2), volume of 
carbon dioxide produced (VCO2), and respiratory exchange ratio (RER) through 
indirect calorimetry and heat production. The gas measurements for oxygen and 
carbon dioxide were normalized to animal body weight and expressed in ml/kg per 
hour. RER is the unit-less ratio of the rate of carbon dioxide production to the rate of 
oxygen consumption (VCO2/VO2). When the animal is metabolizing pure fat for 
energy, its RER is close to 0.70, whereas if it is using pure carbohydrates, RER is 
close to 1.0 (Issekutz et al., 1962). Accordingly, an indication of maximal exertion is 
achieved when RER is ≥ 1.0 but none of the mice were exerted to this level since it 
was not the objective of this study. 
Generally, resting parameters were all lower at 47 weeks than 35 weeks, suggesting 
that mice became less active at rest as they aged (Figure 5.5A-D). 
 134 
 
Figure 5.5. Dot plots showing the metabolic treadmill values at rest for both 
genotypes and age. Values were oxygen consumption (A), CO2 produced (B), 
respiratory exchange ratio (RER, C) and heat produced (D). Each dot is the 




A two-way ANOVA for genotype and age was performed to assess the effect of these 
factors on metabolic values. Age was found to be significantly associated with all the 
cardio-metabolic measures at rest, VO2 (p<0.0001), VCO2 (p<0.0001), RER (p=0.02) 
and heat (p<0.0001). Genotype was only significantly associated with heat 
production (p=0.02) but not with the rest of the parameters. No significant interactions 
between age and genotype were detected on any of the metabolic treadmill 
parameters (Table 5.1).  
 Age genotype 
VO2 p<0.0001 NS 
VCO2 p<0.0001 NS 
RER p=0.02 NS 
Heat p<0.0001 p=0.02 
Table 5.1. Tabular results of two-way ANOVA by age and genotype of the metabolic 




During exercise, no significant differences by age or genotype (or interaction of age 
and genotype) was found in any of the parameters (Figure 5.6A-D). 
 
Figure 5.6. Dot plots showing the metabolic treadmill values during exercise for both 
genotypes and age. Values were oxygen consumption (A), CO2 produced (B), 
respiratory exchange ratio (RER, C) and heat produced (D). Each dot is the 




For metabolic treadmill, a longer time point of 75 weeks was also taken for a subset 
of WtN+ females (n=5) along with the primary outcome time points of 35 and 47 
weeks. This 75-week time point was then compared to the previous time points in 
WtN+ female mice only. At rest, one-way ANOVA between the WtN+ females in the 
three established time points (35, 47 and 75 weeks) showed a significant decrease in 
volume of oxygen consumption (p<0.0001; Figure 5.7A), volume of carbon dioxide 
produced (p<0.0001; Figure 5.7B) and mouse heat production (p<0.0001; Figure 
5.7D) but not in RER (Figure 5.7C) over the time studied. Moreover, post tests for 
trend analysis in VO2 (p<0.0001), VCO2 (p<0.0001) and heat (p<0.0001), showed a 
significant linear decreasing trend. 
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Figure 5.7. Dot plots showing the metabolic treadmill values at rest for WtN+ females 
at the three time points (35, 47 and 75 weeks). Values were oxygen consumption 
(A), CO2 produced (B), respiratory exchange ratio (RER, C) and heat produced (D). 
Each dot is the measurement of a single mouse. Line at mean. (F) is female. P-




During exercise, one-way ANOVA between the WtN+ females showed no significant 
changes in the metabolic treadmill values (Figure 5.8A,C,D) except for a significant 
decrease of CO2 produced over time (p=0.04; Figure 5.8B). Post-test for linear trend 
in CO2 also showed a significant linear trend (p=0.01). 
 
Figure 5.8. Dot plots showing the metabolic treadmill values during exercise for WtN+ 
females at the three time points (35, 47 and 75 weeks). Values were oxygen 
consumption (A), CO2 produced (B), respiratory exchange ratio (RER, C) and heat 
produced (D). Each dot is the measurement of a single mouse. Line at mean. P-
values are one-way ANOVA. W is weeks. 
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5.4.4 Forelimb grip strength  
Grip strength measurements were recorded as described in Section 2.2.7. The three 
repeats measured were averaged and grip strength values were adjusted for the 
weight of each mouse, in order to control for the effects of growth and sex. 
Data were analysed for both sexes and genotypes: WtN+ females and males, wild-
type females and males (Figure 5.9).  
 
Figure 5.9. Dot plots showing the grip strength values for both sexes, genotypes and 
age. Each dot is the mean of three grip strength measurements from a single mouse. 
Line at mean. (F) is female and (M) is male. (g/g) is the grip strength in grams 
adjusted for the mouse body weight in grams. W is weeks. 
 
Two-way ANOVA showed that both genotype (p=0.0004) and age (p<0.0001) were 
significantly associated with grip strength, but there was no interaction between 








All the in vivo functional phenotypic tests aimed to complement each other. There 
was a significant direct impact of age on weight in both sexes, meaning the mice got 
heavier as they aged which is in keeping with what is already well-known for inbred 
male and female mice with a C57BL/6J nuclear background (Figure 5.10). 
Additionally, WtN+ animals were heavier than wt for females only. The relevance of 
this finding is not clear, and could be explained by a ‘batch effect’ as by necessity of 
the breeding scheme, WtN+ and wt animals were drawn from different litters.  
 
Figure 5.10. Body weight information for aged C57BL/6J (000664) mice from The 
Jackson Laboratory. Figures taken from the JAX® website. Boxes extend from the 
25th to 75th percentile. Box line shows median weight and + shows mean weight. 
Whiskers for maximum and minimum weights. 
 
The study of the exploratory behaviour in an open field was performed as a single 
test. Open field tests were first developed in the 1930s in order to assess explorative 
drive, locomotor activity, thigmotaxis behaviour and anxiety in rodents. As such, open 
field reflects a combination of physical and behavioural functions. The incorporation 
of a touch-screen tablet with a specific software tailored to mice allowed for testing of 
basic locomotor parameters of interest in this study. When looking at wild-type and 
WtN+ female and male mice in the two time points, 35 and 47 weeks old, there was 
no significant change in any of the parameters. When comparing the female WtN+ 
groups to the extended time point, 75 weeks old, there were some significant 
differences between the groups, however they were not consistent across the 
locomotor parameters and it was concluded that there was no progressive age-
related deterioration in open field parameters in WtN+ mice. 
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To establish the cardio-metabolic phenotype of mice, the metabolic treadmill was 
used to functionally assess the metabolic rate. Oxygen consumption (VO2) and 
expiration of CO2 were the key outputs. Impaired levels of cardio-metabolic fitness 
could not be detected in WtN+ compared with wild-type animals. It could be argued 
that the metabolic variables reported in this animal assay might not be sufficiently 
sensitive to detect small impairments in cardiovascular fitness. For a more stringent 
and human-equivalent assessment, more variables could ideally have been 
investigated, such as lactate concentrations, the threshold at which aerobic 
metabolisms shifts to anaerobic metabolisms etc. However, these values are quite 
difficult to assess in mouse studies as the one presented here, and those tests that 
were performed here provide an adequate screen in keeping with recommended 
phenotyping protocols. 
At rest, both wt and WtN+ mice became less metabolically active as they aged, 
however, during exercise none of the metabolic parameters measured showed any 
significant differences. 
Forelimb grip strength measurements provided information regarding muscle 
strength. Grip strength (adjusted for body mass) decreased with age in both WtN+ 
and wt animals. In addition, grip strength was lower in WtN+ compared with wt 




Overall, these findings suggest that the mtDNA mutational burden bred into the WtN+ 
mice did not reach the threshold needed for a limiting or impaired locomotor and 
behavioural phenotype, but may cause some decrease in muscle strength. 
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Chapter 6. Mitochondrial, cellular and molecular analyses in the 
WtN+ mouse cohort 
6.1 Introduction 
The generation and the phenotyping of the WtN+ mouse have been discussed in 
Chapter 4 and Chapter 5, respectively, and this present Chapter describes its cellular 
and molecular analyses. 
 
6.2 Experimental Aims 
This work aimed to characterise at the cellular and molecular level the mitochondrial 
dysfunction resulting from mtDNA mutations in the PolgA WtN+ mouse cohort in 
comparison with wild-type (wt) controls. 
 
6.3 Methodology 
In total 95 animals were included in the experimental plan. In order to standardise as 
much as possible the germline mutations between animals, 62 WtN+ experimental 
animals were generated (G3 in the WtN+ breeding strategy, see Section 4.3.1), all 
originating from the same WtN+ grandmother. As a control group, 33 wild-type mice 
were generated by crossing wild-type black 6 (C57BL/6J) females with PolgAwt/wt 
(WtN+) males from the breeding colony. 
 
6.3.1 Tissue processing  
Clipped ear tissue was taken at weaning (age ~4 weeks) and was used for 
genotyping (described in Section 2.2.2), qPCR for mtDNA content, and next 
generation sequencing to investigate mtDNA mutations. All other tissues were 
dissected during organ harvesting. Dissecting of mouse tissues was previously 
explained in Section 2.2.9. DNA used for qPCR and NGS was extracted from tissue 
homogenates as described in Section 2.4.  
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6.3.2 Real-time PCR for mtDNA copy number  
MtDNA content was expressed relative to cell content and was measured in triplicate 
by multiplex qPCR amplification of mitochondrial gene MT-ND5 and the nuclear-
encoded housekeeping gene β-Actin. Primers and probe sequences for this assay 
are found in Section 2.6. 
 
6.3.3 Next generation sequencing of mouse mitochondrial DNA 
Whole mtDNA genomes were enriched using long-range PCR. Primer sequences 
and LR-PCR details found in Section 2.9.1.  
MtDNA point variants were measured on an Illumina MiSeq platform as described in 
Section 2.10. Paired-end fastq files were obtained from the MiSeq platform. 
Bioinformatic sequence analysis and variant calling is described in Section 2.11. 
Ensembl sequence reference used was mm10 (NC_005089.1). MtDNA point variants 




6.3.4 Quadruple immunofluorescence for mouse tissues 
Quadruple immunofluorescence staining and quantification for mouse colon and 
skeletal muscle was performed as detailed in Section 2.7. Microscope snaps of a 
colon (Figure 6.1A) and a skeletal muscle (Figure 6.1B) section are shown below as 




Figure 6.1. Representative immunofluorescence images of a colon and skeletal 
muscle section of a WtN+ female mouse at 48 weeks. (A) Example of representative 
immunofluorescence images for FFPE colon section of a WtN+ female mouse at 48 
weeks. Hoechst was used as a nuclear counterstain as the colonic crypt boundary. 
TOMM20 is the mitochondrial mass marker. Staining was performed in serial 
sections for a NDUFB8 (complex I) and UQCRFS1 (complex III) batch, and a 
subsequent MTCO1 (complex IV) and ATPB (complex V) batch. (B) Example of 
representative immunofluorescence images for frozen skeletal muscle section of a 
WtN+ female mouse at 48 weeks. Laminin is a membrane marker used to define 
individual fibres. Porin is the mitochondrial mass marker. MTCO1 was used for 





Additionally, z-score plots were produced to visually give a representation of the level 
of deficiency for each complex. An example of a z-score plot is found below for 
complex I and III (Figure 6.2A) and complex IV and V (Figure 6.2B). 
 
 
Figure 6.2. Mitochondrial respiratory chain profiles from immunofluorescence results 
for FFPE colon of a WtN+ female mouse at 48 weeks. Graph (A) demonstrates z-
scores distribution for complex I (NDUFB8) and complex III (UQCRFS1); and graph 
(B) for complex IV (MTCO1) and complex V (ATPB). Each point is the z-scores for 
(A) complex I and III or (B) complex IV and V for a single colonic crypt. Bars on the X 
and Y axis indicate category of z-scores: dark blue is negative, light blue is 
intermediate negative, light beige is intermediate positive and orange is normal. 
Dashed lines mark the boundaries of these categories. 
 
6.3.5 Statistical analysis 
Statistical testing was performed using SPSS 24 and Prism V5. Non-parametric 
testing (Spearman correlation) was used for analyses of mtDNA point variants. When 
one-way ANOVA was significant, a post test for multiple comparisons between 




6.4.1 Cellular mitochondrial DNA content in mouse tissue homogenates 
MtDNA content (mtDNA genome copies per cell) did not vary significantly in ear snip 
tissue between experimental female and male wild-type and WtN+ mice at baseline 4 
weeks old (wild-type F, 79 (6), n=16; WtN+ F, 73 (4), n=38; wild-type M, 66 (4), n=24; 
WtN+ M, 68 (3), n=26; one-way ANOVA, p=0.2; Figure 6.3). 
 
Figure 6.3. Mitochondrial DNA copy number levels in baseline ear tissue of wild-type 
and WtN+ mice. MtDNA CN in ear was not significantly different between female and 
male wild-type and WtN+ mice. Every dot represents an individual mouse. Line at 




Cellular mitochondrial DNA copy number in homogenised colon throughout the three 
key harvesting time points (18, 36 and 48 weeks) in wild-type and WtN+ females did 
not vary (wild-type 18w, 146 (8), n=6; WtN+ 18w, 158 (10), n=6; wild-type 36w, 128 
(7), n=4; WtN+ 36w, 139 (7), n=6; wild-type 48w, 141 (9), n=5; WtN+ 48w, 140 (8); 
one-way ANOVA, p=0.3; Figure 6.4A). 
A longer time point of 76 weeks was also taken for a subset of WtN+ females (n=6). 
This 76-week harvesting female time point was then compared to the previous time 
points in WtN+ female mice to assess for an age-related trend in mtDNA CN. This 
analysis showed a significant difference between time points 18, 36, 48 and 76 
weeks (one-way ANOVA, p<0.0001; Figure 6.4B). Tukey’s multiple comparison test 
showed that mtDNA CN in colon of WtN+ females at 76 weeks was significantly 
higher compared to all the previous harvesting time points (Figure 6.4B). 
Colon mtDNA copy number throughout the three key time points (18, 36 and 48 
weeks) did not vary in wild-type and WtN+ males (wild-type 18w, 144 (9), n=10; 
WtN+ 18w, 156 (8), n=7; wild-type 36w, 149 (11), n=4; WtN+ 36w, 157 (9), n=9; wild-
type 48w, 136 (9), n=4; WtN+ 48w, 138 (9), n=8; one-way ANOVA, p=0.5; Figure 
6.4C). 
MtDNA copy number in colon was not significantly different between genotypes and 
sex regardless of age at death (wild-type F, 139 (5), n=15; WtN+ F, 158 (6), n=24; 







Figure 6.4. Mitochondrial DNA copy number levels in homogenised colon. (A) MtDNA 
CN in colon of female wild-type and WtN+ mice at 18, 36 and 48 weeks old was not 
significantly different. (B) MtDNA CN levels in colon of female WtN+ mice at 18, 36, 
48 and 76 weeks old. MtDNA CN in colon was significantly increased in WtN+ 
females at the 76-week harvesting time point. P is p-value for one-way ANOVA. (C) 
MtDNA CN levels in colon of male wild-type and WtN+ mice at 18, 36 and 48 weeks 
old was not significantly different. (D) MtDNA CN levels in colon of female and male 
wild-type and WtN+ mice was not significantly different. Every dot represents an 




Cellular mitochondrial DNA copy number in homogenised skeletal muscle throughout 
the three key harvesting time points (18, 36 and 48 weeks) in wild-type and WtN+ 
females did not vary (wild-type 18w, 1773 (359), n=6; WtN+ 18w, 1662 (128), n=6; 
wild-type 36w, 1500 (198), n=4; WtN+ 36w, 1402 (258), n=6; wild-type 48w, 1240 
(244), n=5; WtN+ 48w, 1422 (201); one-way ANOVA, p=0.7; Figure 6.5A). 
The longer 76-week time point taken for a subset of WtN+ females (n=6) was then 
compared to the previous time points in WtN+ female mice which showed no 
significant difference between time points 18, 36, 48 and 76 weeks (one-way 
ANOVA, p=0.8; Figure 6.5B).  
MtDNA CN in homogenised skeletal muscle was significantly different throughout the 
three key harvesting time points (18, 36 and 48 weeks) in wild-type and WtN+ males 
(one-way ANOVA, p=0.0002; Figure 6.5C). When analysis stratified by genotype was 
performed, mtDNA copy number significantly decreased at the oldest time point in 
comparison with the younger time points in both wild-type (wt 18w, 1645 (125), n=10; 
wt 36w, 1386 (83), n=4; wt 48w, 862 (28), n=4; one-way ANOVA, p=0.003; Figure 
6.5C) and WtN+ males (WtN+ 18w, 1207 (114), n=7; WtN+ 36w, 1551 (161), n=9; 





Figure 6.5. Mitochondrial DNA copy number levels in homogenised skeletal muscle. 
(A) MtDNA CN in skeletal muscle of female wild-type and WtN+ mice at 18, 36 and 
48 weeks old was not significantly different. (B) MtDNA CN levels in skeletal muscle 
of female WtN+ mice at 18, 36, 48 and 76 weeks old was not significantly different. 
(C) MtDNA CN levels in skeletal muscle of male wild-type and WtN+ mice at 18, 36 
and 48 weeks old. MtDNA CN in skeletal muscle was significantly different between 
wt and WtN+ males between the harvesting time points. P is p-value for one-way 
ANOVA. Every dot represents an individual mouse. Line at mean. (F) is female. (M) 
is male. W is weeks. 
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6.4.2 Deep resequencing of mouse mtDNA point variants 
Next generation sequencing of samples from baseline ear snip, homogenised colon 
and skeletal muscle was performed for WtN+ and wild-type female mice. MtDNA 
variant counts (which included the number of non-coding, tRNA, rRNA and protein-
coding variants) observed in ear snip were correlated to those in colon and skeletal 
muscle for the same mouse. Slopes of the regression lines were used to determine 
whether there was any evidence of systematic loss or gain of variants between 
baseline and the age of euthanasia. Slopes for colon and skeletal muscle did not 
differ significantly from the expected correlation line of slope=1, or from each other. 
There was therefore no evidence that mtDNA variants were systematically lost or 
gained in colon (regression line slope 0.99, 95% CI [0.95, 1.025]) or skeletal muscle 
(regression line slope 1.024, 95% CI [0.99, 1.062]) compared with baseline ear snip 
(Figure 6.6).  
 
Figure 6.6. Correlation of number of mtDNA variants per ear snip vs colon and 
skeletal muscle for experimental WtN+ female mice. Var (n) is the count of the 
number of all mtDNA variants with heteroplasmy 2%-98%. MtDNA variants shown for 
all time points, 18, 36, 48 and 76 weeks. Every dot represents an individual mouse. 




I then considered the mtDNA ‘mutation load’ in each mouse by summing the variant 
heteroplasmy levels for each mtDNA variant type. This measure therefore 
encompasses both the number of variants and their heteroplasmy levels. Again the 
slope of the regression lines were examined to see if there was evidence of 
systematic gain or loss of mutation load between baseline (ear snip) and the age at 
euthanasia. On comparing colon with ear snip tissue, there was evidence of a slight 
but statistically significant selection against tRNA variants (regression line slope 0.8, 
95% CI [0.61, 0.99]), but no selection was observed for non-synonymous complex I 
(regression line slope 1.0, 95% CI [0.95, 1.1]) or rRNA (regression line slope 0.95, 
95% CI [0.88, 1.012]) variants (Figure 6.7). 
 
Figure 6.7. MtDNA mutation load for ear snip tissue in relation to homogenised colon 
in WtN+ mice. Load refers to total heteroplasmy load for each variant type. Every dot 
represents an individual mouse. NS_CI refers to the mtDNA non-synonymous 
complex I mutations. rRNA is the ribosomal RNA mtDNA variants. tRNA is the 
transfer RNA mtDNA variants. C is colon. X and Y axis are expressed as log10 




As found for colon, the mutation load of skeletal muscle in relation to ear snip tissue 
for all three mtDNA variant types sat very close to the expected line. However, in 
skeletal muscle no variant type showed a significant difference from expected (Figure 
6.8). No selection was observed against tRNA (regression line slope 1.08, 95% CI 
[0.97, 1.2]), non-synonymous complex I (regression line slope 0.99, 95% CI [0.91, 
1.07]) or rRNA (regression line slope 1.0, 95% CI [0.95, 1.05]) variants. 
 
Figure 6.8. MtDNA mutation load for ear snip tissue in relation to homogenised 
skeletal muscle (skm) in WtN+ mice. Load refers to total heteroplasmy load for each 
variant type. Every dot represents an individual mouse. NS_CI refers to the mtDNA 
non-synonymous complex I mutations. rRNA is the ribosomal RNA mtDNA variants. 
tRNA is the transfer RNA mtDNA variants. M is skeletal muscle. X and Y axis are 





I next considered the heteroplasmy levels of individual mtDNA variants in paired ear 
snip and colon or skeletal muscle samples. Most mtDNA variants were seen at very 
similar heteroplasmy levels in colon compared with ear snip. There were a small 
number of mtDNA variants which were only detected in one or other of the tissues 
(i.e., lying on x or y axis). Distribution of the vast majority of variants sat very close to 
the expected line, suggesting very little selection.  
As in the analyses described above for mutation count and mutation load, I again 
used the slope of the regression line to determine whether there was any systematic 
gain or loss of variant heteroplasmy between baseline and age of euthanasia. In this 
analysis, I saw a very slight, but statistically significant, overall decrease in variant 
heteroplasmy, including all mtDNA variant types for colon (slope 0.95, 95% CI [0.93, 
0.97]) and skeletal muscle (slope 0.93, 95% CI [0.91, 0.95]) (Figure 6.9). 
 
Figure 6.9. Correlation of number of mtDNA heteroplasmies per ear snip vs colon 
and skeletal muscle for experimental WtN+ mice. MtDNA variants shown for all 
variant types and all time points, 18, 36, 48 and 76 weeks. HP is heteroplasmy. 





When examining the effect of mtDNA variant type on the correlation of variant 
heteroplasmy levels in ear snip and colon, I observed that it was only the non-
synonymous mtDNA variants that showed a small but significant selection against 
the expected (regression line slope 0.92, 95% CI [0.89, 0.96]) (Figure 6.10). 
 
Figure 6.10. MtDNA heteroplasmy levels for ear snip variants in relation to colon in 
WtN+ mice per variant type. MtDNA heteroplasmy shown for specific variant types in 
all time points. Every dot represents a variant. HP is heteroplasmy. NC is non-coding. 
Non_syn is non-synonymous. Syn is synonymous. rRNA is ribosomal RNA. tRNA is 




When examining the effect of mouse age on the correlation of variant heteroplasmy 
levels in ear snip and colon, I observed that mtDNA variants in colon of older mice 
appeared to show greater spread in distribution (i.e., to sit further from the expected 
line) (Figure 6.11). This observation is consistent with there being increased drift of 
variants from baseline with increasing age of the animal. This effect is analysed 
further below. 
 
Figure 6.11. MtDNA heteroplasmy levels for ear snip variants in relation to colon in 
WtN+ mice at 18, 36, 48 and 76 weeks. MtDNA heteroplasmy shown for all variant 
types. Every dot represents a variant. HP is heteroplasmy. W is weeks. Expected is a 




From the previous plot, there was a suggestion that the spread, i.e., degree of shift 
from baseline to colon, was wider at 48 and 76 weeks compared to the earlier time 
points. Therefore an analysis of the residuals (r2) of the regression lines of best fit 
was performed. Higher residuals indicate greater differences between observed and 
predicted variant heteroplasmy levels. This would indicate greater dispersion of the 
variant heteroplasmy from baseline. One-way ANOVA of the residuals across all time 
points (18, 36, 48 and 76 weeks) was highly significant (p<0.0001) and showed a 
significant linear trend of increasing residuals with increasing mouse age (p<0.0001) 
(Figure 6.12). This suggests that drift of variant heteroplasmy levels from baseline 
does increase with age in mouse colon. 
 
Figure 6.12. Distribution of residuals from baseline ear snip to colon in WtN+ mice at 





Similarly to colon, when correlating the heteroplasmy levels of individual variants in 
ear snip and skeletal muscle, the distribution of mtDNA variants was very close to 
expected. In skeletal muscle there did not seem to be a change in variant distribution 
with mouse age (Figure 6.13).  
 
Figure 6.13. MtDNA heteroplasmy levels for ear snip variants in relation to skeletal 
muscle in WtN+ mice at 18, 36, 48 and 76 weeks. MtDNA heteroplasmy shown for all 
variant types. Every dot represents a variant. HP is heteroplasmy. W is weeks. 




When specific mtDNA variant types were analysed, non-synonymous mtDNA 
variants showed a small but significant selection against the expected (regression 
line slope 0.9, 95% CI [0.86, 0.94]) (Figure 6.14) as previously seen in colon. 
 
Figure 6.14. MtDNA heteroplasmy levels for ear snip variants in relation to skeletal 
muscle in WtN+ mice per variant type. MtDNA heteroplasmy shown for specific 
variant types in all time points. Every dot represents a variant. HP is heteroplasmy. 
NC is non-coding. Non_syn is non-synonymous. Syn is synonymous. rRNA is 





Again, the residuals of the regression line of best fit were compared across the time 
points to determine if there was an increased drift of variant heteroplasmy from 
baseline with increasing mouse age in skeletal muscle. Although the residuals were 
significantly different between time points for skeletal  muscle, this was driven by the 
residuals being lower at 48 weeks than the other time points and there was no 
significant trend with age as previously seen in the colon samples (Figure 6.15). 
 
Figure 6.15. Distribution of residuals from baseline ear snip to skeletal muscle in 
WtN+ mice at 18, 36, 48 and 76 weeks old. Residuals (r2) were transformed into log10 
values (Y axis). 
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6.4.3 Immunofluorescence for mitochondrial respiratory complexes activity 
The proportion of complex I-deficient colonic crypts increased over time in WtN+ 
mice (non-linear (quadratic) model fit, r=0.76, p<0.001; Figure 6.16). 
 
Figure 6.16. Levels of complex I deficiency in colonic crypts of WtN+ and wild-type 
mice over time. Time points used for WtN+ were 18, 36, 48 and 76 weeks. Wild-type 
values are shown for time points 18 and 48 weeks. Values plotted in the graph are 
deficiency z-scores of <-6. Y axis is log10-transformed values of complex I deficiency. 




The increase in proportion of CI-deficient colonic crypts in WtN+ mice was 
additionally analysed by different severity of CI-deficiency according to z-score cut-off 
(-6, -4.5, -3). All these classes of CI-deficient colonic crypts increased with time in 
WtN+ mice (Figure 6.17).  
 
Figure 6.17. Complex I deficiency over time in colonic crypts of WtN+ mice. Different 
z-score cut-offs show the relative contribution of different degrees of complex I 
deficiency. Regression lines for z-score <-4.5 and <-3 cut-offs are linear whereas for 
<-6 it is quadratic. Shading represents different cut-offs for classing crypts as 
deficient (z-scores of <-6/<-4.5/<-3). Y axis is log10-transformed values of complex I 





The proportions of complex I, III, IV and V deficient crypts at 48 weeks were analysed 
for WtN+ and wild-type mice. The two sexes were pooled for this analysis as there 
was no evidence of an effect of sex on the outcomes of interest. Complex I deficiency 
at the 48-week time point was significantly higher in WtN+ than in wild-type mice (z<-
6 mean (SE), wt, -2.88 (0.08), n=9; WtN+, -2.29 (0.17), n=11; Welch’s t-test, p=0.007; 
Figure 6.18A). Differences were not statistically significant for the other complexes III, 
IV and V (Figure 6.18B, C and D, respectively). 
 
Figure 6.18. OXPHOS complexes deficiency in colonic crypts of wild-type and WtN+ 
mice at 48 weeks. Levels of complex I (A), complex III (B), complex IV (C) and 
complex V (D) deficiency in wt and WtN+ mice colon were plotted. Z is z-score. CI is 
complex I. CIII is complex III. CIV is complex IV. CV is complex V. Dots are mean ± 
SEM for each genotype and deficiency z-score. Shading represents different cut-offs 
for classing crypts as deficient (z-scores of <-6 / <-4.5 / <-3). P is p-value for unpaired 
t-test with Welch’s correction of z<-6 between wt and WtN+. 
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The same immunofluorescence analyses were performed in skeletal muscle, but no 
significant complex I and IV defects were observed between the WtN+ and wild-type 
mice (data not plotted).  
A linear regression model was then used to investigate the relationship between 
complex I deficiency in colon with age and mtDNA mutation types. In order to adjust 
for any differences in number and types of variants at baseline between groups of 
mice of different ages, this model contained age along with the variant type of 
interest. A specific linear regression analysis was performed for every mtDNA variant 
type and showed none of the mutation types, whether measured by total count or 
mutation load (summed heteroplasmy), correlated significantly with complex I defect 
after adjustment for the age of the mouse (Table 6.1). 
Mutation type Regression coefficient (95% CI) P-value 
Total HP (count) 0.01 (-0.03, 0.05) 0.6 
Coding gene (count) 0.01 (-0.03, 0.05) 0.7 
Non-syn coding gene (count) 0.00 (-0.08, 0.07) 0.9 
Non-syn CI (count) -0.03 (-0.12, 0.06) 0.5 
rRNA (count) -0.02 (-0.19, 0.16) 0.9 
tRNA (count) 0.08 (-0.08, 0.23) 0.3 
Non-syn CI (summed HP) 0.00 (0.00, 0.01) 0.6 
rRNA (summed HP) 0.00 (-0.01, 0.01) 0.8 
tRNA (summed HP) 0.00 (-0.01, 0.01) 1.0 
Table 6.1. Correlations between complex I defects in colon, baseline mutation loads 
and age. Values shown for WtN+ mice cohort. Linear regression model used. Table 
is of regression coefficients (B, with 95% CI), and p-value. 95% CI overlapping 0, and 
p>0.05 indicate no significant effect of that factor (mutation load or count) on the 
outcome (complex I defect). Count is the number of mtDNA variants for that mutation 





As expected, mtDNA CN at baseline in ear snip was not significantly different 
between the experimental WtN+ mice cohort and wild-type control mice. This is 
reassuring, as it suggests that mtDNA depletion is unlikely to be a confounding factor 
in our analyses of the effects of the mtDNA mutations present in the WtN+ genotype. 
MtDNA CN in colon was not different between wild-type and WtN+ mice at most time 
points. However, in mice aged to 76 weeks there was an increase in mtDNA CN 
compared to younger animals. This is likely to suggest a compensatory response to 
mitochondrial respiratory chain deficiency as this was the time point at which mice 
showed the highest levels of CI deficiency. In contrast to our findings in colon, 
mtDNA CN in skeletal muscle of the male groups decreased with age in both WtN+ 
and wild-type mice, perhaps in keeping with a decrease in activity levels with age.  
Our comparisons of heteroplasmy levels of variants between baseline (ear snip) and 
colon or skeletal muscle samples allowed us to determine whether there was any 
systematic selection against certain variant types during the life of the animal. Any 
such effects were very small, however there was evidence of slight selection against 
tRNA and non-synonymous variants. These selection effects appeared to be much 
weaker than those observed in the germline (see Chapter 4), suggesting that once 
the heteroplasmic mtDNA variants are established in the germline they cannot be 
strongly selected against in tissues during the animal’s lifespan. Future work could 
test this effect in a highly replicative tissue such as blood to see if there is more post-
embryonic selection possible, as has been described for human mtDNA pathogenic 
mutations such as m.3243A>G. 
The amount of drift of mtDNA variants in colon compared to baseline significantly 
increased with age (as determined by comparison of the regression residuals). This 
linear increase with age was not observed for skeletal muscle. The older WtN+ mice 
time point, 76 weeks, showed more spread away from the expected line than at 
earlier time points, suggesting that over the life of the mouse, the heteroplasmy 
levels of mutations in colon are able to progressively drift further away from baseline. 
Overall, these sequencing findings indicate that mtDNA point mutations in the WtN+ 
mouse appear to be functionally important in colon but not in skeletal muscle. This is 
in keeping with expectations, as colonic crypts are a well-established model of the 
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clonal expansion of mtDNA point mutations with age, whereas it is mtDNA deletions 
that mainly affect skeletal muscle. 
In a similar way, on immunofluorescence analyses of tissue sections, I observed 
mosaic CI deficiency in colonic crypts but not in skeletal muscle fibres. Again, this 
confirmed the pathogenic potential of mtDNA point mutations in ageing colon but not 
muscle. These respiratory chain defects in colon were almost exclusively of CI, with 
minimal defects of CIII, CIV and CV. This presumably reflects the fact that it is far 
more likely for mtDNA point mutations to affect CI genes as they comprise a much 
larger proportion of the mtDNA genome.  
The CI defects in colon increased progressively with mouse age. Linear regression 
analyses confirmed that this effect was explained by the increasing age of the mice, 
and not by differences in baseline mutation levels (counts or loads). Any effect of the 
baseline mutation levels very largely disappeared once age was corrected for. 
Overall, this fits very well with a model of clonal expansion, as it suggests that age 
drives the complex I defect, largely regardless of the baseline mutation count. In 
other words, even quite high levels of mutations at baseline cannot lead to 
respiratory chain defects within individual colonic crypts until there has been 




Overall, these experiments demonstrate that the WtN+ mouse model that I have 
developed appears to have several characteristics that make it a promising model for 
the age-associated clonal expansion of mtDNA point mutations: 
1. A pool of mtDNA mutations present at baseline with a range of heteroplasmy 
levels; 
2. Drift of the heteroplasmy levels of these mutations which increases over time in 
colon, in keeping with the turnover of mtDNA in colonic crypts; 
3. A progressive increase in the proportion of CI deficient crypts with age, which is 
not mediated by a change in the overall number or heteroplasmy level of 
mutations in homogenised tissue. 
These CI deficient crypts are assumed to represent the end-point of clonal expansion 





Chapter 7. Clonal expansion of mtDNA mutations leading to 
complex I deficiency in single colonic crypts 
7.1 Introduction 
In the preceding chapters I have described the generation of a new derivative of the 
PolgA mouse, ‘WtN+’, which contains multiple heteroplasmic mtDNA point mutations, 
transmitted via the maternal germline, along with a wild-type nuclear background. As 
described in Chapter 6, this mouse appeared to have a number of characteristics that 
suggested it was a feasible model for studying the clonal expansion of mtDNA point 
mutations in ageing and disease, including antiretroviral treatment. 
In order to confirm that the increases in the proportions of CI-deficient colonic crypts 
observed in the WtN+ mouse were due to the clonal expansion of mtDNA mutations 
within individual crypts it was necessary to perform molecular studies comparing CI-
deficient and normal crypts to the homogenised colon. 
A few studies report capturing of single colonic crypts in frozen tissue by laser 
microdissection (Taylor et al., 2003; Greaves et al., 2012; Baines et al., 2014; 
Kauppila et al., 2016), but to date no studies have reported mtDNA isolation in FFPE 
colon tissue due to the difficulty in successfully obtaining good DNA yield and quality. 
Given that the identification of CI-deficient crypts requires the use of 
immunohistochemistry on FFPE tissue (as opposed to histochemistry on unfixed 
frozen tissue), it is highly desirable to be able to study mtDNA in colonic crypts from 
FFPE tissue. 
 
7.2 Experimental Aims 
To confirm that the clonal expansion of mtDNA mutations has caused the observed 




7.3.1 Laser microdissection of single colonic crypts 
FFPE colon sections were cut on to uncharged and noncoated glass slides at 4 µm 
for laser microdissection and underwent immunofluorescence staining and 
microscopy imaging as described in Sections 2.7.4 and 2.7.5, respectively. Images of 
immunofluorescently labelled colon sections were used as a map to then manually 
find the complex I deficient crypts under brightfield illumination on the laser 
microdissection microscope. Single mouse colonic crypts were laser microdissected 
as described in Section 2.8 (Figure 7.1). 
 
Figure 7.1. Example of a laser microdissected colonic crypt from a WtN+ mouse used 
in this study. Images of the colon section taken before (A) and after (B) dissecting 
out of a single mouse colonic crypt. Scale bar is 150 µm. 
 
Laser microdissection of single colonic crypts and optimal amplification of DNA 
sequences for subsequent deep sequencing had to undergo several rounds of 
optimisation. Optimisation work included LR-PCR from single and pooled colonic 
crypts, which was not successful, testing of different number of crypts in a pool, 
qPCR on pools of single crypts and different sizes of PCR amplicons. Pools of 
colonic crypts were tested from two until 20, and DNA amplicons were obtained in 
pools of 15 colonic crypts. Real-time qPCR performed in some representative single 
colonic crypts gave Ct values of 33-40, which indicated very low amounts of mtDNA, 
in keeping with the failure of PCR amplification for sequencing from single colonic 
crypts. Different sizes of amplicons were also tested in primers amplifying interest 
areas of mtDNA complex I, and the best fragments to use were three ~600bp 
amplicons and three ~300bp amplicons. 
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For each sample, 15 single colonic crypts were cut and pooled. Every time single 
cell(s) or single colonic crypt(s) term is used in this Chapter, it will refer to a pool of 
15 single colonic crypts. 
As the respiratory chain defects I had observed on immunofluorescence staining 
were overwhelmingly affecting CI, I studied CI-deficient crypts and compared them 
with CI-normal crypts and with the homogenised colon from the same mouse. 
 
7.3.2 Next generation sequencing of mouse mitochondrial DNA 
Primers for the amplicons of the complex I region in the mitochondrial genome were 
designed to amplify areas with specific mtDNA variants previously seen at >10% 
heteroplasmy levels in homogenate colon tissue of WtN+ mice. 
Mouse mtDNA was enriched using a PCR protocol consisting of the same reagents 
as were used for the LR-PCR protocol (Section 2.9.1). PCR conditions consisted of 
an initial denaturation at 95°C for three minutes, followed by 45 cycles of 
denaturation at 95°C for 30 seconds, annealing at 55°C for 30 seconds and 
extension at 68°C for 30 seconds, and one with a final extension step at 72°C for five 
minutes. Primer sequences for the six fragments amplified are found in Table 7.1. 
 
Table 7.1. Primers for the amplification of mitochondrial genome fragments from 
complex I used for next generation sequencing of mouse single colonic crypts. 
Primers from IDT. 
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MtDNA point variants were measured on an Illumina MiSeq platform as described in 
Section 2.10. Paired-end fastq files were obtained from the MiSeq platform. 
Bioinformatic sequence analysis and variant calling is described in Section 2.11. 
Ensembl sequence reference used was mm10 (NC_005089.1). MtDNA point variants 
present at 2% to 98% heteroplasmy were reported. Coverage graph is found in 
Appendix 10.10. 
Fragment 1 spanned from position m.2665 to m.3331; fragment 2 from m.3131-
m.3841; fragment 3 from m.4793-m.5102; fragment 4 from m.10627-m.11270; 
fragment 5 from m.11629-m.11950; and fragment 6 from m.13815-m.14115. 
Fragments are mapped in Figure 7.2. 
 
Figure 7.2. Schematic of the mouse mitochondrial genome, mapped with the 
amplified fragments from complex I used for next generation sequencing of mouse 
single colonic crypts. Fragments in blue (1, 2 and 4) are longer amplicons (~600bp). 




Complex I deficiency was established using immunofluorescence for complex I, using 
NDUFB8 subunit antibody. Single colonic crypts were categorised as normal if the 
fluorescence for NDUFB8 was in the normal range (z-score>-3), and deficient if 
NDUFB8 z-score values fell below -6, as described in Section 2.7.6. 
For the study of single colonic crypts presented in this Chapter, only representative 
females from the 48-week time point were used; two wild-type: mouse 104 and 
mouse 111; and two WtN+: mouse 76 and mouse 77. For each WtN+ mouse, one 
normal complex I and two complex I deficient single colonic crypt pools were 
analysed. 
Nine mtDNA mutations with varying levels of heteroplasmy found initially in the 
sequencing results of homogenised colon of representative mice, were used to 
design the NGS primers for the sequencing of the six fragments across complex I 
genes in single colonic crypts. The heteroplasmy levels of these pre-specified 
mutations were then analysed in the normal and CI-deficient single colonic crypts of 
the WtN+ mice (Table 7.2) and in the normal single crypts of the wild-type. These 
pre-specified mutations were all non-synonymous complex I mtDNA variants, and 
therefore expected to have a functional effect on CI within cells.  
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Table 7.2. MtDNA heteroplasmy levels for the non-synonymous complex I mutations 
chosen from homogenate colon and used to investigate clonal expansion in single 
colonic crypts. MtDNA heteroplasmy levels are shown for the two WtN+ mice studied 
(mouse 76 and 77), in complex I normal and deficient single colonic crypts; whereas 
these mutations were not found in the wild-type mice.  means variant not present. 
Ref is reference base, Alt is alternate base. Normal means non-deficient complex I. 




Deep sequencing of homogenised colon was done for the whole mitochondrial 
genome (results for the mouse cohort were discussed in Chapter 6). Mutation load, 
the overall summed heteroplasmy of non-synonymous complex I variants, in WtN+ 
mice was higher in CI-deficient colonic crypts than in CI normal crypts or in 
homogenised colon (Figure 7.3). Note that in Figure 7.3 I am initially presenting the 
analysis of all non-synonymous CI mutations captured by the MiSeq assay, whether 
part of the pre-specified set of mutations or not. I later show this analysis restricted 
only to those pre-specified mutations (see below). 
As expected, mutation loads in crypts from wild-type mice were very low, although 
were slightly higher than seen in colon homogenate (where no mutations were seen). 
This may reflect low levels of somatic mtDNA mutations in colon of these mice, or 
may reflect an increase in assay noise due to amplifying from very low starting 
quantities of mtDNA in single crypts.  
 
Figure 7.3. All mtDNA mutational load for non-synonymous complex I variants in wild-
type and WtN+ mice. Grey box is mutation load for homogenate colon, which 
includes all mtDNA non-synonymous CI variants. Red dot is mutation load for 
complex I deficient crypts. Green dot is mutation load for complex I normal crypts. 
Red and green dots represent results for the non-synonymous CI variants present in 
the six fragments sequenced in single colonic crypts. 
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Although the amplicons were designed to detect specific non-synonymous CI mtDNA 
mutations, other CI variants and tRNA mutations were also captured. Unlike for CI 
mutations, tRNA mutation loads did not appear to segregate with CI-deficient crypts 
(Figure 7.4). This suggests that it is indeed non-synonymous CI mutations that are 
driving CI deficiency in single crypts, and not other mutation types.  
 
Figure 7.4. All mtDNA mutational load for tRNA variants in wild-type and WtN+ mice. 
Grey box is mutation load for homogenate colon. Red dot is mutation load for 




I then performed the same analysis of mutation load restricted only to the pre-
specified mtDNA non-synonymous complex I mutations shown in Table 7.2. The 
distribution pattern was very similar to that found before for all non-synonymous CI 
mutations with higher mutation loads in CI-deficient single crypts of WtN+ mice 
compared with CI-normal crypts or colon homogenate (Figure 7.5). None of these 
mutations were seen in single crypts of wild-type mice. 
 
Figure 7.5. Pre-specified mtDNA non-synonymous complex I mutations in wild-type 
and WtN+ mice. These only include the pre-specified list of mutations from Table 7.2 
seen in the homogenate colon for that mouse. Grey box is mutation load for 
homogenate colon. Red dot is mutation load for complex I deficient crypts. Green dot 




Next, analysis of the heteroplasmy levels of the specific mtDNA mutations between 
CI-deficient and normal crypts was performed, by comparing each to its 
heteroplasmy level in homogenised colon of the same mouse. The fold-change of 
heteroplasmy for every pre-specified mtDNA mutation between homogenised colon 
and single crypts was calculated by dividing the heteroplasmy of the mutation in the 
normal or CI-deficient colonic crypt by the heteroplasmy of the same mutation in the 
colon homogenate of the same WtN+ mouse. In the two WtN+ mice, there was a 
significant increase in heteroplasmy of mtDNA non-synonymous CI mutations in 
single colonic crypts compared to the respective colon homogenate (fold-change 
mean 2.6, 95% CI [1.2, 4]). In CI-normal single colonic crypts, mutation heteroplasmy 
levels were numerically lower than in colon homogenate although this did not quite 
reach statistical significance (fold-change mean 0.64, 95% CI [0.24, 1.05]) (Figure 
7.6). Fold changes of heteroplasmy levels relative to colon homogenate in CI-
deficient single crypts were significantly higher than for CI-normal crypts (p=0.021).  
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Figure 7.6. Fold-change of heteroplasmy levels for the pre-specified mtDNA non-
synonymous complex I mutations in WtN+ mice. These only include the pre-specified 
list of mutations from Table 7.2 seen in the homogenate colon for that mouse. Data 
plotted for both WtN+ mice. Dotted line at 1 indicates homogenate colon 
heteroplasmy levels. Each dot is an individual pre-specified mtDNA point mutation. 
Red dot is mutation load for complex I deficient crypts. Green dot is mutation load for 
complex I normal crypts. P is p-value for t-test. HP is heteroplasmy. Lines at mean 




Finally, I investigated whether the CI-deficiency in individual crypts was driven by the 
clonal expansion of a specific mtDNA mutation. From the protein-coding, non-
synonymous complex I variants included in this assay, four mtDNA variants were 
clearly identified which strongly segregated with complex I deficiency in colonic 
crypts: mt.3205C>T, found in MT-ND1, S(serine)/L(leucine); mt.4829C>G, found in 
MT-ND2,  P(proline)/A(alanine); mt.4833C>T, found in MT-ND2, 
T(threonine)/I(isoleucine); and mt.11025G>A, found in MT-ND4, 
A(alanine)/T(threonine) (Figure 7.7). Of these, mt.11025G>A appeared likely to have 
the greatest effect as it reached the highest heteroplasmy levels in CI-deficient single 
crypts along with very low heteroplasmy levels in CI-normal crypts. 
 
Figure 7.7. Heteroplasmy levels for the pre-specified individual mtDNA non-
synonymous complex I mutations detected in WtN+ mice. These only include the pre-
specified list of mutations from Table 7.2 seen in the homogenate colon for that 
mouse, represented on the X axis. Arrows indicate specific mtDNA mutations which 
segregate with complex I deficiency. Of these, mt.11025 (darker arrow) appears to 
be the most important. Grey box is mutation load for homogenate colon. Red dot is 
mutation load for complex I deficient crypts. Green dot is mutation load for complex I 




In humans, a pathogenic homoplasmic mtDNA point mutation in the MT-ND4 gene of 
complex I (mt.11778G>A) is associated with LHON. This mtDNA mutation and a few 
others in MT-ND1, MT-ND4 and MT-ND6 are the primary causative variants in the 
majority of LHON cases, which show a specific clinical phenotype affecting the optic 
nerve cells and presenting with visual loss (Yu-Wai-Man et al., 2002; Carelli et al., 
2004). 
The above example sets a precedent for how single mtDNA point variants in 
pathogenic locations of complex I genes can trigger mitochondrial dysfunction in 
specific organs. In the case presented in this Chapter, four mtDNA point mutations 
were identified as the main drivers of complex I deficiency in single colonic crypts of 
WtN+ mice. 
When comparing these mtDNA point mutations driving complex I deficiency in single 
colonic crypts to their heteroplasmy levels in homogenised colon, a substantial shift 
was found in heteroplasmy, being higher in single crypts compared to colon 
homogenates. Such finding explains why although the total mutational load in colon 
homogenate is relatively low, within single colon cells the individual mtDNA point 
mutations can accumulate to high levels and therefore cause a biochemical defect, 
as observed in immunofluorescence for complex I. 
Differences in heteroplasmy levels of non-synonymous complex I mutations were 
able to explain the mosaic pattern of complex I normal and deficient crypts. This 
effect of non-synonymous complex I variants was not apparent from looking at the 
sequencing data for the homogenates only. This parallels very well published 
observations in human colon in ageing, where there was no substantial increase in 
overall mutation burden with age, but the proportion of mitochondrially-deficient 
crypts increases with age due to clonal expansion (Baines et al., 2014; Greaves et 
al., 2014).  
Seven subunits of complex I are encoded by the mitochondrial genome, ND1-ND6 
and ND4L, and are thought to be in charge of pumping protons; whereas the 38 
remaining subunits making up complex I are nuclear encoded, and are thought to be 
responsible for oxidation of NADH and electron transfer (Janssen et al., 2006). 
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In this study, the mtDNA mutation which showed the most dramatic segregation with 
CI deficiency in single crypts, mt.11025G>A, was found in the gene ND4. It could be 
argued that this non-synonymous substitution may affect the assembly of the whole 
of complex I as ND4 is assembled at a late stage, together with ND5, in the 
hydrophobic membrane arm (Mathiesen and Hagerhall, 2002). ND4 is therefore 
essential for the assembly of the membrane arm of complex I, which is the first 
complex responsible for proton translocation in the OXPHOS system (Figure 7.8). 
 
Figure 7.8. Schematic graph of mammalian mitochondrial complex I structure. The 
proton pumping module of complex I, located in the hydrophobic membrane arm, is 
composed of the seven subunits encoded by mtDNA, ND1-ND6 and ND4L. Image 
taken from (Mimaki et al., 2012). 
 
Pathogenic mutations in mitochondrial ND4 assembly causing defects or truncations 
in humans have not been reported in the literature, but they could be key for the 
proper anchorage of complex I to the mitochondrial inner membrane. 
The other two mtDNA mutations likely to be driving CI-deficiency (mt.4829C>G and 
mt.4833C>T) were found in the ND2 gene. ND2 is also found in the membrane arm 
of complex I, according to the current model of complex I assembly (Figure 7.8), and 
is rarely affected by pathogenic mutations in humans. In a single case though, a 
mutation in ND2 was found to be pathogenically associated with LHON (Brown et al., 
1992). In patient-derived cells containing a non-synonymous mutation in ND2 
(mt.4681) found at above 95% heteroplasmy, there was evidence of a complex I 
defect presenting with Leigh Syndrome (Ugalde et al., 2007). 
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At this point, it is not clear to which extent these mutations disrupt the conformation 
of these subunits, but it is plausible that single deleterious mtDNA point mutations 
need to be present at high heteroplasmy levels in single cells in order to produce 
deficiency. It is also possible that the CI deficiency initially observed during 
immunofluorescence was driven by more than one mtDNA non-synonymous point 
mutation that have clonally expanded at the single crypt level. 
A potential limitation of studying pooled crypts could be argued. By pooling crypts, I 
was more likely to see multiple high level heteroplasmies, whereas if a true single 
crypt were studied I may be more likely to observe a single high level clonally 
expanded mtDNA variant. Studying pooled crypts would therefore actually make it 
harder to detect clonal expansion of individual mutations, but I was nevertheless able 
to do this successfully (Figures 7.5/7.6). This approach has therefore proven 





There were shifts in mtDNA mutation heteroplasmy levels in single colonic crypts 
compared with the homogenate tissue. This is strong direct evidence of clonal 
expansion of mtDNA point mutations leading to a mosaic pattern of CI deficiency. 
This confirms that the observations described in Chapter 6 are indeed the result of 
clonal expansion, and confirms that our WtN+ mouse model is a feasible model for 
studying clonal expansion in vivo.  
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Chapter 8. Investigating the effects of antiretroviral drug exposure 
on clonal expansion of mtDNA mutations in ‘WtN+’ mice 
8.1 Introduction 
The first FDA-approved antiretroviral drug, AZT, was reported to cause mitochondrial 
myopathy in HIV-treated patients (Helbert et al., 1988; Dalakas et al., 1990; Peters et 
al., 1993). Some studies showed cessation of AZT therapy to stop or alleviate 
myopathy clinical symptoms (Helbert et al., 1988; Masanes et al., 1998).  
The polymerase γ hypothesis stated that NRTIs cause mitochondrial toxicity by 
inhibiting pol γ during mtDNA replication (Lewis, 2003). Biochemical studies defined 
the affinity of NRTIs to be greater for the mitochondrial pol γ than for other nuclear 
DNA polymerases (Kakuda, 2000). A “hierarchy” of pol γ in vitro inhibition was then 
proposed for specific NRTIs: ddC>ddI>d4T>>3TC>TDF>AZT>ABC (Johnson et al., 
2001; Lim and Copeland, 2001; Lewis et al., 2003). 
AZT is a relatively weak polymerase γ inhibitor but has been hypothesised to also 
cause mtDNA mutagenesis (Balcarek et al., 2010; Cooper and Lovett, 2011), likely 
by inhibiting mitochondrial thymidine kinase 2 (TK2) leading to imbalance of dNTP 
pools (Rylova et al., 2005; Akman et al., 2008). In addition, inhibition of pol γ by 
incorporation of AZT into the elongating mtDNA chain may make AZT less likely to be 
efficiently removed from the mtDNA by the pol γ (Lim and Copeland, 2001). 
As reported in the literature, mouse models have been used to study effects of 
antiretroviral drugs, in particular NRTIs and protease inhibitors (Koczor et al., 2010; 
Koneru et al., 2014; Zhang et al., 2014; Zhang et al., 2015). Studies in mice showed 
that AZT exposure in utero, without HIV infection, led to cardiac dysfunction (Walker 
et al., 2004a), and damaged cardiomyocytic mitochondria were observed in mice 
exposed to AZT/3TC in utero and postnatally (Bishop et al., 2004). MtDNA damage 
in heart tissue of AZT-treated mice was found in a subsequent study (Chan et al., 
2007). These findings are relevant for human studies since AZT was frequently used, 
either alone or in combination, to treat HIV-infected pregnant women to prevent 
mother-to-child transmission of HIV, as well as their newborn infants. There was also 
some evidence reported linking AZT to mild cardiomyopathy in humans, but this has 
not been conclusively proven by subsequent studies (Herskowitz et al., 1992). It was 
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also observed that the active form of AZT, AZT-triphosphate, altered mitochondrial 
dynamics in myoblast cultured cells (Nomura et al., 2017). AZT-treated animals show 
abnormal mitochondrial morphology as well as reduced mtDNA content, 
mitochondrial RNA and polypeptide synthesis in skeletal muscle compared with 
untreated animals (Lewis et al., 1992).  
It has previously been demonstrated that NRTI exposure is associated with an 
excess of mtDNA mutations in HIV positive people. I have hypothesised that this 
increase in mtDNA mutations results in accelerated clonal expansion of pre-existing 
(age-associated) mtDNA mutations, rather than increased mutagenesis. This effect 
on mtDNA might plausibly drive phenotypic features of ageing in people living with 
HIV. To date, it has not been possible to test this hypothesis empirically as there has 
not been a good model in which to study the age-associated clonal expansion of 
mtDNA mutations within a feasible timescale.  
The PolgA WtN+ mouse model that I have described in the preceding chapters is 
therefore a potential tool for assessing the causative effects of NRTIs on mtDNA 
mutations and the ageing phenotype. This rodent model was used which 
demonstrates physiological ageing within a feasible timescale in order to investigate 
clonal expansion.  
 
8.2 Experimental Aims 
To determine whether NRTI therapy modifies the rate of clonal expansion of mtDNA 




The WtN+ mouse cohort was used for the following investigation. The generation, 
phenotyping and cellular and molecular analyses of the WtN+ mouse have been 
described in Chapters 4, 5 and 6, respectively. 
 
8.3.1 Zidovudine dosage in WtN+ female mice 
Retrovir (zidovudine, AZT) syrup 50 mg/5ml was acquired as a liquid formulation 
(ViiV Healthcare, GlaxoSmithKline). To achieve a human equivalent dose of 120 
mg/kg/d, 24.7 mg AZT were added per 30 ml bottle of drinking water. Dosing per ml 
of drinking water was calculated based on anticipated daily volumes of water 
consumed per mouse. Prior to commencing the experiment, the palatability of 
Retrovir was tested on a separate pilot cage of mice to ensure it did not affect oral 
intake and adjustments were made to the drinking water if necessary. It was 
confirmed that the AZT did not affect oral water intake. 
Weight loss and anaemia were recognised adverse effects of the genotype and/or 
NRTI treatment, with humane limits of >30% weight loss, and clinical score 
>moderate (10-14). 
 
8.3.2 Tissue processing  
Clipped ear tissue was taken at weaning (age ~4 weeks) and was used for qPCR for 
mtDNA content and next generation sequencing to investigate mtDNA mutations. All 
other tissues were dissected during organ harvesting. Dissecting of mouse tissues 
was previously explained in Section 2.2.9. DNA used for qPCR and NGS was 
extracted from tissue homogenates as described in Section 2.4.  
 
8.3.3 Real-time PCR for mtDNA copy number  
MtDNA content was expressed relative to cell content and was measured in triplicate 
by multiplex real-time qPCR amplification of mitochondrial gene MT-ND5 and the 
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nuclear-encoded housekeeping gene β-Actin. Primers and probe sequences for this 
assay are found in Section 2.6. 
 
8.3.4 Next generation sequencing of mouse mitochondrial DNA 
Whole mtDNA genomes were enriched using long-range PCR. Primer sequences 
and LR-PCR details found in Section 2.9.1.  
MtDNA point variants were measured on an Illumina MiSeq platform as described in 
Section 2.10. Paired-end fastq files were obtained from the MiSeq platform. 
Bioinformatic sequence analysis and variant calling is described in Section 2.11. 
Ensembl sequence reference used was mm10 (NC_005089.1). MtDNA point variants 
present at 2% to 98% heteroplasmy were reported. 
 
8.3.5 Quadruple immunofluorescence for mouse tissues 
Quadruple immunofluorescence staining and quantification for mitochondrial 
respiratory chain defects in mouse colon and skeletal muscle was performed as 
detailed in Section 2.7. 
 
8.3.6 Phenotypic testing 
Phenotypic tests included clinical scoring, open field tests, metabolic treadmill and 
grip strength tests as described in Section 2.2. Effects of AZT were analysed in the 
phenotypic tests performed.  
 
8.3.7 Statistical analysis 
Specific statistical analysis were carried out using correlation, linear regression, 
ANOVA, or two-tailed unpaired t-test as appropriate. When ANOVA was significant, a 




8.4.1 Zidovudine-induced toxicity 
Three cages of WtN+ female mice (n=14 mice in total) were dosed via drinking water 
with AZT. They were 20 weeks of age at the start of treatment. This age was chosen 
to ensure that only adult mice were exposed to AZT, in order to model exposure to 
AZT in an HIV positive person for a finite period during adulthood. The treatment had 
been first checked for palatability without any problems.  
After 7 weeks of AZT treatment, of an intended 12 weeks, a subset of mice (n=6) 
developed rapid onset of weight loss (ranging from 18-30%), anaemia, lethargy and 
dehydration (Figure 8.1). Due to toxicity, this subset of WtN+ female mice reached a 
pre-specified humane endpoint and were culled at 27 weeks, by schedule 1 method. 
This occurred after 7 weeks of exposure to AZT.  
 
Figure 8.1. Body weights for WtN+ female mice on AZT treatment for 7 weeks during 
which they developed toxicity. This subset of mice (n=6) developed weight loss very 




Other littermate mice (n=8) who had also had 7 weeks of AZT treatment however 
showed no weight loss, only mild anaemia, and no other adverse effects. These mice 
were monitored daily and soaked diet was given as a precaution, until weights were 
confirmed to have remained stable, and any mild anaemia had resolved. This group 
remained well and were able to complete the planned protocol of AZT treatment. 
Those mice not experiencing toxicity were treated for 12 weeks. After stopping the 
drug dosing, a period of washout was allowed before harvesting of the animal. This 
washout period was designed to allow any inhibition of pol γ caused by AZT to 
resolve. Thus, when tissues were harvested, I should observe any effects of altered 
clonal expansion, but not the acute effects of current AZT treatment, such as mtDNA 
depletion. 
From these eight AZT-treated WtN+ mice, four were culled at 36 weeks and four at 
48 weeks. The WtN+ AZT mice harvested at 36 weeks therefore had AZT treatment 
for 12 weeks and then a washout period of 3 weeks before euthanasia. The WtN+ 
AZT harvested at 48 weeks, had AZT treatment for 12 weeks as well and then a 
longer washout period of 15 weeks before euthanasia (Figure 8.2). 
 
Figure 8.2. Timeline of AZT drug dosing and washout. Three groups of mice (n=14) 
were dosed with zidovudine liquid formulation diluted in drinking water. All WtN+ 
female mice started treatment at 20 weeks. The first cage (n=6) was dosed for 7 
weeks before having to be euthanised due to toxicity at 27 weeks. The second cage 
(n=4) was dosed for 12 weeks and had a 3-week washout period without the drug 
before harvesting at 36 weeks. The third cage (n=4) was dosed for 12 weeks too and 
had a 15-week washout period before harvesting at 48 weeks. Orange is the duration 
of AZT treatment. N is number. 
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8.4.2 Cellular mitochondrial DNA content in mouse tissue homogenates 
MtDNA content (mtDNA genome copies per cell) did not vary significantly in 
homogenised colon between female WtN+ AZT-treated and untreated mice at 36 
weeks old (mean (SE) mtDNA copies/cell; WtN+ 36w AZT, 123 (10), n=4; WtN+ 36w, 
139 (7), n=6; unpaired t-test, p=0.2; Figure 8.3A). At 48 weeks, mtDNA CN in colon 
was significantly lower in WtN+ AZT compared to untreated WtN+ mice (WtN+ 48w 
AZT, 114 (7), n=4; WtN+ 48w, 140 (8), n=6; unpaired t-test, p=0.048; Figure 8.3A).  
Cellular mtDNA content was not significantly different in homogenised skeletal 
muscle between female WtN+ AZT and untreated mice at 36 (WtN+ 36w AZT, 1694 
(70), n=4; WtN+ 36w, 1402 (258), n=6; unpaired t-test, p=0.4) and 48 weeks old 
(WtN+ 48w AZT, 1982 (196), n=4; WtN+ 48w, 1422 (201), n=6; unpaired t-test, 
p=0.09; Figure 8.3B).  
MtDNA content in homogenised frontal cortex was not significantly different between 
WtN+ AZT and untreated mice at 48 weeks (WtN+ 48w AZT, 1020 (99), n=4; WtN+ 
48w, 990 (134), n=6; unpaired t-test, p=0.9; Figure 8.3C).  
MtDNA CN was not different in the tail of WtN+ AZT mice compared to the untreated 
WtN+ mice at 48 weeks (WtN+ 48w AZT, 142 (16), n=4; WtN+ 48w, 140 (8), n=6; 
unpaired t-test, p=0.9; Figure 8.3D). 
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Figure 8.3. Mitochondrial DNA copy number levels in homogenised tissues of female 
AZT-treated WtN+ and untreated WtN+ mice. (A) MtDNA CN in colon of WtN+ AZT 
at 27, 36 and 48 weeks, and WtN+ at 18, 36 and 48 weeks. MtDNA CN in colon was 
not significantly different in AZT-treated and untreated groups at 36 weeks but it was 
significantly lower in AZT-treated compared to untreated at 48 weeks. (B) MtDNA CN 
in skeletal muscle of the same groups was not significantly different between the 36 
and 48-week groups. (C) MtDNA CN in frontal cortex for AZT groups and untreated 
48-week WtN+ mice. MtDNA CN in brain was not significantly different between the 
48-week groups. (D) MtDNA CN in tail of AZT groups and untreated 48-week WtN+ 
mice. MtDNA CN in tail was not significantly different between the 48-week groups. 
Every dot represents an individual mouse. Line at mean. (F) is female. W is weeks. 
 
Despite small differences in mtDNA at different time points and in different tissues, in 
general there was no consistent trend of mtDNA copy number levels across the 
tissues tested.  
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8.4.3 Deep resequencing of mouse mtDNA point variants 
Next generation sequencing of samples from baseline ear snip, homogenised colon 
and skeletal muscle were analysed in order to make comparisons of AZT-treated to 
untreated WtN+ female mice. MtDNA variant counts (which included the number of 
non-coding, tRNA, rRNA and protein-coding variants) observed in ear snip were 
correlated to those in colon and skeletal muscle for the same mouse, in the AZT-
treated and untreated WtN+ mouse groups. There was no effect of AZT on the 
correlation of variant numbers between baseline (ear snip) and colon or skeletal 
muscle (Figure 8.4). This suggests that AZT treatment was not associated with 
systematic loss or gain of variants. 
 
Figure 8.4. Correlation of number of mtDNA variants per ear snip vs colon and 
skeletal muscle for WtN+ AZT-treated and untreated mice. Var (n) is the count of the 
number of all mtDNA variants with heteroplasmy 2%-98%. MtDNA variants shown for 
36-week and 48-week AZT time points, but excluded the 27-week toxicity time point. 
Every dot represents an individual mouse. C is colon. M is skeletal muscle. C_AZT is 




The mutation load, the overall summed heteroplasmy for each mtDNA variant type, of 
colon was also well correlated to that of the ear snip tissue. As observed for the 
untreated WtN+ mice, there was a very slight selection against tRNA variants in 
colon (regression line slope 0.87, 95% CI [0.78, 0.97]). No selection was observed 
for non-synonymous complex I (regression line slope 0.9, 95% CI [0.75, 1.05]) and 
rRNA (regression line slope 0.8, 95% CI [0.6, 1.002]) variants in colon of AZT-treated 
mice (Figure 8.5).  
 
Figure 8.5. MtDNA mutation load for ear snip tissue in relation to homogenised colon 
in WtN+ AZT-treated mice. Load refers to total heteroplasmy load for each variant 
type. Every dot represents an individual mouse. NS_CI refers to the mtDNA non-
synonymous complex I mutations. rRNA is the ribosomal RNA mtDNA variants. tRNA 
is the transfer RNA mtDNA variants. C is colon. X and Y axis are expressed as log10 




I next examined the correlation between heteroplasmy levels of individual variants in 
ear snip and colon of AZT-treated mice. At both 48 weeks (regression line slope 
0.84, 95% CI [0.76, 0.92]) and 36 weeks (slope 0.9, 95% CI [0.84, 0.96]) (Figure 8.6), 
there was evidence of slight selection against mtDNA variant heteroplasmy levels in 
colon. 
 
Figure 8.6. MtDNA heteroplasmy levels for ear snip variants in relation to colon in 
WtN+ AZT-treated mice. MtDNA heteroplasmy shown for all variant types at 36-week 
and 48-week AZT time points, but excluded the 27-week toxicity time point. Every dot 
represents a variant. C is colon. HP is heteroplasmy. Expected is a positive linear 




Residuals (r2) are the difference between observed and expected values on the 
regression line of best fit. Therefore, the distribution of variant heteroplasmy residuals 
is a measure of how much drift there is in heteroplasmy from baseline ear snip to 
colon. In the AZT-treated WtN+ mice, I observed that the drift of mtDNA mutations in 
colon increased. AZT treatment was associated with a significant increase in the 
dispersion of mtDNA mutation heteroplasmy in colon compared with baseline. This 
dispersion was greater at the 48-week compared with the 36-week time point. One-
way ANOVA was significant (p<0.0001), and further post hoc test showed a 
significant difference between AZT-treated and untreated residuals in colon at 36 
weeks (p<0.0001) and at 48 weeks (p<0.0001) (Figure 8.7A). Residuals in colon 
showed a significant progressive increase with age in AZT-treated mice (slope 
significantly non-zero, p=0.006) as opposed to no significant effect on treatment 
naïve mice (slope not different from zero, p=0.6) (Figure 8.7B). 
 
Figure 8.7. Distribution of residuals in colon in AZT-treated and untreated WtN+ mice. 
(A) Dispersion of residuals from baseline ear snip to colon in both groups, 36 and 48 
weeks old. (B) Increase of residuals in colon for all time points measured in AZT 
(black) and treatment naïve (green) mice. 27-week toxicity time point is included. 




The same analyses were then applied to skeletal muscle. No effect of AZT treatment 
was observed in the correlation of total mutation load (summed heteroplasmy) 
between baseline ear snip and skeletal muscle mtDNA variants in non-synonymous 
complex I, rRNA and tRNA positions (Figure 8.8). 
 
Figure 8.8. MtDNA mutation load for ear snip tissue in relation to homogenised 
skeletal muscle (skm) in WtN+ AZT-treated mice. Load refers to total heteroplasmy 
load for each variant type. Every dot represents an individual mouse. NS_CI refers to 
the mtDNA non-synonymous complex I mutations. rRNA is the ribosomal RNA 
mtDNA variants. tRNA is the transfer RNA mtDNA variants. M is skeletal muscle. X 
and Y axis are expressed as log10 values. Expected is a positive linear correlation 




Next, I examined the heteroplasmy levels of individual mtDNA variants in skeletal 
muscle compared with ear snip of AZT-treated WtN+ mice. In both the 48-week 
group (regression line slope 0.86, 95% CI [0.79, 0.92]) and the 36-week (slope 0.93, 
95% CI [0.88, 0.98]) there was slight selection against variant heteroplasmy in 
skeletal muscle (Figure 8.9).  
 
Figure 8.9. MtDNA heteroplasmy levels for ear snip variants in relation to skeletal 
muscle in WtN+ AZT-treated mice. MtDNA heteroplasmy shown for all variant types 
at 36-week and 48-week AZT time points, but excluded the 27-week toxicity time 
point. Every dot represents a variant. M is skeletal muscle. HP is heteroplasmy. 




As for the analyses on colon, I then used the regression residuals to assess the 
amount of drift of mtDNA variants in skeletal muscle compared to ear snip. Unlike in 
colon, there was no significant effect of either age or AZT treatment on the dispersion 
of variants in skeletal muscle (Figure 8.10A, Figure 8.10B). 
 
Figure 8.10. Distribution of residuals in skeletal muscle in AZT-treated and untreated 
WtN+ mice. (A) Dispersion of residuals from baseline ear snip to skeletal muscle in 
both groups, 36 and 48 weeks old. (B) Residuals in skeletal muscle for all time points 
measured in AZT (black) and treatment naïve (green) mice. 27-week time point is 
included. Dots are mean ± SEM for each time point. 
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8.4.4 Sequencing analysis of AZT-related toxicity 
I then examined the mtDNA analysis performed in baseline ear snip for the subset of 
AZT-treated mice that were euthanised due to toxicity at 27 weeks old and compared 
to the other AZT-treated mice that did not get treatment-related toxicity. This was in 
order to determine whether the group exhibiting toxicity had a predisposition to more 
severe effects of AZT due to differences in baseline mtDNA mutations. This analysis 
showed that there was no difference in the mutation counts or loads (summed 
heteroplasmy) at baseline that would explain why one subset got AZT toxicity and the 
other did not (Figure 8.11).  
 
Figure 8.11. MtDNA mutation count and load for WtN+ AZT-treated mice with toxicity 
and without. Count is the number of total mtDNA variants with heteroplasmy 2%-
98%. Load refers to total heteroplasmy load for each variant type. Every dot 
represents an individual mouse. Dotted line at mean. CI refers to the mtDNA non-
synonymous complex I mutations. rRNA is the ribosomal RNA mtDNA variants. tRNA 
is the transfer RNA mtDNA variants. Tox is the subset of AZT mice that got toxicity. 




The same mtDNA analysis was performed in colon and skeletal muscle to compare 
the subset of AZT-treated mice that were euthanised due to toxicity at 27 weeks old 
to the other AZT-treated mice. As seen for the baseline results, this again showed 
that there was no difference in the mutation counts between the AZT-treated mice 
with toxicity and the ones without toxicity for both colon (Figure 8.12A) and skeletal 
muscle (Figure 8.12B).  
 
Figure 8.12. MtDNA mutation count and load in colon and skeletal muscle of WtN+ 
AZT-treated mice with toxicity and without. Values are shown for colon (A) and 
skeletal muscle (B). Count is the number of total mtDNA variants with heteroplasmy 
2%-98%. Load refers to total heteroplasmy load for each variant type. Every dot 
represents an individual mouse. Dotted line at mean. CI refers to the mtDNA non-
synonymous complex I mutations. rRNA is the ribosomal RNA mtDNA variants. tRNA 
is the transfer RNA mtDNA variants. Tox is the subset of AZT mice that got toxicity. 
No_tox is the subset that did not get toxicity. Y axis is expressed as log10 values. 
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8.4.5 Immunofluorescence for mitochondrial respiratory complexes activity 
As detailed previously, WtN+ female mice were treated with AZT from week 20 to 
week 32 (shaded blue on plots), then returned to normal drinking water and culled at 
week 36 or 48. Some AZT-treated mice were also culled at week 27 due to anaemia. 
Complex I defects were much higher in AZT-treated mice at week 36, then 
decreased by week 48, though not back to the level of untreated mice (Figure 8.13A).  
At 48 weeks, the difference between AZT-treated and untreated groups was 
significant for crypts with deficiency z-scores of z<-3 (p=0.001) and z<-4.5 (p=0.039), 
but not the severe deficiency of z<-6 (p=0.33) (Figure 8.13B). 
 
Figure 8.13. Complex I deficiency in colonic crypts of different genotypes and AZT 
exposure. (A) CI deficiency increased dramatically in the AZT-treated mice compared 
to the untreated group. Wild-type values are represented in the last time point as a 
reference. Shaded blue is AZT treatment duration. 27-week AZT mice included as 
valid data point. (B) CI deficient crypts in treated and untreated at 36 and 48 weeks. 
Dots are mean ± SEM for each time point (A) and deficiency z-score (B). CI is 
complex I. Wt is wild-type. W is weeks. Z is z-score. 
 
The remaining complexes analysed in colon (complexes III, IV and V) did not show 
any significant deficiency (data not plotted). 
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The same immunofluorescence analysis was performed in skeletal muscle, but no 
significant complex I defects were observed in any of the AZT-exposed WtN+ mice, 
the untreated WtN+ or the wild-type mice (Figure 8.14).  
 
Figure 8.14. Complex I deficiency in skeletal muscle of different genotypes and AZT 
exposure. Shaded blue is AZT treatment duration. 27-week AZT mice included as 
valid data point. Dots are mean ± SEM for each time point. CI is complex I. Wt is 
wild-type. W is weeks.  
 
The other complex analysed in quadruple immunofluorescence of skeletal muscle, 
complex IV, also did not show any significant deficiency (data not plotted). 
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8.4.6 Open field tests 
Open field test data were obtained as previously described in Section 2.2.5, and 
results for the untreated ageing mouse cohort were already analysed in Section 
5.4.2. 
Analysis was performed for the AZT-treated and untreated female WtN+ mice at 35 
and 47 weeks old, in all the open field parameters. Only the rearing of AZT mice at 
47 weeks was significantly increased (p=0.03) compared to the WtN+ treatment 
naïve mice of the same time point (Figure 8.15B). The other measures of locomotor 
activity were not significantly different in the AZT groups.  
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Figure 8.15. Dot plot figures showing the open field test values for AZT-treated and 
untreated female WtN+ mice at 35 and 47 weeks old. Open field values measured 
were number of touches (A), number of rears (B), distance explored by the mice (C), 
the velocity they kept (D) and the step length (E). Each dot represents an individual 
animal. Line at mean. (n) is number. (cm) is centimetre. (cm/ms) is centimetre per 
millisecond. (F) is female. W is weeks. P is p-value for t-test. 
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8.4.7 Metabolic treadmill tests  
Metabolic parameters were measured as previously described in Section 2.2.6, and 
results for the untreated ageing mouse cohort were already analysed in Section 
5.4.3. 
Metabolic treadmill results were only taken at the 35-week time point for AZT-treated 
mice. At rest, metabolic treadmill parameters in 35-week old AZT-treated mice were 
significantly lower compared with untreated WtN+ mice, except for RER (Figure 
8.16). Specifically, the AZT-treated group showed significant decreases in VO2 
(p=0.0005; Figure 8.16A), VCO2 (p=0.0005; Figure 8.16B) and heat (p=0.0002; 




Figure 8.16. Dot plots showing the metabolic treadmill values at rest for AZT-treated 
and untreated female WtN+ mice at 35 weeks old. Values were oxygen consumption 
(A), CO2 produced (B), respiratory exchange ratio (RER, C) and heat produced (D). 
Each dot is the measurement of a single mouse. P is p-value for t-test. Line at mean. 




During exercise, there were no significant differences between AZT-treated and 
untreated WtN+ mice at 35 weeks on any parameter (Figure 8.17). 
 
Figure 8.17. Dot plots showing the metabolic treadmill values during exercise for 
AZT-treated and untreated female WtN+ mice at 35 weeks old. Values were oxygen 
consumption (A), CO2 produced (B), respiratory exchange ratio (RER, C) and heat 




8.4.8 Forelimb grip strength 
Grip strength measurements were recorded as explained in Section 2.2.7. The three 
repeats measured were averaged and grip strength was adjusted for body weight. 
Results for the untreated ageing mouse cohort were already analysed in Section 
5.4.6. 
As observed for the untreated WtN+ female mice, the AZT-treated groups showed a 
significant decrease in grip strength between 35 and 47 weeks old (two-tailed 
unpaired t-test, p=0.02). Grip strength values were plotted to compare AZT-treated 
and untreated female WtN+ mice at 35 and 47 weeks old. A two-way ANOVA was 
performed for the female sex, to assess whether there was an interaction between 
age and AZT drug consumption on grip strength. The two-way ANOVA showed a 
strong association of grip strength with age (p=0.0002), but there was no effect of 
AZT (Figure 8.18). Therefore, grip strength decreased significantly with age, but not 
with AZT. 
 
Figure 8.18. Dot plot showing the grip strength values for AZT-treated and untreated 
female WtN+ mice at 35 and 47 weeks old. Each dot is the mean of three grip 
strength measurements from a single mouse. (F) is female. (g/g) is the grip strength 




Whilst the adverse effects observed, weight loss and anaemia, were expected as 
part of the ageing phenotype in this model, these were clearly potentiated in some 
mice by the AZT treatment. Anaemia has been linked with zidovudine use in HIV-
infected humans (Richman et al., 1987; Dainiak et al., 1988; Fischl et al., 1990; 
Falguera et al., 1995; Semba et al., 2002; Volberding et al., 2004; Agarwal et al., 
2010; Dash et al., 2015). 
It was not clear why some mice experienced significant weight loss whereas others 
did not. I hypothesized that this may have been a ‘double hit’ of the mitochondrial 
defect and the treatment, however I was not able to demonstrate any differences in 
baseline, colon or skeletal muscle mtDNA mutations at euthanasia time point that 
predicted toxicity. 
MtDNA CN results showed that there were no consistent patterns of mtDNA 
depletion with AZT treatment. The small changes observed were predicted by the 
fact that AZT is only a weak inhibitor of pol γ and as such, there was no expectation 
to observe large amounts of mtDNA depletion. 
Sequencing of the mitochondrial genome of colon showed a selection against tRNA 
variants in the AZT WtN+ group, which was already found in Chapter 6 for untreated 
WtN+ mice, as opposed to no selection observed in skeletal muscle for these groups. 
The selection was no different in the presence or absence of AZT treatment. It should 
be specifically noted that no increase in number of mtDNA mutations was seen with 
AZT treatment, suggesting that AZT was not having a mutagenic effect in this 
experiment, at least within the limits of sensitivity of our MiSeq assay. 
There was however, a progressive increase in residuals (i.e. drift of variants) over 
time in the colon of AZT-treated mice. This effect was much smaller without AZT 
treatment. This meant that AZT treatment resulted in a greater than expected 
divergence in mtDNA variant heteroplasmy between baseline ear snip and colon. 
These results altogether suggested that AZT may have modified clonal expansion of 
mtDNA mutations by accelerating drift of variant heteroplasmy, as hypothesised. 
These effects were not seen in skeletal muscle. As discussed previously, AZT is a 
relatively weak pol γ inhibitor and therefore did not cause significant mtDNA depletion 
in our model. This suggests that the accelerated drift of mtDNA heteroplasmy was 
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not caused by a molecular bottleneck effect (as occurs when the number of mtDNA 
molecules is profoundly reduced, for example during embryogenesis). Instead I 
hypothesise that the interfering effect of AZT on mtDNA replication (via pol γ and/or 
TK2) is nevertheless sufficient to increase the turnover of the mtDNA pool, leading to 
accelerated drift in mutation heteroplasmy.  
The AZT-exposed 36-week WtN+ mice had a markedly worse complex I defect in 
colon than the untreated, and this difference persisted, although was reduced, in the 
48-week AZT group. These findings could be due do the differences in washout 
durations. The 36-week group had a drug washout period of three weeks before the 
harvesting of the animal, which may not have allowed for complete recovery of 
mtDNA replication. The 48-week group had 15 weeks washout, which would certainly 
be expected to be long enough for complete recovery. The observation that CI 
defects remain significantly higher in previously AZT-exposed mice at 48 weeks 
compared with untreated mice despite the long period of drug washout is further 
strong evidence that clonal expansion may have been affected. This is in keeping 
with the predictions of in silico simulation models of clonal expansion, where after a 
finite period of NRTI exposure, the COX defect is predicted to continue to increase, 
even after the drug has been washed out (Payne et al., 2011). 
In terms of phenotyping results, no relevant differences were observed in the AZT 
cohort in the open field test. Similarly, grip strength was not associated with AZT 
treatment. In the metabolic treadmill test, AZT mice had significantly reduced 
metabolic values at rest but not during exercise. This suggests that the AZT-treated 
mice have adopted a more sedentary behaviour, perhaps due to either mitochondrial 
dysfunction or subclinical anaemia. However, the lack of effects of AZT treatment on 
metabolic parameters on exercise suggests that the AZT treatment did not lead to 




This experiment gave some preliminary evidence that partial inhibition of mtDNA 
replication by an NRTI antiretroviral drug may increase clonal expansion of mtDNA 
mutations in the colon of our WtN+ mouse model as: 
1. AZT treatment was associated with an increase in the drift of mtDNA mutations 
in colon; 
2. AZT treatment resulted in an increase in CI-deficient colonic crypts (the end 
result of clonal expansion of mtDNA mutations), despite no evidence of mtDNA 
depletion and no increase in overall mtDNA mutation burden; 
3. This effect appeared to exist even after washout of the drug, meaning it was not 
just a transient effect of current drug exposure. 
Nevertheless, this effect was small and would need to be confirmed over a longer 
time course. Unfortunately, this was also limited by toxicity concerns.  
This experiment also provided proof-of-concept that clonal expansion is a potentially 
modifiable process in our mouse model. 
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Chapter 9. General Discussion 
9.1 Major findings 
9.1.1 Mitochondrial DNA damage in human brain, HIV infection and 
antiretroviral treatment 
The study of mtDNA damage in HIV infection in the setting of antiretroviral treatment 
and ageing was performed in frontal cortex homogenised samples. Age-associated 
mtDNA changes were observed as an increase in mtDNA point mutations and 
deletions and a decrease in mtDNA content. All of those changes were augmented in 
the HIV infected cohort in comparison to uninfected controls. Depletion of mtDNA has 
already been reported in ageing and neurodegenerative conditions such as 
Parkinson’s disease (Grunewald et al., 2015; Dolle et al., 2016; Pyle et al., 2016). 
These measures of molecular mtDNA damage (mtDNA point mutations, deletions 
and mtDNA content) were not associated with HIV disease progression markers, 
including lymphocyte counts and HIV RNA viral load, ART regimens or 
neurocognitive impairment measurements. These findings show an increase in ‘brain 
ageing’ in HIV-infected patients, which has been previously reported in brain imaging 
studies (Underwood et al., 2017; van Zoest et al., 2017), but not in a molecular study 
like this one. 
To this author’s knowledge, the sequencing approach used in this study was novel in 
that whole mitochondrial genome was sequenced and therefore all mtDNA variant 
types were analysed. 
The age-associated decrease in mtDNA quantity and quality in PLWH compared to 
uninfected controls was observed to be augmented by the effects of HIV infection but 
not by ART. These findings contradict the myriad of in vitro and in vivo studies that 
have demonstrated associations between mtDNA depletion and ART, specifically 
certain older NRTIs which inhibit pol γ (Arnaudo et al., 1991; Casademont et al., 
1996; Dalakas et al., 2001; Lim and Copeland, 2001; Cote et al., 2002; Walker et al., 
2004b; Buffet et al., 2005; Haugaard et al., 2005; Cherry et al., 2006). The 
penetrance of ART in the CNS needs further investigation in order to determine if 
antiretroviral agents penetrate differently into the brain parenchyma, but comparison 
of ART levels in CSF and serum suggest that for many ART drugs, CNS levels are 
likely to be lower (Letendre et al., 2008; Yilmaz et al., 2012). It is therefore possible 
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that the level at which ART needs to be present in the CNS in order to cause mtDNA 
damage is not reached, meaning that the HIV effect predominates over any ART 
effect. As it seems to be HIV rather than ART that is driving the mtDNA defects, then 
full suppression of virus in the CNS (which is challenging due to the presence of CNS 
reservoirs) is probably a more important clinical consideration than the potential 
toxicities of ART drugs.  
Viral proteins released in the cellular microenvironment could have a more highly 
deleterious effect in CNS cells than in other tissues. The fact that HIV infection on its 
own, without ART, produced the mtDNA changes observed is likely due to an HIV-
mediated neurotoxicity associated with mitochondrial dysfunction. This could be 
explained by the fact that neurons contain large amounts of mitochondria, therefore 
mtDNA damage plausibly leads to neuronal dysfunction. These mtDNA changes 
could either be a direct effect or an indirect effect, that is, mtDNA damage could 
either be the cause or consequence of neuronal injury in HIV. Moreover, gliosis and 
neuronal loss are common phenomena in brains of patients with HAD and although 
severe forms of neurocognitive impairment are less prevalent now than in previous 
decades, mitochondrially-induced neurotoxicity could still have an impact in the 
conformation, health or even survival of CNS cell function. 
No consistent relationship could be established in our findings of mtDNA damage 
and the neurocognitive impairment of the HIV cohort. Despite that the majority of HIV 
patients were on antiretroviral treatment, they were predominantly 
immunosuppressed with low CD4 counts. The fact that the HIV positive group 
showed advanced HIV (mean CD4 count 143 cells/µl) places some limitations on the 
generalisability of our findings to the whole HIV-infected population. More extensive 
studies should be conducted in larger sets of cases where HIV is consistently 
suppressed, however the availability of brain tissue from such patients is very limited. 
Moreover, a large number of factors are likely to contribute to NCI in people living 
with HIV, so it may be that the effects of mtDNA changes are masked by other 
factors, for example, depression and lifestyle factors (De Francesco et al., 2019). 
In addition, the clinical records provided to us from the biobanks reported that the 
majority of patients who were on ART at the time of last assessment had taken many 
different classes of antiretroviral regimens throughout their course of disease, 
sometimes in an on and off manner over many years. The nature of long-term and 
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such highly heterogeneous exposure to combination antiretroviral therapy makes it 
very difficult to assess the separate effects of individual classes of ART in 
mitochondrial molecular studies like the ones presented here. 
Finding good animal or cellular models of the brain in which to study the impact of 
both HIV and ART simultaneously remains a challenge. Rodent studies of transgenic 
animals expressing env, tat or pol HIV genes cannot fully mimic HIV infection in 
human hosts (Saylor et al., 2016). This human environment is difficult to replicate 
because it requires infectious and inflammatory molecular processes, the host 
immune response and the fact that the HIV genome integrates in different types of 
cells around the body. Monkey models have been used to study simian 
immunodeficiency virus (SIV) in order to mimic HIV pathogenesis, but to this author’s 
knowledge, there are not any rodent studies that have looked at the combined effect 
of ART and HIV on brain (Gorantla et al., 2012). 
Limitations from the methodology used in the human brain study include that the 
DNA content obtained came from a homogenate of all the cell types found in the 
frontal grey matter of the brain. Therefore, results reported were expressed at the 
whole-tissue level. The poor morphological quality of fresh frozen brain tissue from 
the biobanks precluded any single cell studies. This likely reflects the post-mortem 
interval inherent in autopsy studies. If higher quality fresh frozen brain tissue had 
been available, laser microdissection of specific neurons could have been conducted, 
along with immunofluorescence for OXPHOS complex activity. This single cell assay 
would have given an indication of the mtDNA point mutation and deletion load in 
specific brain cell types. Another technique would have been fluorescence-activated 
cell sorting (FACS) to separate out astrocytes or glial cells in order to obtain a more 
homogeneous population for the study of mtDNA CN and the sequencing of mtDNA 
point mutations. If whole tissue was provided and there had been more time, other 
functional analyses could have been done including Western blotting for OXPHOS 
complex proteins. FFPE brain tissue from these biobanks could be studied as this 
should retain a higher quality tissue architecture. It may however be technically 




9.1.2 PolgA ‘WtN+’ mouse model of clonal expansion of mtDNA mutations in 
ageing 
I generated a new mouse model with which to study the natural history of 
mitochondrial DNA mutations in ageing and disease. Specifically this model allowed 
us to study the critical biological process of clonal expansion of mitochondrial DNA 
mutations within cells – something which has not been previously possible. 
This mouse was characterised at the cellular, molecular and organismal levels. The 
data generated supported the hypothesis that the phenotypic consequences of 
mitochondrial DNA mutations in ageing result from the clonal expansion of the 
mutations within cells, rather than the mutations per se. This hypothesis has been 
widely discussed in the literature but has never been able to be empirically proved. 
The aim of the mouse cohort was to produce a good model of clonal expansion, 
which according to the results presented was successful.  
Our novel WtN+ mouse model is unique and better in comparison to other current 
models, which are not optimal. The prototype model of mitochondrial ageing, the 
PolgA mouse, continuously produces very high levels of somatic mtDNA mutations 
which far exceed those seen in aged humans. This leads to a number of serious 
problems in its use as a model of human ageing, including: overly high mutation 
levels; the ageing phenotype being predominantly driven by very early mitochondrial 
dysfunction in stem cells, not by clonal expansion in somatic tissues; and since new 
mutations are constantly being produced, it is impossible to tell what is clonal 
expansion and what is mutagenesis (Trifunovic et al., 2004; Kujoth et al., 2005). 
Another rodent model derived from the PolgA mouse, the tRNAALA mouse, has a 
single trapped mtDNA germline mutation. This is much less representative of human 
ageing than a pool of multiple mtDNA mutations as I have generated in our study. 
Also, the mutation in the tRNAALA mouse is present at a very high heteroplasmy level 
at baseline and appears to be selected against during life (Kauppila et al., 2016). 
During the breeding scheme for our WtN+ mice, the fertility difficulties that arose 
could suggest an early embryonic lethality. To further look into that, future work could 
investigate mtDNA mutations in embryos and oocytes of those mice although that 
was not part of the original study design.  
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Phenotypic investigations of the WtN+ model as presented in Chapter 5 showed that 
the model did not have a dramatic progeroid phenotype. This makes it difficult to 
make clear conclusions about the link between clonal expansion of mtDNA mutations 
and physical manifestations of the ageing process. However, a limitation for the 
phenotypic characterisation could be that the mice could have been aged for longer 
had there been more time, in order to show a more accentuated ageing phenotype. 
WtN+ aged mice were however weaker, with lower grip strength relative to their size, 
compared to wild-type mice. This is likely to indicate that there is some detrimental 
phenotypic effect of the mtDNA mutations on muscle function and/or body 
composition. 
MtDNA copy number was higher in colon of the oldest WtN+ mice, which was likely 
to be a compensatory response to the increasing complex I deficiency. 
Selection of mtDNA variants was stronger throughout successive generations of 
WtN+ mice (as described in Chapter 4) than during the lifetime of the experimental 
G3 WtN+ mice (as described in Chapter 6), suggesting the mechanism of germline 
purifying selection was more stringent than the one observed for somatic tissues, i.e., 
the extent to which the inherited mtDNA mutations were subject to selection during 
oogenesis/embryogenesis was stronger than any effect during the life of the mouse.  
The WtN+ mice generated showed multiple mtDNA variants which were transmitted 
through the maternal germline. These were present at a wide range of heteroplasmy 
levels from 2% (the limit of the assay) to >50%. On the one hand, relatively high level 
heteroplasmies (around 50%) are ideal for studying clonal expansion as they will be 
expected to allow the largest shifts in heteroplasmy. However, as a model of mtDNA 
mutations in humans this is a potential limitation, as the mutations that ultimately 
clonally expand in single cells in ageing humans are likely to be initially present at 
very low heteroplasmy levels (Payne et al., 2012). In a similar way, in our human 
brain sequencing data, somatic mtDNA mutations were generally present at low 
heteroplasmy levels (<10%). In our mouse model, very low-level heteroplasmic 
mutations (near 2%) were frequently lost during maternal transmission, such that it 
was the higher level heteroplasmies that tended to persist through successive 
generations. Clonal expansion of mtDNA mutations is thought to be a gradual 
process, which requires many cycles of mtDNA turnover. Over a typical human 
lifespan (~80 years) there is likely to be sufficient time for even very low level 
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heteroplasmic mtDNA mutations to clonally expand within individual cells. In contrast, 
in a mouse model of clonal expansion this needs to be achieved in a timespan that 
fits with the life expectancy of the laboratory mouse as well as other experimental 
constraints (<~2 years). In order for clonal expansion events to be observed within 
this shorter timescale likely requires baseline heteroplasmy levels to be higher. 
Therefore, although our mouse model did not perfectly recapitulate mtDNA mutations 
in normal human ageing, it nevertheless provides a useful model with which to study 
the clonal expansion of mtDNA mutations. 
There were very small changes in skeletal muscle mtDNA mutations, as opposed to 
colon, confirming previous work in colonic crypts, which showed it to be the best 
tissue in which to study clonal expansion of mtDNA point mutations (Baines et al., 
2014).  
Finally, the study of pooled individual mouse colonic crypts empirically proved the 
clonal expansion of complex I mutations. This approach shows that clonal expansion 
cannot be reliably inferred simply by looking for changes in heteroplasmy levels in 
tissue homogenates compared with baseline. At the whole tissue level, I saw no 
systematic increases in mutation heteroplasmy levels, and in some cases, slight 
negative selection. Instead, I showed that the increasing drift of heteroplasmy levels 
away from baseline with increasing age in colon is what provides evidence that clonal 
expansion could occur. This concept was then confirmed through the single crypt 
analyses. 
One limitation of our work is that this is only a model for the clonal expansion of 
mtDNA point mutations and not for deletions. Deletions in our study were not 
generated, and I expect that they would not be tolerated to be transmitted through 
the maternal germline. Therefore, a model of the clonal expansion of mtDNA 
deletions would require another means of generating deletions in the mouse. A 
transgenic mouse model expressing mouse Twinkle with PEO patient mutations 
results in accumulation of mtDNA deletions but does not show a premature ageing 
phenotype possibly due to the short lifespan of mice not allowing phenotype 
expression (Tyynismaa et al., 2005). Therefore, better mouse models to study 
mtDNA deletions are needed. 
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9.1.3 Antiretroviral drug exposure on WtN+ mice 
The initial question was to investigate whether AZT produced de novo mtDNA 
mutations or lead to clonal expansion of existing mtDNA mutations. AZT was used to 
explore whether the rate of clonal expansion of mtDNA mutations in our novel WtN+ 
mouse model was able to be modified.  
A subset of AZT-treated WtN+ mice reached a humane endpoint at 27 weeks, 
whereas other AZT-treated littermates remained well. If AZT was responsible for the 
toxicity observed in the 27-week WtN+ mice, there were no differences in underlying 
mtDNA mutations that appeared to have been responsible. Analysis in baseline 
tissue addressed the question of whether the mice that developed toxicity were 
predisposed by a high baseline mutation load, which did not seem to be the case. 
When the same analysis was performed for colon and skeletal muscle at the 
corresponding harvesting time points, no significant mtDNA variant differences were 
observed between mice with toxicity and mice without. Therefore, no clear 
explanation could be found for the rapid development of toxicity to the antiretroviral 
drug AZT in a subset of treated WtN+ mice. 
The duration of AZT treatment that was used was limited by the onset of treatment 
toxicity that affected a subset of the WtN+ mice in this study. In order to see a 
change in clonal expansion, prolonged treatment would be needed as this change 
presumably requires many cycles of mtDNA replication to be able to take place. This 
experiment did nevertheless use a similar duration of AZT treatment than other 
previous rodent studies, which did not measure clonal expansion (Zhang et al., 2014; 
Zhang et al., 2015). However, ideally I would have given even longer treatment had I 
not had concerns about cumulative toxicity. 
As was expected, changes in mtDNA CN with AZT treatment in WtN+ mice were 
small as AZT is only a mild inhibitor of polymerase γ. Future work could use more 
potent inhibitors of polymerase γ which induce significant depletion of mtDNA to see 
if this caused more profound effects on clonal expansion of mtDNA mutations. 
The fact that no increase in mtDNA mutation number occurred during AZT treatment 
meant AZT did not act by increasing mutagenesis de novo but rather by clonal 
expansion. However, future analyses should study lower level variants, at less than 
2% heteroplasmy, to fully exclude this effect. 
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In conclusion, sequencing results showed that AZT treatment: (1) did not modify the 
selection of mtDNA variants in WtN+ mice; (2) modified clonal expansion of mtDNA 
mutations in colon but not in skeletal muscle; and (3) did not increase mtDNA de 
novo mutations. These effects were achieved without inducing significant mtDNA 
depletion. 
 
9.1.4 Next generation sequencing technology for studying mtDNA mutations 
NGS is a powerful tool for studying heteroplasmic mtDNA point mutations and 
allowed us to study these mutations at great breadth (whole mtDNA genome) and 
great depth (to 2% heteroplasmy) in both the human and the mouse studies. There 
are however some limitations of NGS technologies for the study of mtDNA mutations.  
Although read lengths for Illumina sequencing (including MiSeq) have improved in 
recent years, they remain relatively short (150-250bp reads). In our analyses of the 
transmission and clonal expansion of mtDNA point mutations I typically observed 
~30-40 variants at >2% heteroplasmy per mouse. I have considered each variant as 
being independent, as the short read lengths mean that it is not possible to determine 
which variants sit on the same molecules of mtDNA. In fact, it is likely that some of 
the mtDNA mutations were clustered into clades. Future studies should investigate 
ways to reliably deep sequence long read lengths of mtDNA, preferably whole 
mtDNA genome in a single read. For example, Oxford Nanopore and Pacific 
Biosciences offer novel sequencing technologies with long read lengths.  
NGS allowed our assays to cover all mtDNA variants across the whole mtDNA 
genome at a high read depth. However, very low level heteroplasmic variants (<2%) 
were excluded from our investigations in order to set a stringent filter below which 
mutations could be considered assay noise. Any threshold set in NGS deep 
sequencing analysis is somewhat subjective but considering only mtDNA mutations 
above 2% heteroplasmy, a conservative threshold, gave us high confidence that 
these mutations were in fact real. On the other hand, use of this threshold meant that 
I could not report changes in mutations present at very low heteroplasmy levels 
(<2%), which are nevertheless of potential importance when studying clonal 
expansion of mtDNA mutations. Future work could include looking at below 2% 
heteroplasmy level variants, but this may require more sophisticated NGS assays. 
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To overcome NGS limitations, a strand-specific unique molecular tagging technique 
was developed by the Loeb group (Schmitt et al., 2012; Schmitt et al., 2015). This 
method called duplex sequencing was created to reduce error by employing unique 
oligonucleotide barcodes to independently tag and sequence each strand of each 
duplex DNA molecule. The true mutations will be found in both strands and scored 
once, whereas sequencing errors will be found in only one strand and discarded. The 
authors claim this sensitive methodology can detect a single mutation present among 
>107 wild-type molecules and estimate its error rate to be <4 x 10-10 (Schmitt et al., 
2012; Schmitt et al., 2015). Another similar technique that has been developed in 
order to avoid artefactual errors during deep sequencing was a high throughput 
assay for the accurate sequencing of the HIV-1 protease gene, called Primer ID 
(Jabara et al., 2011). A block of degenerate nucleotides is attached to the cDNA 
primer to create distinct combinations or Primer IDs. The Primer ID is flanked by a 
three nucleotide barcode. When the Primer ID and the barcode are repetitively 
identified, a consensus sequence is formed (Jabara et al., 2011). A unique molecular 
tagging approach similar to these methods was designed during this project (data not 
shown in this thesis), but due to time constraints I was not able to finalise optimising 




9.2 Final conclusion 
The work in this thesis has provided a novel rodent model for the study of clonal 
expansion of mtDNA point mutations, the WtN+ mouse. Using molecular and 
immunohistochemical techniques, it was confirmed that mitotic tissues, particularly 
colon, are the best for the study of clonal expansion. Clonal expansion of complex I 
mutations in single colonic crypts was further confirmed using single cell work. 
Phenotypic descriptions of this WtN+ mouse showed an increase in weakness with 
age, which may be suggestive of premature frailty. However, the model did not show 
a dramatic premature ageing phenotype. In addition, our experiments with the NRTI 
zidovudine suggest that I am able to modify clonal expansion in this mouse. 
Investigations conducted in human brain concluded that the mtDNA damage 
observed was driven by the effect of HIV infection itself, independently of ART. 
Nonetheless, these experiments supported the concept of an accelerated molecular 














Chapter 10. Appendices 
10.1 Mouse monitoring sheets for clinical scoring 
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10.2 Clinical scoring  
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10.3 Study plan submission 
Experimental Plan 
PolgA (WtN derivative) and WT mice (male and female) will be aged and 
phenotyped. Of principle interest are age-associated mitochondrial dysfunction and 
tissue fibrosis, especially in skeletal muscle, bowel and liver. Approximately 1/3 of the 
mice will be killed at each of three time-points: 4 months, 8 months, and 12 months. 
The last time-point may be extended to 18 months depending on the speed of onset 
of the ageing phenotype in WtN mice. Mice will be weighed monthly (starting at 4 
months), increased to weekly if clinical concern. Clinical phenotypic scoring will be 
performed monthly (starting at six months), increased to weekly if clinical concern. 
Behavioural testing: open field testing, grip strength and metabolic treadmill tests will 
be performed at 7 and 11 months. Blood samples: Blood (up to 0.2 ml) will be taken 
from mice restrained in an appropriate device every four months. Therapy: A group of 
WtN mice (n=16, female) will have AZT (zidovudine) treatment added to drinking 
water. This therapy is given to try and alter the rate of accumulation of mtDNA 
mutations and slow any ageing phenotype. To achieve a human equivalent dose 
requires 120mg/kg/d, as 24.7mg AZT per 30ml bottle of drinking water. Water bottles 
will be weighed to estimate drug intake per mouse per day (assumed to be 5mL). 
Animals will be dosed from six through to 10 months of age. Prior to commencing the 
experiment the palatability of the drug will be tested on a separate cage of mice and 
adjustments made to the drinking water if necessary (but previous published data 
suggest there is no effect). At the end of the experiment mice will be humanely killed 
by a schedule one method. 
Adverse Effects Interventions 
Phenotyping of young mice (<12 months) is not expected to cause any adverse 
effects. Older WtN mice (>12 months) may develop age related health issues e.g. 
reduced mobility, poor coats, however these features are expected to be mild in the 
WtN derivative of PolgA mice. The adverse effect will be recognised by clinical 
examination of animals and use of health score sheets. Animals showing more than 
moderate signs of conditions associated with aging would be humanely killed. The 
impact of the conditions may be reduced by provision of soft bedding and soaked 
diet. Clinical scores above moderate (10-14) would result in euthanasia. The rate of 
deterioration in these strains is variable therefore clinical score sheets will be used to 
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help assess these mice. Any genetically altered mouse that is showing signs of 
distress due to accelerated ageing will be killed on advice of the vet. Mice who lose 
>30% of body weight would be humanely killed irrespective of its clinical condition. 
Blood sampling: Animals could haemorrhage from the site of venepuncture, the likely 
incidence is <1%. The animal will be observed immediately after sampling, and 
checked again 5 minutes later. Adoption of appropriate methods of haemostasis will 
minimize the risk of this affect. If normal methods of haemostasis are not successful 
within a short period of time, the mice will be humanely killed. Therapy: We do not 
anticipate that administration of the AZT therapy will cause significant adverse 
effects. The effect, if any, on the ageing phenotype is expected to depend on whether 
the therapy alters the balance of mutant and wild-type mtDNA molecules. Whilst it is 
hoped that the therapy will slow the rate of onset of the ageing phenotype it is 
possible that it might accelerate it. However any effect on the rate of onset of ageing 
phenotype in older animals is expected to be much less than that attributable to the 
PolgA genotype. It would be rare that AZT therapy would cause toxic effects at the 
dose employed here (<5%). If adverse effects are observed at any time we will give 
appropriate supportive care e.g. fluids and/or soaked diet as necessary. Animals that 
exhibit a hunch posture, abnormal locomotion and ruffled fur coat, or diarrhoea would 
be humanely killed if they failed to respond to supportive care (warmth, fluids) within 
48 hours. Mice who lose >25% of body weight would be humanely killed. Behavioural 
testing: Behavioural testing is not expected to cause any adverse effects other than 
mild stress during exposure to the apparatus. 
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10.4 Protocol Number 2 for Genetically Altered Animals 
Protocol Title *  
Phenotyping of genetically altered animals 
 PIL Holder Responsible *  
Brendan Payne / Carla Roca 
 PIL Holder Email Address *  
Start Date *  
End Date (If Known) 31.8.2019 
Number of animals *  
86 
Species and Strain(s) *  
Mouse: PolgAmut and WT (B6) 
Current Cage Id(s) *  
Severity *  
Moderate  
Experimental Plan *  
Refer to the project licence protocol steps and list only the steps that these animals 
will go through 
PolgA (WtN derivative) and WT mice will be aged and phenotyped. Of principle 
interest are age-associated mitochondrial dysfunction and tissue fibrosis, especially 
in skeletal muscle, bowel and liver. Approximately 1/3 of the mice will be killed at 
each of 3 time-points: 4 months, 8 months, and 12 months. The last time-point may 
be extended to 18 months depending on the speed of onset of the ageing phenotype 
in WtN mice.  
 230 
WT mice will be weighed monthly (starting at 2 months), increased to weekly if 
clinical concern. GA mice will be weighed weekly, increased to twice weekly if clinical 
concern. 
Clinical phenotypic scoring in WT mice will be performed monthly (starting at 6 
months), increased to weekly if clinical concern. In GA mice scoring will be performed 
weekly, increased to twice weekly if clinic concern. 
Behavioural testing: open field testing, grip strength and metabolic treadmill tests will 
be performed at 7 and 11 months. 
Blood samples: Blood (up to 0.2 ml) will be taken from mice restrained in an 
appropriate device every 4 months. 
Therapy: A group of WtN mice will have AZT (zidovudine) treatment added to drinking 
water. This treatment is given to try and alter the rate of accumulation of mtDNA 
mutations and slow any ageing phenotype. To achieve a human equivalent dose 
requires 120mg/kg/d, as 24.7mg AZT per 30ml bottle of drinking water. Water bottles 
will be weighed to estimate drug intake per mouse per day (assumed to be 5mL). 
Animals will be dosed from 20 through to 40 weeks of age. Prior to commencing the 
experiment the palatability of the drug will be tested on a separate cage of mice and 
adjustments made to the drinking water if necessary (but previous published data 
suggest there is no effect).  
At the end of the experiment mice will be humanely killed by a schedule one method. 
Adverse Effects Interventions *  
Detail adverse effects, interventions and state humane end points 
Phenotyping of young mice (<12 months) is not expected to cause any adverse 
effects. Older WtN mice (>12 months) may develop age related health issues e.g. 
reduced mobility, poor coats, however these features are expected to be mild in the 
WtN derivative of PolgA mice. The adverse effect will be recognised by clinical 
examination of animals and use of health score sheets.  
Animals showing more than moderate signs of conditions associated with aging 
would be humanely killed. The impact of the conditions may be reduced by provision 
of soft bedding and soaked diet. Clinical scores above moderate (10-14) would result 
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in euthanasia. The rate of deterioration in these strains is variable therefore clinical 
score sheets will be used to help assess these mice. Any GA mouse that is showing 
signs of distress due to accelerated ageing will be killed on advice of the vet. Mice 
who lose >30% of body weight would be humanely killed irrespective of its clinical 
condition.  
Blood sampling: Animals could haemorrhage from the site of venepuncture, the likely 
incidence is <1%. The animal will be observed immediately after sampling, and 
checked again 5 minutes later. Adoption of appropriate methods of haemostasis will 
minimize the risk of this affect. If normal methods of haemostasis are not successful 
within a short period of time, the mice will be humanely killed. 
Therapy: Our experience with this genotype shows that most mice tolerate AZT 
therapy without significant adverse effects beyond mild anaemia. However some 
animals have developed more rapid onset of weight loss. This is likely to be a 
combined effect of the PolgA genotype and the treatment. If adverse effects are 
observed at any time we will give appropriate supportive care e.g. fluids and/or 
soaked diet as necessary. Animals that exhibit a hunch posture, abnormal 
locomotion and ruffled fur coat, or diarrhoea would be humanely killed if they failed to 
respond to supportive care (warmth, fluids) within 48 hours. Mice who lose >30% of 
body weight would be humanely killed. Mice should be weighed and have clinical 
scoring twice weekly whilst on treatment. This should be increased to three times 
weekly if >5% weight loss. If >15% weight loss, treatment should be stopped and 
supportive care given. 
Behavioural testing: Behavioural testing is not expected to cause any adverse effects 
other than mild stress during exposure to the apparatus. 
Metabolic treadmill: May cause mild and short-lived stress. 
Special requirements and/or instructions  
Stocking densities should be kept consistent (4-6 mice per box). 








1. Urogenitus (Bladder, prostate & urethra) – Remove excess fat, lay flat on blue biopsy 
pad on tissue cassette. Unfurl the two seminal vesicles, and orient the bladder on the 
top & urethra at the bottom. Cover tissue with another biopsy pad, and fix whole 
urogenitus. 
2. Right Testis – Cut longitudinal, half is fixed, half is frozen. 
3. Left Testis – Cut transverse, half is fixed, half is frozen. 
4. Prostate, half is fixed, half is frozen 
5. Right Kidney – Cut longitudinal, half is fixed, half is frozen. 
6. Left Kidney – Cut transverse, half is fixed, half is frozen. 
7. Skin – Shave skin from back, use paper towel to cut 2 slivers. One is fixed, the other is 
frozen 
8. Brain – Cut between hemispheres. Left hemisphere is fixed, the right hemisphere is 
frozen. 
9. Fat – Scraped from the right side underneath the skin and is frozen (fat dissolves in 
formalin). 
10. Muscle – Muscle is taken from the thigh. Take half of right thigh and half of left thigh 
and fix, the other half of rest and left thighs are frozen in isopentane first. 
11. Lung – Left lung (2lobes) is fixed, the right lung is frozen. 
12. Heart – Cut longitudinal, half is fixed and half is frozen in isopentane. 
13. Spleen - Half the spleen goes into the tissue cassette with the Liver. The other half of 
the spleen gets frozen. 
14. Liver– Triangular lobe of liver goes into tissue cassette. Cut a capsule off the 
bilobulated lobe and discard. Cut a sliver from the exposed capsule and place into 
tissue cassette. Cut a capsule off the large lobe and discard. Cut a sliver from the 
exposed capsule. Cut two squares from this sliver, one gets frozen for RNA, the other 
gets frozen for protein. The rest of the liver gets frozen.  
15. Pancreas – This is located wrapped around the proximal SI next to the stomach. It is 
hard to distinguish from fat, however, if required, the pancreas sinks and fat floats in 
water. Half the pancreas is fixed, the other half is frozen. 
16. SI – Measure the SI its contents are then collected. 2 ends of the SI are frozen. The rest 
is rolled up into a coil and fixed 
17. Colon – The contents of the colon is collected. 2 ends of the colon are frozen. The rest 
is fixed. 
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18. Caecum – The contents of the caecum is collected. 
19. Stomach – The contents of the stomach is emptied. The stomach is rolled up. A sliver 






10.6 Tests in the neuropsychological battery (provided by D. Moore) 
Estimate of Premorbid Functioning 
Wide Range Achievement Test (WRAT-3) – Reading Subtest (Wilkinson, 1993). The 
WRAT-3 reading subtest provides information on a subject’s ability to recognize and 
name letters and their ability to pronounce words out of context.  Subjects are 
instructed to individually read and pronounce a list of 42 words.  Individuals who 
obtain less than five points on this section are then instructed to read the letters of 
the alphabet.  This test is intended to measure word recognition, not speech or 
diction. (5 min.) 
 
Verbal Fluency 
Letter Fluency Tasks. (Borkowski, Benton, and Spreen, 1967).  On the Letter Fluency 
Test the subject is asked to say as many words as possible that begin with the letters 
"F," "A," and "S," excluding proper names and different forms of the same word.  For 
each letter, the subject is allowed one minute to generate words.  Performance is 
measured by the total number of correct words generated. Perseverations (i.e., 
repetitions of a correct word) and intrusions (i.e., words not beginning with the 
designated letter) are also recorded, as well as variants (the same word with a 
different suffix (e.g., “big, bigger, biggest). (5 min.) 
 
Speed of Information Processing 
Trail Making Test A (Army Individual Test Battery, 1944; Reitan and Davison, 1974).  
This is a measure of psychomotor speed, attention and cognitive sequencing.  
Subjects are asked to connect quickly (in ascending order) a series of randomly 
arranged dots numbered from 1 to 25. (1 min.) 
WAIS-III Digit Symbol (Wechsler, 1997).  This is a test of psychomotor speed, 
concentration, and graphomotor abilities that requires the respondent to match 
symbols to numbers as quickly as possible, using a visual reference at the top of the 
page. (3 min.) 
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WAIS-III Symbol Search (Wechsler, 1997).  This test requires psychomotor speed, 
attention, and concentration.  Subjects are asked to scan two groups of symbols 
visually and determine if either of two target symbols matches any of five symbols 
appearing in an array to the right of the target symbols.  The subject attempts to 
complete as many items as possible within a 120-second time limit. (3 min.) 
 
Attention / Working Memory 
WAIS-III Letter-Number Sequencing (Wechsler, 1997).  The examiner reads a 
combination of scrambled numbers and letters that the subject is then asked to 
reproduce orally with the numbers first in ascending order, followed by the letters in 
alphabetical order.  As the test progresses, items presented to the subject contain 
more numbers and letters.  There are three items in each trial, and each trial has 
different combinations of numbers and letters.  This test requires concentration, 
attention, and an ability to store and organize information in memory for a short 
duration. (5-10 min.) 
Paced Auditory Serial Addition Task  (PASAT) (Gronwall, 1977). In this test, a set of 
randomized digits is serially presented via tape recording (or computer generated 
voice in Spanish).  Subjects are asked to add the current number to the number that 
preceded it and respond with the total. Thus, after each new digit is presented, a new 
total is achieved. The number of correct responses is scored.  This also is an 
effective test of speed of information processing.  (10 min.) 
 
Learning and Recall (2 Domains) 
Hopkins Verbal Learning Test - Revised  (HVLT-R; Benedict, Schretlen, Groninger, 
and Brandt, 1998). The HVLT-R provides information on the ability to learn and 
immediately recall verbal information across trials, as well at the ability to recall and 
recognize this information after a delay.  A list of 12 words (four words from each of 
three semantic categories) is presented to the subject over three trials.  After each 
trial, the subject is asked to recall as many items as possible from the list in any 
desired order.  A 20-minute delay follows the administration of the three trials, after 
which the subject is asked to recall the list.  Subjects are then read a list of 24 words, 
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one at a time, and are asked if the word appeared in the original list.  The items 
presented during the recognition phase contain the originally presented words, words 
in the same semantic class, and unrelated words. In order to minimize practice 
effects that may arise from repeated administrations in a longitudinal design as we 
are proposing here, six alternate forms of the test are available.  There is no time limit 
on this test.  (10-15 min.) 
Brief Visuospatial Memory Test - Revised  (Benedict, 1997).  This test provides a 
measure of ability to learn and immediately recall visuospatial information. Delayed 
recall and recognition are also assessed.  Subjects are presented with an 81/2" by 
11" card containing six simple designs in a 2" by 3" matrix.  The display is presented 
for 10 seconds, after which the subject is asked to reproduce as many of the designs 
as possible in their correct location on a blank sheet of paper.  A total of three 
learning trials are administered.  After a 25-minute delay, subjects are once again 
asked to reproduce the matrix.  This is followed by a recognition trial in which 
subjects are shown 12 designs, one at a time, and asked if the design appeared in 
the original matrix.  The recognition trial consists of the six original designs and six 
foils.  A copy trial is administered in order to rule out poor performance due to 
graphomotor or visuospatial impairment.  In the copy trial, subjects are given the 
display along with a blank sheet of paper and asked to copy the designs.  There is no 
time limit for the recall, recognition or copy trials. (15-20 min.) 
 
Abstraction / Executive Functioning 
Trail Making Test B (Part A is considered under Speed of Information Processing) 
(Army Individual Test Battery, 1944; Reitan and Davison, 1974).  This is a measure 
of psychomotor speed, attention, and cognitive sequencing.  Part B requires subjects 
to connect a series of randomly arranged circles in a designated sequential order, 
based on alternating numbers and letters (i.e., 1 to A to 2 to B, etc.)  In addition to the 
skills required in part A of this test, shifting cognitive sets is also required. (5-10 min.) 
Wisconsin Card Sorting Test: Computer Version-2 (Research Edition: 64-item 
version) (Berg, 1948; Grant and Berg 1948; Heaton, Chelune, Talley, Kay, and 
Curtiss, 1993; Heaton and PAR Staff, 1993).  This is a measure of executive function 
that requires planning, use of feedback, and shifting of cognitive sets.  Subjects are 
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required to match a card that appears on the bottom part of the computer screen to 
one of four stimulus cards that are present on the upper part of the computer screen.  
The stimulus cards have four different designs on them -- the first has a red triangle, 
the second has two green stars, the third has three yellow crosses, the fourth has 
four blue circles.  The cards that subjects are required to match to one of the four 
stimulus cards vary in color, geometric form, and number.  Subjects receive feedback 
each time on correct or incorrect performances, and must use this feedback to alter 
their choices as the criteria for correct responses changes throughout the test.  There 
is no time limit for this test.  (15-30 min.) 
 
Motor Skills 
Grooved Pegboard (Kløve, 1963).  This is a test of fine motor coordination and 
speed.  In this test, subjects are required to place 25 small metal pegs into holes on a 
3" x 3" metal board. All pegs are alike and have a ridge on one side, which 
corresponds to a notch in each hole on the board.  First the dominant hand is tested, 
and subjects are asked to place the pegs in the holes as fast as they can.  This is 
then repeated with the nondominant hand, and the total time for each hand is 
recorded (5 minutes). 
 
Spanish-Language Tests 
In order to assess Spanish-speaking subjects with a battery similar to the one 
administered to the English-speaking subjects, a number of tests have been selected 
that utilize similar paradigms but are more reflective of Hispanic culture and common 
Spanish language usage. Normative data from approximately 200 Spanish-speaking 
subjects are available for Dr. Artiola's instruments (Artiola et al., 1999), and additional 
norms have been developed for other tests in the battery by Drs. Heaton and 
Cherner in San Diego and are being published. When equivalent tests were not 
available, English-language tests and instructions were translated and adapted into 
Spanish by HNRC staff, using standard back-translation procedures.  Individuals 
from five different Spanish-speaking regions (i.e. Mexico, Puerto-Rico, Cuba, 
Colombia, and Argentina) verified the translations.  The WRAT-3 was not translated 
and was omitted from the Spanish-language battery. 
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Hopkins Verbal Learning Test-Revised. The majority of words in this list learning task 
were translated from the English, but some items had to be modified for 
appropriateness in Spanish (Cherner, Suarez, Lazzaretto, Artiola i Fortuny, Rivera-
Mindt et al, 2006). 
Letter Fluency (PMR).  Similar to the Letter Fluency (Borkowski, Benton, and Spreen, 
1967), but using the letters P, M, and R. 
 
Self-assessment of Every-day functioning and Mood 
Activities of Daily Living Questionnaire (ADL).  The ADL is a brief self-administered 
questionnaire (modified for use at the HNRC from Lawton and Brody’s Instrumental 
Activities of Daily Living scale) in which the participant reports the amount of 
assistance needed in accomplishing basic everyday tasks (e.g., shopping, cleaning, 
managing medications) under two conditions: when these tasks were accomplished 
at their best performance level and when these tasks are attempted at their current 
performance level.  This measure allows the examiners to determine the extent to 
which changes in functioning may have occurred since optimal functioning and this 
information is useful in assisting clinicians in their determination of an AAN diagnosis.  
(10 minutes). 
 
Beck Depression Inventory (BDI) (Beck, 1976). The BDI consists of 21 questions, 
each having 4 graded statements (labeled 0 to 3) ordered to show increasing 
symptoms of depression.  The items of the BDI are clinically derived and there are 
numerous studies of reliability and validity. This measure is widely used in 
psychiatrically and medically ill populations and is a standard instrument for self-
report symptoms of depressed mood (5-10 min.) 
 
Patient's Assessment of Own Functioning Inventory (PAOFI) The PAOFI is a brief 
self-administered questionnaire in which the participant reports the frequency with 
which he/she experiences difficulties with memory, language and communication, 
use of his/her hands, sensory-perception, higher level cognitive and intellectual 
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functions, work and recreation.  This instrument aids clinicians in their determination 














7100056883 3TC APV D4T DDI NVP ZDV
7100107766 3TC ABC EFV
7100547672 ABC APV D4T RTV
7100616568 EFV NVP
7100626868 3TC ABC ZDV
7100658283 /
7101328666 ATV FTC RTV TFV
7102536771 EFV FTC TFV
7200186777 /
7200267172 ATV RTV FTC TFV








CG118 KTA FTC TFV
CG157 /
1004 NFV ZDV 3TC
1008 /
1010 3TC ATV RTV TFV
1021 /
1026 ATV ABC 3TC TFV




1093 ATV EFV RTV TFV
1099 /
1113 ATV ABC 3TC RTV
1119 3TC
1129 3TC ABC KTA ZDV
1141 ABC DRV RTV T20 TFV
1143 EFV FTC TFV
1152 3TC D4T NVP FTC TFV
1159 /
2004 3TC ABC NVP
2005 /
2012 KTA ZDV 3TC ABC
2035 /
2066 ABC APV D4T
2074 ABC DDI TFV
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List of antiretroviral drug regimens for HIV patients used for the study cohort in 
Chapter 3. PATID is patient ID. CURRENT MEDARV are the antiretroviral drugs that 
the patients were taking at the time of their last assessment. Drugs in orange are 





2092 EFV FTC TFV
4002 NVP ZDV 3TC
4028 /
4049 /
4067 KTA TFV ZDV 3TC
4083 ATV RTV FTC TFV
4091 3TC ABC ATV KTA T20
4109 FTV RTV FTC TFV SQV ZDV 3TC
4127 3TC ZDV 3TC EFV KTA NFV RTV EFV FTC TFV
4135 KTA FTC TFV NVP ZDV 3TC
4139 ABC 3TC KTA
4144 EFV FTC TFV
4149 DRV RTV RGV TMC
4175 EFV FTC TFV
4179 DRV RTV FTC TFV
5007 DDI EFV KTA NVP TFZ ZDV 3TC ABC
5008 DDI RTV TFV FTV
5016 /
5055 DRV RTV FTC TFV
5057 3TC ABC ATV DDI KTA RTV TFV ZDV
5072 /
6007 ABC D4T NFV
6009 3TC DLV FTV IDV NFV NVP ZDV
6037 3TC ABC D4T FTV IDV KTA RTV ZDV
6040 /
6046 ZDV 3TC ABC
6050 /





6081 ATV FTC RTV TFV
6083 FTC NVP TFV FTC TFV
10001 3TC D4T KTA
10011 /
10016 /
10025 3TC IDV ZDV
10063 /
10089 EFV FTC TFV
10104 3TC DDI DLV NFV TFV
10114 3TC D4T DDI HU KTA
10133 /
10147 ATV RTV FTC TFV
10251 RGV FTC TFV
































































































































































































































































































































































































































































































































































































































































































































































































































































List of antiretroviral drug regimens for HIV patients used for the study cohort in 
Chapter 3. PATID is patient ID. PAST MEDARV are the antiretroviral drugs that the 
patients took at some point in the past. Drugs in orange are antiretroviral combination 



























































































































































































































































































































































































































































































































3TC 3TC; lamivudine (Epivir)
ABC ABC; abacavir (Ziagen)
ADV ADV; adefovir dipivoxil (Preveon; Hepsera)
APV APV; amprenavir (Agenerase)
ATR ATR; efavirenz 600mg + emtricitabine 200mg + tenofivir DF 300mg (Atripla)
ATV ATV; atazanavir (Reyataz)
CBV CBV; zidovudine + lamivudine (Combivir)
COM COM; emtricitabine 200mg + rilpivirine 25mg + tenofovir DF 300mg (Complera)
CPV CPV; capravirine
D4T d4T; stavudine (Zerit)
DDC ddC; zalcitabine (Hivid)
DDI ddI; didanosine (Videx)
DLV DLV; delaviridine (Rescriptor)
DTG DTG; dolutegravir (Tivicay)
EFV EFV; efavirenz (Sustiva)
EMV EMV; MKC-422, emivirine (Coactinon)
EPZ EPZ; ziagen + epivir (Epzicom)
EVG EVG; Elvitegravir
EVO EVO;  atazanavir 300mg + cobicistat 150mg (Evotaz)
FPV FPV; fosamprenavir (Lexiva)
FTC FTC; emtricitabine (Coviracil; Emtriva)
IDV IDV; indinavir (Crixivan)
KTA LPV/RTV; lopinavir/ritonavir (Kaletra)
MVC MVC; maraviroc (Selzentry)
NFV NFV; nelfinavir (Viracept)
NVP NVP; nevirapine (Viramune)
PRE PRE; darunavir 800mg + cobicistat 150mg (Prezcobix)
QUA QUA; TRU + elvitegravir + cobicistat (Stribild formally Quad)
RGV RGV; raltegravir (Isentress)
RPV RPV; rilpivirine (Edurant)
RTV RTV; ritonavir (Norvir)
FTV SQV2 or FTV; saquinavir-sgc (Fortovase)
SQV SQV; saquinavir (Invirase)
T20 T20; enfuvirtide; pentafuside (Fuzeon)
TFV TFV, PMPA; tenofivir DF (Viread)
DRV DRV; TMC-114, darunavir (Prezista)
TMC TMC; TMC-125, etravirine (Intelence)
TMQ TMQ; abacavir 600mg + dolutegravir 50mg + lamivudine 300mg (Triumeq)
TPV TPV; tipranavir (Aptivus)
TRU TRU; emtricitabine + tenofovir (Truvada)
TZV TZV; AZT + 3TC + abacavir; zidovudine + lamivudine + abacavir (Trizivir)
VCV VCV; vicriviroc
ZDV ZDV; AZT, zidovudine (Retrovir)
ZTV ZTV; AR-177 (Zintevir)
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10.9 Coverage for deep sequencing of mouse mtDNA point variants in ear, 
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